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Zusammenfassung 
Das Proteom lebender Zellen befindet sich im ständigen Umbau, da zelluläre Proteine beschädigt 
werden und abgebaut werden müssen oder Zellen sich an veränderte physiologische Bedingungen 
anpassen. Die zellulären Prozesse, die den Erhalt des funktionalen Proteoms garantieren, werden 
unter dem Begriff Proteostase zusammengefasst. Das Proteasom stellt dabei eines der 
bedeutendsten intrazellulären Abbausysteme für beschädigte oder nicht benötigte Proteine dar. 
Insbesondere fehlgefaltete Proteine müssen zeitnah abgebaut werden um proteotoxische Effekte, 
wie zum Beispiel die Bildung von Proteinaggregaten zu vermeiden. Der Abbau zellulärer Proteine 
durch das Proteasom stellt einen sehr energieaufwändigen Prozess in der Zelle dar. 
Dementsprechend gibt es Hinweise auf eine Verknüpfung und wechselseitige Regulation zwischen 
den bedeutendsten Energieproduzenten der Zelle, den Mitochondrien, und proteasomaler Aktivität. 
Darüber hinaus korreliert proteasomale Dysfunktion mit mitochondrialer Fehlfunktion im Rahmen 
von Alterungsprozessen. Es ist allerdings wenig darüber bekannt, inwieweit mitochondriale Funktion 
und proteasomale Aktivität direkt miteinander verknüpft sind, vor allem im Kontext chronischer 
Defekte der mitochondrialen Atmungskette. Darüber hinaus ist weitgehend unbekannt, in welchem 
Ausmaß diese Prozesse spezifisch zur Lungenalterung oder zur Entwicklung von altersbedingten 
Lungenkrankheiten wie der chronisch obstruktiven Lungenerkrankung beitragen. 
Im ersten Teil dieser Studie wurde die Verknüpfung zwischen mitochondrialer Fehlfunktion und der 
proteasomalen Aktivität analysiert. Hierfür wurde die proteasomale Funktion in sogenannten 
„mtDNA mutator Mäusen“, einem Model für chronische Fehlfunktion der mitochondrialen 
Atmungskette, untersucht. Eine verminderte Proteasomaktivität und eine Reduktion der Anzahl von 
26S und 30S Proteasomen in embryonalen Fibroblasten dieser Mäuse bestätigten eine enge 
Verknüpfung von mitochondrialer und proteasomaler Funktion. Eine verminderte Proteasomfunktion 
wurde darüber hinaus auch in dermalen Fibroblasten von Patienten gezeigt, die einzelne definierte 
Mutationen in Genen der mitochondrialen Atmungskette aufweisen. Zusätzlich wurde 
herausgefunden, dass zu den bereits beschriebenen Signalwegen, weitere regulatorische 
Mechanismen existieren, die mitochondriale und proteasomale Funktion miteinander verknüpfen. 
Um zu untersuchen inwieweit Umwelteinflüsse die mitochondriale Funktion in der Lunge 
beeinflussen, wurde im zweiten Teil der Studie der Effekt von Zigarettenrauch auf mitochondriale 
Funktion und Qualitätskontrolle in Lungenepithelzellen bestimmt. Alveoläre Epithelzellen der Maus 
zeigten eine deutliche Hyperfusion der Mitochondrien und eine begleitende Erhöhung der 
metabolischen Aktivität nach der Behandlung mit Zigarettenrauchextrakt. Die durch 
Zigarettenrauchextrakt induzierte mitochondriale Hyperfusion war jedoch nicht mit einer 
proteostatischen Veränderung der Mitochondrien verknüpft. Darüber hinaus wurde In dieser Studie 
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keine Beeinflussung der mitochondrialen Proteinqualitätskontrolle durch das Proteasom festgestellt. 
Mitochondriale Hyperfusion scheint daher eine überlebensfördernde Anpassung von alveolären 
Epithelzellen an nicht-toxische Konzentrationen von Zigarettenrauchextrakt darzustellen. 
Im letzten Teil der Studie wurde die Rolle beider Systeme, Proteasom und Mitochondrien, im 
Rahmen der Lungenalterung untersucht. Dazu wurden Alterungsprozesse sowie proteasomale 
Funktion in der Lunge von jungen und alten Wildtyp-Mäusen, Proteasom Reporter-Mäusen und 
Immunoproteasom Knockout-Mäusen untersucht. Dabei wurde beobachtet, dass die Untereinheiten 
des Immunoproteasoms in Lungen alter Mäusen hochreguliert waren und dementsprechend die 
Caspase-ähnliche Aktivität des Proteasoms vermindert war. Knockout-Mäuse für die 
Immunoproteasom Untereinheiten LMP2 oder LMP7 waren jedoch vor physiologischer 
Lungenalterung nicht geschützt. Diese Ergebnisse legen nahe, dass die veränderte Funktion des 
Immunoproteasoms nicht ausschlaggebend für die physiologische Lungenalterung ist. Weiterhin 
deuten sie darauf hin, dass die Alterungsprozesse in gesunden Lungen keine Veränderung der 
proteasomalen Funktion einschließen. Darüber hinaus wurde in frühzeitig alternden mtDNA mutator 
Mäusen keine Verknüpfung zwischen mitochondrialer Fehlfunktion und physiologischer 
Lungenalterung gefunden. 
Zusammenfassend bestätigt diese Studie die Hypothese, dass proteasomale und mitochondriale 
Funktion eng miteinander verknüpft sind. Darüber hinaus wird gezeigt, dass sowohl das 
mitochondriale wie auch das proteasomale System Reservekapazitäten haben, die sie dazu befähigen 
trotz milder Beanspruchungen durch Umwelteinflüsse oder während physiologischer 
Alterungsprozessen funktionsfähig zu bleiben. Da jedoch beide Systeme eng miteinander verbunden 
sind könnten bei einer kumulativen Belastung durch altersbedingte Fehlfunktion und Exposition mit 
schädlichen Umwelteinflüssen, wie z.B. Zigarettenrauch, mitochondriale und proteasomale 
Fehlfunktion einen Grenzwert überschreiten und somit zu vorzeitigen Alterungsprozessen und der 
Entwicklung von altersbedingten Krankheiten beitragen. 
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Summary 
In living cells the cellular proteome is under constant remodeling as cells adapt to altered 
physiological states or as cellular proteins become misfolded and need to be degraded. The cellular 
processes which grant maintenance of a functional proteome are collectively called proteostasis. The 
proteasome constitutes one of the major intracellular protein degradation systems and is responsible 
for the turnover of damaged or unwanted proteins with almost 90% of the intracellular proteins 
being potential proteasome substrates. Especially for misfolded proteins, a timely degradation is 
necessary to avoid proteotoxic stress, e.g. by formation of protein aggregates. Degradation of 
proteins by the proteasome system is a very energy demanding process. Hence it was speculated 
that proteasomal function is interconnected with the function of mitochondria. Additionally, a 
correlation between mitochondrial and proteasomal dysfunction exists since a decline in the function 
of both systems is well recognized as hallmark of aging. However, it is unclear how proteasomal and 
mitochondrial function are directly linked together, especially in settings of chronic mitochondrial 
respiratory chain dysfunction. Moreover, limited knowledge is available to which extent proteasomal 
and mitochondrial functions contribute to aging processes specifically in lung tissue during healthy 
aging or in the development of age-related lung diseases such as chronic obstructive pulmonary 
disease.  
In the first part of this study, the connection between mitochondrial dysfunction and the proteasome 
was assessed by analyzing proteasome function in the so-called “mtDNA mutator” mouse model, a 
model of chronic mitochondrial respiratory chain dysfunction. A strong interconnection between 
mitochondrial and proteasomal function was confirmed in mouse embryonic fibroblasts of mtDNA 
mutator mice as in these cells decreased proteasomal activity and reduced levels of assembled 26S 
and 30S proteasomes was found based on a pronounced mitochondrial respiratory chain 
dysfunction. Importantly, human dermal fibroblasts from patients with single mutations in 
mitochondrial genes accordingly showed reduced proteasome activity. Furthermore, it was shown 
that in addition to acute regulation by reactive oxygen species or ATP levels, further signaling 
mechanisms exist, which connect mitochondrial and proteasomal function in chronic settings.  
Second, to assess mitochondrial alterations in response to environmental challenges in the lung, the 
effect of cigarette smoke exposure on mitochondrial function and quality control in alveolar 
epithelial cells was analyzed. Murine alveolar epithelial cells exhibited pronounced mitochondrial 
hyperfusion after treatment with cigarette smoke extract, which was accompanied by increased 
metabolic activity. Cigarette smoke extract-induced mitochondrial hyperfusion was not associated 
with a protein stress response at mitochondria. Furthermore, no alteration in mitochondrial protein 
quality control by the proteasome was observed. Therefore, mitochondrial hyperfusion seems to be 
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an adaptive pro-survival response of alveolar epithelial cell mitochondria to nontoxic concentrations 
of cigarette smoke extract.  
Finally, the specific involvement of both systems, proteasome and mitochondria, in healthy aging of 
the lung was assessed. Therefore typical features of healthy lung aging and proteasome function 
were analyzed in young and aged wildtype, proteasome reporter and immunoproteasome knockout 
mice. Hereby, it was observed that immunoproteasome subunits were upregulated in the lungs of 
aged mice and the caspase-like proteasome activity was concomitantly decreased. However, aged 
knockout mice for the immunoproteasome subunits LMP2 or LMP7 showed no alteration in 
proteasome activities while exhibiting typical lung aging phenotypes. This suggests that 
immunoproteasome function is dispensable for physiological lung aging in mice. These results 
indicate that healthy aging of the lung does not involve impairment of proteasome function. 
Furthermore, no connection between mitochondrial dysfunction and lung aging was found in 
prematurely aging mtDNA mutator mice. 
Altogether, this study confirms the hypothesis that the functions of the proteasome and 
mitochondria are closely connected. Furthermore, it shows that mitochondria as well as the 
proteasome system provide some spare capacity, which enables them to remain functional upon 
mild insults during healthy aging or exposure to mild environmental hazards. However, due to the 
close interconnection of both systems, the simultaneous burden of an age-related functional decline 
together with noxious environmental exposures such as cigarette smoke might push proteasomal 
and mitochondrial dysfunction beyond a damage threshold thereby contributing to the pathogenesis 
of disease states or to a combined functional decline of both systems as described in aging. 
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1 Introduction 
1.1 Protein homeostasis by the proteasome 
Proteins are almost indefinitely versatile macromolecules and are involved in nearly every cellular 
process. The properties of a protein are by large determined by its amino acid sequence. However, 
for an appropriate cellular function, proteins need to be in a correctly folded state and integrated in 
a functional protein interaction network (Hartl et al., 2011; Powers and Balch, 2013; Meiners and 
Ballweg, 2014). Importantly, proteins must preserve conformational flexibility for correct function 
and therefore possess only limited thermodynamic stability in their native state (Hartl et al., 2011). 
Furthermore, altered external conditions, e.g. due to different metabolic conditions or physiological 
or environmental stressors, additionally challenge the stability of protein conformations (Morimoto 
and Cuervo, 2014). For these reasons, protein homeostasis, i.e. the maintenance of a functional 
proteome, is of vital importance for the cell. The term proteostasis covers all cellular processes which 
grant protein homeostasis throughout the whole life cycle of a protein and involves protein 
maturation, maintenance of protein folding, and degradation of irreparably misfolded or unwanted 
proteins (Figure 1-1) (Powers and Balch, 2013; Meiners and Ballweg, 2014; Morimoto and Cuervo, 
2014). Protein folding is usually coupled with protein synthesis (Hartl et al., 2011; Meiners and 
Ballweg, 2014). However, as protein translocation in some organelles, e.g. the endoplasmic reticulum 
or mitochondria, requires proteins to be unfolded some proteins are ultimately folded only after they 
reach their target organelle (Zimmermann et al., 2006; Schmidt et al., 2010). Maturation of proteins 
into their proper folding state and maintenance of a native conformation is mostly assisted by 
chaperone proteins either in the cytosol or in the target organelles. Newly synthesized or misfolded 
proteins expose hydrophobic sequences which tend to form protein aggregates. Chaperones 
transiently bind to these exposed hydrophobic sequences of unfolded or partially folded proteins, 
thereby preventing aggregate formation. Subsequent ATP-triggered release from the chaperone 
promotes folding into the functional conformation with several binding and release cycles being 
possible to ensure correct folding (Hartl et al., 2011). In case folding attempts remain unsuccessful, 
misfolded proteins are targeted for degradation. Since misfolded proteins are especially prone to 
form aggregates, a timely degradation is needed (Buchberger et al., 2010; Meiners and Ballweg, 
2014). Two major protein degradation systems exist in the cell: the ubiquitin proteasome system and 
the autophagy-lysosomal pathway (Meiners and Ballweg, 2014). Autophagy refers to “self-eating” 
and involves sequestration of substrates in double-membraned autophagic vesicles and subsequent 
degradation in the lysosome. During macroautophagy, which is often simply called autophagy, 
cytosolic cargo is engulfed by elongation of a double membrane which eventually seals to form the 
autophagosome. After fusion of the autophagosome with the lysosome, cargo is degraded by 
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lysosomal hydrolases (Levine and Kroemer, 2008). Thereby, a wide range of substrates, such as 
protein aggregates but also whole organelles, can be degraded by autophagy (Kroemer et al., 2010). 
Although autophagy was long considered to be a bulk degradation pathway, more selective 
autophagy pathways such as microautophagy or chaperone mediated autophagy were discovered 
(Kaushik and Cuervo, 2012). Degradation of specific substrates and soluble proteins is, however, 
mainly executed by the ubiquitin proteasome system (Meiners and Ballweg, 2014). 
 
Figure 1-1: Proteostasis during the lifecycle of proteins 
Proteostasis takes place throughout the lifecycle of proteins. Proteins are synthesized as a linear polypeptide chain at the 
ribosomes. Folding into their native structure is assisted by chaperones. Chaperones also maintain the native folding of 
proteins in the cytosol as well as in other compartments such as endoplasmic reticulum or mitochondria. Sustained protein 
misfolding induces protein degradation mainly via the proteasomal pathway. For this purpose proteins are tagged with a 
polyubiquitin chain for recognition by the proteasome and degraded into small peptides. Dysfunctional protein aggregates 
are mainly removed by engulfment in autophagosomes and degraded after fusion of the autophagosome with lysosomes. 
Degradation products after autophagic or proteasomal degradation are mostly recycled for the synthesis of new proteins 
(Meiners and Ballweg, 2014). 
1.1.1 The ubiquitin proteasome system 
The proteasome is an evolutionary conserved multi-subunit protease and is the major protein 
degradation pathway in the cell with up to 90 % of the cellular proteome being potential proteasome 
substrates. The proteasome degrades native as well as misfolded proteins and thus is important for 
cellular stress responses but also for regulatory and housekeeping purposes (Finley, 2009; Schmidt 
and Finley, 2013). Generally, attachment of a Lysin-48 (K48)-linked polyubiquitin chain to target 
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proteins, by a cascade of E1, E2 and E3 ubiquitin ligases, serves as a signal for substrate recognition 
by the proteasome. However, also ubiquitin-independent degradation patways and pathways 
involving ubiquitination on different sites than K48 have been described (Finley, 2009; Komander and 
Rape, 2012).  
1.1.1.1 Proteasome structure and function 
The proteasome consists of a core particle, the 20S proteasome, which can associate with several 
regulatory particles which mediate substrate recognition and proteasome activation (Meiners et al., 
2014). The core particle itself consists of four heptameric rings, two α and two β rings in the order 
“αββα”, which build up a barrel-like structure (Figure 1-2). Each of the rings consists of seven related 
but distinct subunits (α1-7 and β1-7) with the subunits β1, β2 and β5 harboring the catalytic active 
sites. Assembly of the proteasome core complex from the 28 individual subunits follows a tightly 
regulated process and is mediated by proteasome assembly chaperones. The catalytic subunits are 
assembled as inactive propeptides to avoid premature cleavage of substrates. As a last step of the 
assembly process the propeptides are autocatalytically cleaved with the active sites facing the inner 
side of the mature proteasome (Ditzel et al., 1998; Murata et al., 2009).  
In the assembled proteasomes the active site of the catalytic subunits lies inside of the central cavity 
and access to the central channel of the proteasome barrel is restricted by the N-termini of the α 
subunits. Due to this arrangement the “naked” 20S proteasome core is rather inert and has only low 
degradation activity (Groll et al., 2000; Finley, 2009; Meiners et al., 2014).  
The proteasome contains three distinct catalytic activities. The proteasome subunit β1 preferentially 
cleaves substrates after amino acids with acidic residues, β2 after basic residues and β5 after 
hydrophobic residues. The three different active sites are therefore also called caspase-like (C-L), 
trypsin-like (T-L) and chymotrypsin-like (CT-L) activity, respectively (Finley, 2009; Murata et al., 2009).  
The proteasome does not degrade substrates to single amino acids but produces a diverse mix of 
small oligopeptides (Finley, 2009; Groettrup et al., 2010). While most of these peptides are 
subsequently degraded to singular amino acids by cytosolic peptidases, some of the generated 
peptides are further processed and mounted on major histocompatibility complex (MHC) class I 
molecules and serve as signaling molecules for the immune system (Finley, 2009; Groettrup et al., 
2010; Tanaka, 2013). To further assist this process alternative catalytic proteasome subunits are 
induced in lymphoid tissue and under specific conditions such as virus infection or Interferon (IFN)-γ 
stimulation and are incorporated into the proteasome core complex. These alternative subunits, 
LMP2 (β1i), MECL-1 (β2i), and LMP7 (β5i), are preferably incorporated into newly formed 
proteasomes which assemble into an alternative form of the 20S proteasome known as the 
immunoproteasome (i20S)(Groettrup et al., 2010; Meiners et al., 2014; Schmidt and Finley, 2013). 
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The immunosubunits are proposed to have altered cleavage specificities and kinetics (Groettrup et 
al., 2010; Mishto et al., 2014) thereby shifting peptide production towards peptides with 
hydrophobic C-termini which are preferentially bound by MHC class I molecules (Groettrup et al., 
2010). Additionally, immunoproteasomes have been proposed to play a protective role in the cellular 
response to oxidative stress, which is, however, still a matter of debate (Aiken et al., 2011; Ebstein et 
al., 2013; Nathan et al., 2013; Seifert et al., 2010). Notably, proteasomes can also exist in mixed 
forms containing both standard subunits and immunosubunits which further increases the possible 
variation in cleavage specificity and peptide production by the proteasome (Ferrington and 
Gregerson, 2012; Meiners et al., 2014; Zanker et al., 2013).  
Besides standard- and immunoproteasomes, a third tissue specific proteasome subforms has been 
described. The alternative subunit β5t was found exclusively expressed in the thymus and 
incorporates together with LMP2 and MECL-1 in the thymoproteasome (t20S). The β5t subunit 
exhibits decreased chymotrypsin-like cleavage activity and thymoproteasomes were found to be 
important for selection of CD8+ T-cells in the thymus (Murata et al., 2007; Tanaka, 2013).  
1.1.1.2 Regulation of proteasome function 
Proteasome activity is mainly regulated by binding of regulatory particles which modulates 
proteasomal turnover rate and substrate specificity. Four different proteasome activators are known 
up to date: the 19S regulatory particle, the PA28αβ-, the PA28γ- or the PA200-regulatory particle. 
Proteasomal activators can bind to one or both ends of the 20S core particle thereby mediating 
conformational changes in the α subunits leading to an open conformation which enables substrate 
access. This arrangement leads to pronounced activation of the proteasome upon assembly of 
regulatory particles and ensures a highly specific turnover as only substrate proteins are gated to the 
active sites (Gallastegui and Groll, 2010; Li and Rechsteiner, 2001; Meiners et al., 2014; Schmidt and 
Finley, 2013). In addition to the proteasomal activators another regulatory particle, PI31, exists and 
was initially described as an inhibitor of proteasomal activity, which is, however, still under debate 
(Meiners et al., 2014; Schmidt and Finley, 2013).  
The 19S regulatory particle is the most abundant and best studied regulator. It consists of two parts: 
the 10 subunit base complex and the 9 subunit lid complex (Finley, 2009). Binding of the 19S 
regulator particle can occur either at one end of the 20S core or at both ends, resulting in 26S and 
30S proteasome formation, respectively (Figure 1-2). The 19S regulator is required for the 
degradation of polyubiquitinated proteins as it is responsible for substrate recognition, 
deubiquitination, unfolding and translocation into the proteasome core (Finley, 2009; Meiners et al., 
2014; Unverdorben et al., 2014). 19S-dependent degradation is strictly ATP-dependent and ATP 
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withdrawal leads to disassembly of 19S particles from the 20S proteasome (Kim et al., 2012; Liu et al., 
2006a).  
 
Figure 1-2: Schematic depiction of 30S proteasome particles and subunits 
The 30S proteasome consists of two 19S regulatory particles on both sides of the 20S core particle. The 20S core particle 
consists of two α rings assembled by the subunits α1-7 and two β rings assembled by the subunits β1-7. The 19S regulatory 
particle can be further divided in base and lid and is assembled by several ATPase (Rpt) and non-ATPase (Rpt) subunits 
(Figure modified from: Murata et al., 2009). 
In contrast to the common 19S regulatory particle, the alternative regulators PA28αβ, PA28γ and 
PA200 promote ATP- and ubiquitin-independent degradation. However, further research is still 
needed to delineate the specific substrates and functions of these alternative regulators. PA28αβ is 
induced in cells treated with INF-γ and highly expressed in professional antigen presenting cells and is 
therefore believed to play a role in immune defense and antigen presentation (Cascio, 2014). PA28γ 
which is present exclusively in the nucleus and PA200 might be involved in degradation of 
transcription factors and cell cycle regulators or acetylated histones, respectively (Meiners et al., 
2014; Schmidt and Finley, 2013). To be degraded in an ubiquitin-independent process substrate 
proteins need to be at least partially unfolded which can occur in response to aging, protein 
oxidation or other stress-induced modifications. Additionally, also native proteins which contain large 
intrinsically disordered sequences can be degraded via ubiquitin-independent mechanisms (Ben-
Nissan and Sharon, 2014; Finley, 2009). Of note, different regulatory particles can simultaneously 
attach to different ends of the proteasome core which opens the possibility of alternative 
proteasome complexes such as for example 19S-20S-PA28 (Meiners et al., 2014). 
An overview about the gene and protein nomenclature of the proteasome subunits and regulatory 
particles analyzed in this study is given in Table 1-1. 
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Table 1-1: Gene and protein names of proteasome subunits analyzed in this study 
Gene name Protein name Localization in the proteasome 
PSMA3 α7 20S α ring 
PSMB6 β1 20S β ring 
PSMB7 β2 20S β ring 
PSMB5 β5 20S β ring 
PSMB8 LMP7 (β5i)  i20S β ring 
PSMB9 LMP2 (β1i) i20S β ring 
PSMB10 MECL-1 (β2i) i20S β ring 
PSMC3 Rpt5 19S ATPase subunit 
PSMD7 Rpn8 19S non-ATPase subunit 
PSMD11 Rpn6 19S non-ATPase subunit 
PSME1  PA28α PA28αβ 
PSME3 PA28γ PA28γ 
 
Beyond binding of regulatory particles, proteasome activity can be regulated by posttranslational 
modifications of proteasomal subunits or by non-covalently binding of signaling molecules. Several 
posttranslational modifications such as acetylation, phosphorylation, N-acetyl-glucosaminylation or 
oxidation have been detected on proteasomal subunits with most modifications being located at the 
20S α subunits or at the 19S regulatory particle. However, it is by now not fully understood how 
these modifications are introduced and how they affect proteasomal activity. Acetylation of both the 
20S proteasome and proteasomal regulators might increase proteasomal activity. One study found 
activation of the proteasome after 20S acetylation (Wang et al., 2013), while another demonstrated 
increased degradation of model substrates after PA28γ acetylation (Liu et al., 2013). Phosphorylation 
of the proteasome was reported to have activating as well as inactivating effects on the proteasome 
depending on the positions and the kinases involved (Liu et al., 2006b; Lokireddy et al., 2015; Zhang 
et al., 2007a). Attachment of O-linked N-acetylglucosamine (O-GlcNAcylation) to 19S subunits 
decreased 26S complex formation and proteasome activity (Xu et al., 2012; Zhang et al., 2003). 
Similarly, oxidative modifications were shown to decrease proteasome activity and levels of 26S 
complexes (Breusing and Grune, 2008; Livnat-Levanon et al., 2014). In addition to posttranslational 
modifications, non-covalent binding of small signaling molecules can affect proteasomal activity. The 
most important mediator hereby is the binding of ATP which, as outlined above, is required for 26S 
complex formation (Kim et al., 2012; Liu et al., 2006a; Peth et al., 2013). Furthermore, NADH was 
shown to reversibly bind to 19S subunits thereby stabilizing 26S proteasome formation in the 
absence of ATP. Concordantly, increasing the NADH/NAD+ ratio increased proteasome activity 
(Tsvetkov et al., 2014).  
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In summary, proteasomal degradation is tightly regulated mainly by the attachment of regulatory 
particles to the proteasomal core. These regulators thereby mediate quantitative changes in 
proteasomal degradation but also qualitative differences as they can also modify substrate 
specificity. It is important to note that many posttranslational modifications also modify proteasomal 
activity by interfering with complex formation of regulatory particles with the 20S core. This further 
emphasizes the important role of proteasomal regulators as a fast and adaptive system to regulate 
proteasomal degradation. 
1.2 Mitochondrial function and protein homeostasis 
Mitochondria are organelles derived from an endosymbiotic fusion of α-proteobacteria with 
eukaryotic cells. This unique background leads to some special biological features of these 
organelles. Mitochondria are double membraned organelles thereby establishing an intraorganellar 
compartmentalization in matrix, inner mitochondrial membrane (IMM), intermembrane space (IMS) 
and outer mitochondrial membrane (OMM). Additionally, mitochondria contain their own DNA 
(mitochondrial DNA: mtDNA) with several hundred copies of mtDNA existing in every cell. While 
most mitochondrial genes have been transferred to the nucleus during evolution, the mtDNA is still 
coding for 13 essential proteins of the mitochondrial respiratory chain as well as for 22 tRNAs and 2 
ribosomal RNAs (16S and 12S) of the mitochondrial protein biosynthesis machinery (Gaziev et al., 
2014; Mishra and Chan, 2014; Nunnari and Suomalainen, 2012). The main cellular task for 
mitochondria is energy metabolism by generating ATP as a result of oxidative phosphorylation in the 
respiratory chain (Nicholls and Ferguson, 2002). The respiratory chain consists of four protein 
supercomplexes (complex I-IV) which build up the electron transport chain (ETC) that utilizes energy, 
which is gained by the oxidation of nutrients, to generate a proton gradient across the inner 
mitochondrial membrane. Notably, correct assembly of the supercomplexes of the ETC requires a 
synchronized expression of nuclear DNA and mtDNA-encoded subunits. The gradient generated by 
the ETC builds up a electrochemical membrane potential (ΔΨ) which drives the fifth protein complex 
in the respiratory chain, the mitochondrial ATP synthase (complex V), to generate ATP by controlled 
reflux of protons into the mitochondrial matrix (Figure 1-3)(Mishra and Chan, 2014; Nicholls and 
Ferguson, 2002). Besides ATP production, mitochondria also are important for apoptosis and several 
cellular biosynthesis pathways such as iron-sulfur-cluster synthesis. Furthermore, they serve as a 
signaling hub for example by mediating reactive oxygen species (ROS) production or Ca2+ signaling 
(Chandel, 2014; Liesa and Shirihai, 2013; Mishra and Chan, 2014). 
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Figure 1-3: Mitochondrial compartmentalization and respiratory chain function 
Mitochondria are double membraned organelles consisting of an outer mitochondrial membrane, an intermembranespace, 
the inner mitochondrial membrane and the matrix. The inner mitochondrial membrane is folded inwards thereby increasing 
its surface area and generating additional intermembranespace compartments called cristae. The mitochondrial respiratory 
chain is located in the inner mitochondrial membrane in the cristae regions. Electrons are fed into the respiratory chain by 
oxidation of NADH or FADH2 at complex I or complex II, respectively. Electron transport along the respiratory chain is 
mediated by the soluble shuttle molecules ubiquinone (CoQ) and cytochrome c (Cyt c). ETC activity leads to transport of 
protons from the matrix to the intermembrane space at complex I, III and IV thereby building up the mitochondrial 
membrane potential. Proton backflow through complex V powers ATP production in the mitochondrial matrix. ATP and ADP 
are exchanged with the cytosol via the ATP-ADP translocase in the inner mitochondrial membrane. While most 
mitochondrial proteins are encoded by nuclear DNA, the 13 depicted subunits of the respiratory chain complexes I, III, IV 
and V are encoded by mitochondrial DNA and translated in the mitochondrial matrix (Figure modified from Mishra and 
Chan, 2014).  
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1.2.1 Mitochondrial protein homeostasis 
To maintain these crucial mitochondrial functions, protein homeostasis in the mitochondria needs to 
be tightly regulated. Therefore, sophisticated quality control systems have evolved to cope with 
damage of mitochondrial structures. Although mitochondria possess their own genome, most 
mitochondrial proteins are encoded by nuclear DNA. These mitochondrial proteins are translated in 
the cytosol, recognized by a mitochondrial target sequence and transported through the 
mitochondrial protein import machinery into their target compartment where they are folded into 
their functional conformation (Schmidt et al., 2010). Of note, a first layer of protein quality control 
comes into action at a very early stage, as damaged or mistargeted proteins can be degraded by the 
proteasome even before their import (Anand et al., 2013; Bragoszewski et al., 2013; Wrobel et al., 
2015). For maintenance of protein homeostasis in the mitochondria, several additional quality 
control mechanisms exist which involve the mitochondrial unfolded protein response (mtUPR), 
mitochondrial dynamics, degradation of mitochondrial proteins by the proteasome in a process 
termed mitochondria-associated degradation (MAD) and degradation of whole mitochondria via the 
autophagy pathway. 
1.2.1.1 Mitochondrial unfolded protein response 
Mitochondria possess their own arsenal of molecular chaperones which assist proteins in folding and 
refolding. Especially as mitochondrial proteins are imported in an unfolded state, a functional folding 
environment is required to avoid protein aggregation in mitochondria. Matrix chaperones include 
mitochondrial variants of the cytosolic heat shock proteins (HSPs) such as the mitochondrial 
mtHSP70 or HSP60. In the intermembrane space the TIM9-TIM10 complex of the mitochondrial 
import machinery performs chaperone activity and facilitates protein folding (Campello et al., 2013; 
Pellegrino et al., 2013; Schmidt et al., 2010). In addition to chaperones, mitochondria house several 
proteases such as the Lon or ClpP proteases in the matrix which perform quality control as well as 
housekeeping proteolytic tasks (Anand et al., 2013). Additionally, the membrane bound m-AAA 
(facing the matrix) or i-AAA (facing the IMS) protease complexes or free proteases such as the OMA1 
protease in the IMS extend the protease capacities to membrane and IMS compartments (Anand et 
al., 2013; Campello et al., 2013). 
If protein damage in the mitochondria exceeds the folding capacity of the mitochondrial chaperone 
system, a mitochondrial unfolded protein response (mtUPR) is triggered. The mtUPR signals to the 
nucleus and induces expression of mitochondrial chaperones and proteases thereby increasing the 
mitochondrial proteostasis capacity in order to restore mitochondrial homeostasis (Jovaisaite et al., 
2013). Most studies assessing the mtUPR were performed in C. elegans. In this model organism, 
accumulating misfolded proteins in the mitochondrial matrix are degraded by the matrix protease 
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ClpP into small peptides. These peptides are transported into the cytosol and lead to activation of the 
transcription factor ATFS-1. ATFS-1, which contains both a mitochondrial and a nuclear targeting 
sequence, then translocates to the nucleus where it enhances transcription of mitochondrial quality 
control proteins such as HSP60 or mtHSP70 chaperones (Pellegrino et al., 2013). In mammals, the 
mechanism involved in mitochondria to nucleus signaling is far less understood since no mammalian 
orthologue of ATFS-1 exists. However, it was shown that mammalian mtUPR involves e.g. the 
transcription factor CHOP (Arnould et al., 2015; Jovaisaite et al., 2013; Pellegrino et al., 2013). 
Furthermore, in mammals a mechanistically distinct unfolded protein responses for the 
mitochondrial IMS (IMSUPR) exist which leads to increased expression of IMS proteases, induction of 
proteasome activity and increased mitochondrial biosynthesis (Papa and Germain, 2011; Pellegrino 
et al., 2013; Radke et al., 2008).  
1.2.1.2 Mitochondrial dynamics 
Mitochondria are not static but form a dynamic network of tubular organelles with constant fusion 
and fission activity. The final shape and network connectivity is determined by the balance between 
fusion and fission events (Youle and van der Bliek, 2012). The mitochondrial network dynamically 
reacts to cellular stress and constitutes an important mechanism for mitochondrial quality control 
(Figure 1-4). Mitochondrial fusion allows content mixing in mitochondria, thereby diluting mild 
damage that might be present in a subset of mitochondria. Fused mitochondria share a common set 
of proteins and mtDNA molecules. Therefore, fused mitochondria can complement each other and 
compensate for damaged proteins or mtDNA mutations in one of the fused mitochondria (Mishra 
and Chan, 2014; Youle and van der Bliek, 2012). Mitochondrial fission, on the other hand, allows for 
segregation of severely damaged mitochondria. Defective mitochondria can contaminate the 
mitochondrial network, for example by increased ROS production in the respiratory chain which 
causes protein oxidation in the mitochondria. Mitochondrial fission acts as a quality control 
mechanism by sequestering damaged mitochondria from the mitochondrial network. Each fission 
step produces asymmetrically polarized mitochondria with damaged mitochondria failing to recover 
and repolarize (Twig et al., 2008; Youle and van der Bliek, 2012). Degradation of fusion mediators on 
these damaged organelles by the proteasome renders them incapable of reentering the 
mitochondrial network leaving behind fragmented mitochondria which are subsequently degraded 
via the autophagy pathway (Jin and Youle, 2012; Tanaka et al., 2010; Twig et al., 2008). Mitochondrial 
fission together with the removal of severely damaged mitochondria by autophagy thereby increases 
average mitochondrial health. Mitochondrial health is therefore highly affected by the frequency of 
fusion and fission events (Patel et al., 2013). 
In addition to mitochondrial quality control, mitochondrial fusion and fission affects mitochondrial 
bioenergetic function. Hence, by dynamically adapting to cellular stress and cellular energy demands, 
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mitochondrial morphology also represents an important adaptive mechanism for general cellular 
homeostasis (Liesa and Shirihai, 2013). Mitochondrial elongation was reported in response to a 
variety of stressors and was therefore termed stress-induced mitochondrial hyperfusion (Blackstone 
and Chang, 2011; Gomes et al., 2011; Tondera et al., 2009). Mitochondrial hyperfusion provides a 
stress resolving mechanism for the cell as elongated mitochondria show increased efficiency in ATP 
synthesis thereby contributing to the cells’ ability to repair cellular damage. Additionally, hyperfused 
mitochondria are protected from degradation by autophagy (Blackstone and Chang, 2011; Gomes et 
al., 2011). Hence stress-induced mitochondrial hyperfusion is regarded to be a pro-survival response 
(Blackstone and Chang, 2011; Tondera et al., 2009). Mitochondrial fragmentation, on the other hand, 
is an early event upon induction of apoptosis. In this sense, mitochondria also contribute to the 
induction of controlled cell death during overwhelming cellular stress (Elgass et al., 2012; Liesa et al., 
2009). 
The molecular machinery mediating mitochondrial fusion and fission consists of several large 
GTPases of the dynamin-related protein family. The key proteins in these processes are 
dynamin-related protein (DRP) 1 (mitochondrial fission), Mitofusin (MFN) 1 and MFN2 (outer 
membrane fusion) and optic atrophy (OPA) 1 (inner membrane fusion) (Scorrano, 2013). The 
mitochondrial fission protein DRP1 resides in the cytosol and needs to be translocated to 
mitochondria prior mitochondrial fission. DRP1 localization and thereby fission activity is regulated 
by phosphorylation events. Phosphorylation at Ser616 induces mitochondrial localization and 
subsequent fission while phosphorylation at Ser637 inactivates DRP1 (van der Bliek et al., 2013). The 
fusion mediators MFN1 and MFN2 reside in the outer mitochondrial membrane. MFN1 is described 
to tether mitochondria together in the fusion process. The exact role of MFN2 still needs to be 
elucidated but it is suggested to participate in later steps of fusion (Scorrano, 2013). Although usually 
both mitofusins are expressed in the same cell, MFN1 and MFN2 can maintain fusion without the 
second mitofusin, showing at least partial redundancy (van der Bliek et al., 2013). Outer membrane 
fusion is almost always coordinated with inner membrane fusion, which is mainly mediated by OPA1. 
Several isoforms of OPA1, including at least two long and three short isoforms, are generated by 
differential cleavage of OPA1 with both long and short isoforms being required for fusion (Quiros et 
al., 2013; Scorrano, 2013). Upon mitochondrial stress, fusion is inhibited by proteasomal degradation 
of MFN1 and MFN2 and proteolytic cleavage of long OPA1 isoforms by the IMS protease OMA1 (van 
der Bliek et al., 2013; Cohen et al., 2008; Quiros et al., 2013). 
Introduction  
16 
 
Figure 1-4: Mitochondrial dynamics as part of the mitochondrial quality control system 
Mitochondrial dynamics are characterized by a cycle of fusion and fission events. Mitochondrial fusion is mediated by MFN1 
and MFN2 responsible for OMM fusion and OPA1 for IMM fusion. Mitochondrial fusion allows content mixing and thereby 
complementation in damaged mitochondria. Furthermore, under conditions of mild cellular stress the mitochondrial 
network becomes hyperfused thereby increasing cellular ATP production and sparing mitochondria from autophagy. 
Mitochondrial fission is mediated by DRP1 and leads to generation of asymmetrically polarized daughter mitochondria. If 
transient depolarization of daughter mitochondria can be resolved mitochondria reenter the mitochondrial network. 
Sustained depolarization, however, leads to degradation of MFN1 and MFN2 by the proteasome and to proteolytic cleavage 
of OPA1 thereby preventing refusion. Fragmented and depolarized mitochondria are subsequently degraded by mitophagy 
(Figure modified from Liesa and Shirihai, 2013).  
1.2.1.3 Mitochondria-associated degradation 
In addition to degradation of mitochondrial proteins by mitochondrial proteases, mitochondrial 
proteins can be degraded by the cytosolic ubiquitin proteasome system. First evidence of 
degradation of mitochondrial proteins by the ubiquitin proteasome system was given by the finding 
that several mitochondrial proteins are ubiquitinated in the cell and inhibition of the proteasome 
leads to accumulation of ubiquitinated mitochondrial proteins (Livnat-Levanon and Glickman, 2011; 
Margineantu et al., 2007). Indeed, several E3 ubiquitin ligases were found to reside in the OMM and 
can ubiquitinate mitochondrial proteins (Heo and Rutter, 2011). As the proteasome is excluded from 
mitochondrial compartments and can only interact at the cytosolic site of the outer mitochondrial 
membrane a protein retro-translocation mechanism has been proposed to work at the outer 
mitochondrial membrane (Taylor and Rutter, 2011). In response to mitochondrial damage the 
cytosolic protein VMS1 localizes to mitochondria and recruits the AAA ATPase p97/VCP and its 
adaptor protein Npl4. VCP then acts as a translocase and uses ATP to extract proteins from the 
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mitochondrial membrane and subsequently shuttles them to the proteasome (Heo and Rutter, 2011; 
Heo et al., 2010; Taylor and Rutter, 2011). Due to its similarity with the endoplasmic reticulum-
associated degradation (ERAD) pathway (Claessen et al., 2012), this mitochondrial degradation 
process was termed mitochondria-associated degradation (MAD) (Chatenay-Lapointe and Shadel, 
2010). While the VCP-Npl4 complex is also involved in ERAD where it colocalizes with the adaptor 
protein Ufd1, VMS1 seems to be exclusive for mitochondrial localization of VCP (Taylor and Rutter, 
2011). To date, several proteins which are degraded by this pathway have been recognized such as 
the mitochondrial fusion mediators MFN1 and MFN2 (Cohen et al., 2008; Karbowski and Youle, 2011; 
Ross et al., 2015; Xu et al., 2011). Most mitochondrial substrates for the proteasome are proteins of 
the outer mitochondrial membrane. However, also proteins from inner compartments were 
described as substrates for proteasomal degradation. The mechanism how these proteins are 
translocated to the proteasome, however, remains unclear (Azzu and Brand, 2010; Azzu et al., 2010; 
Heo and Rutter, 2011; Karbowski and Youle, 2011).  
Additionally, proteasomes can be recruited to the outer mitochondrial membrane themselves and 
even adaptor proteins for proteasomes on mitochondria were described. (Launay et al., 2013; 
Nakagawa et al., 2007; Yoshii et al., 2011) However, whether proteasomal localization to 
mitochondria is parallel to MAD or interacts with MAD is still unclear (Livnat-Levanon and Glickman, 
2011).  
1.2.1.4 Mitophagy 
If complementation of mitochondrial function by fusion, or refolding or degradation of mitochondrial 
proteins fails to repair mitochondrial damage, whole organelles can be degraded via the autophagy-
lysosomal pathway. This mitochondria-specific autophagy is called mitophagy (Youle and Narendra, 
2011). Several distinct mitophagy pathways have been described to date. For example in 
erythrocytes, removal of mitochondria during differentiation is executed via a pathway dependent 
on the protein NIX at the OMM (Mishra and Chan, 2014). Mitophagy as a response to mitochondrial 
damage, however, is mainly regulated by the PINK1/Parkin pathway (Campello et al., 2013; Jin and 
Youle, 2012; Youle and Narendra, 2011). PINK1 is constantly expressed and imported into 
mitochondria followed by rapid degradation by mitochondrial proteases. Mitochondrial damage 
leads to impairment in mitochondrial membrane potential and thereby reduced import of PINK1 in 
the IMM. Thereby, PINK1 selectively accumulates on damaged mitochondria while it is degraded in 
healthy mitochondria (Jin and Youle, 2012; Narendra et al., 2010). Upon accumulation of PINK1, the 
E3 ligase Parkin translocates to mitochondria where it induces ubiquitination of several OMM 
proteins such as MFN1, MFN2 or VDAC1 (Chan et al., 2011; Geisler et al., 2010; Tanaka et al., 2010; 
Yoshii et al., 2011). Ubiquitination of OMM proteins subsequently triggers degradation of some 
proteins by the proteasome system utilizing the MAD pathway. Accordingly, mitophagy also was 
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found to be decreased in the absence of VCP or after proteasome inhibition (Chan et al., 2011; 
Tanaka et al., 2010; Yoshii et al., 2011). Additionally, Parkin induces polyubiquitination with lysine 
63-linked polyubiquitin chains, which are usually linked to signaling but not proteasomal 
degradation, and thereby facilitates binding of the ubiquitin receptor protein p62 to mitochondria. 
p62 can further interact with the autophagy regulator LC3B fostering the engulfment of mitochondria 
into autophagosomes (Geisler et al., 2010; Youle and Narendra, 2011). However, the exact role of 
p62 is still unclear as it may or may not be required for PINK1/Parkin mediated mitophagy (Jin and 
Youle, 2012). Importantly, mitochondrial fission and degradation of mitofusins by the proteasome 
facilitates mitophagy probably by reducing mitochondrial size and thereby enabling inclusion into the 
autophagosome (Mishra and Chan, 2014; Youle and Narendra, 2011).  
1.3 Interconnections between mitochondrial and proteasomal function 
As outlined above, mitochondria possess an extensive arsenal of quality control. The ubiquitin 
proteasome system, although excluded from mitochondria by the mitochondrial membranes, 
contributes at several stages to mitochondrial quality control. Proteasomes degrade misfolded 
mitochondrial proteins in the MAD pathway. Additionally, mitochondrial fusion and fission mediators 
are degraded by the proteasome and therefore effective segregation of damaged organelles from 
the mitochondrial network requires proteasomal activity. Lastly, proteasomes might also be involved 
in the initiation of Parkin-mediated mitophagy.  
Furthermore, another possible link between mitochondria and proteasomes is given by the facts that 
the proteasome and most proteostatic processes are highly dependent on ATP (Buchberger et al., 
2010; Kim et al., 2012; Liu et al., 2006a; Zhang et al., 2007b) and the mitochondrial respiratory chain 
is the main ATP-generating process in the cell (Brand and Nicholls, 2011; Nicholls and Ferguson, 
2002). 
Consequently, it is tempting to speculate that mitochondrial function and proteasomal function are 
closely interconnected and play important roles in maintaining cellular and organismal health. 
However, only few publications directly explored the interconnection between mitochondrial and 
proteasomal function.  
1.3.1 Effect of proteasome function on mitochondria 
Some evidence exists for the effect of proteasomal inhibition on mitochondrial function. Treatment 
with nontoxic doses of proteasome inhibitors decreased activity of mitochondrial respiratory chain 
complexes I, II, III and V in human fetal fibroblasts (Torres and Perez, 2008). Furthermore, 
proteasome inhibitor treatment of Chinese hamster ovary cells reduced mitochondrial membrane 
potential and increased mitochondrial superoxide generation (Maharjan et al., 2014). Additionally, 
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treatment of neurons with proteasome inhibitors was associated with a decrease in mitochondrial 
membrane potential as an early step during apoptosis (Goldbaum et al., 2006; Papa et al., 2007). 
Furthermore, in cells with a chronic, mild decrease in proteasome activity, a reduction of maximal 
oxygen consumption and decreased viability in the absence of glucose was shown (Sullivan et al., 
2004) indicating impaired mitochondrial function. Moreover, increased association of mitochondria 
with autophagosomes was observed in response to proteasome inhibition (Sullivan et al., 2004). 
Furthermore, growth of a yeast mutant with a heat sensitive subunit of the 19S proteasome at the 
restrictive temperature led to reduced mitochondrial numbers by induction of mitophagy (Takeda et 
al., 2010). Additionally, a siRNA screen in Drosophila S2 cells revealed reduced mitochondrial 
numbers and increased mitophagy in response to the silencing of proteasomal genes (Fukuoh et al., 
2014). 
In addition to a reduction in mitochondrial function, proteasome inhibition affects mitochondrial 
morphology and network dynamics. Yeast Rpn11 mutant cells showed decreased growth on glycerol 
as well as mitochondrial fragmentation (Rinaldi et al., 2007). In contrast, Rpn3 mutants presented 
large mitochondrial aggregates indicative of increased fusion (Joshi et al., 2011). Furthermore, 
deletion of the yeast homologue for PA200, Blm10, also induced mitochondrial fragmentation (Tar et 
al., 2014). Similarly, in human cell lines treated with proteasome inhibitor and in C. elegans treated 
with siRNA against proteasome subunits a fragmented mitochondrial network was observed (Livnat-
Levanon et al., 2014). However, it has to be noted that mitochondrial fragmentation and loss of 
mitochondrial membrane potential usually precedes apoptosis (Liesa et al., 2009) and proteasome 
inhibition is known to induce apoptosis (Frankland-Searby and Bhaumik, 2012). Therefore, caution 
has to be taken when assessing the effects of proteasome inhibition on mitochondria, to distinguish 
between physiological effects due to altered proteasome activity and secondary effects in cell death 
pathways. 
Altogether, proteasome inhibition seems to reduce mitochondrial function thereby increasing 
mitochondrial ROS production and induction of mitophagy. This is well in accordance with the above 
described role of the proteasome in mitochondrial quality control. Reduced quality control increases 
mitochondrial damage which might add to increased mitochondrial ROS production by electron 
leakage from the respiratory chain (Balaban et al., 2005; Murphy, 2009). Consequently, mitophagy is 
induced to degrade damaged mitochondria and to compensate for impaired proteasomal quality 
control. Additionally, as the fusion and fission mediators MFN1 and MFN2 and DRP1 are degraded by 
the proteasome (Cohen et al., 2008; Wang et al., 2011), an effect of proteasome inhibition on 
mitochondrial dynamics can well be explained.  
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1.3.2 Effect of mitochondrial function on the proteasome 
In addition to the effect of proteasome dysfunction on mitochondria, some reports demonstrate 
effects of mitochondrial dysfunction on proteasome function. Mitochondria are the powerhouse of 
the cell and proteasomes are a huge ATP-consuming machine. Hence, it seems plausible that 
mitochondrial metabolism can affect proteasome activity. Metabolic sensors such as adenosine 
monophosphate-activated protein kinase (AMPK) or protein kinase A (PKA) can induce 
posttranslational modifications of the proteasome and thereby modulate its activity (Ronnebaum et 
al., 2014; Zhang et al., 2007b). AMPK is the major energy sensor of the cell and is activated upon low 
ATP availability. AMPK activation subsequently stimulates ATP producing processes and inactivates 
ATP consuming processes (Hardie et al., 2012). Indeed, AMPK activation was shown to decrease 
proteasome activity, while in turn AMPK inhibition increased proteasomal activity (Ronnebaum et al., 
2014; Viana et al., 2008; Xu et al., 2012). Two potential mechanisms how AMPK influences 
proteasomal activity have been described. On the one hand, AMPK activation induces O-GlcNAc 
transferase mediated O-GlcNAcylation of the proteasome promoting 20S-19S disassembly (Xu et al., 
2012). On the other hand, AMPK interacts with Rpn6 and was shown to directly phosphorylate this 
subunit (Moreno et al., 2009). However, how this modification affects proteasome activity is still 
unknown. In contrast to AMPK-induced inactivation, PKA induces phosphorylation of the 19S 
proteasome subunits Rpt6 and Rpn6 thereby increasing proteasome activity (Lokireddy et al., 2015; 
Zhang et al., 2007a). However, although inhibition of mitochondria can for example induce AMPK 
activation (Distelmaier et al., 2014), a direct connection between mitochondrial and proteasomal 
function via AMPK or PKA has not yet been described.  
In addition to metabolic control of the proteasome, it was reported that an increased need for 
mitochondrial quality control by the proteasome can lead to proteasomal activation. Induction of the 
unfolded protein response of the mitochondrial intermembrane space by overexpression of an 
unstable IMS protein induced an increase in proteasome activity (Papa and Germain, 2011). Likewise, 
a recent report showed that a defect in the mitochondrial protein import machinery and therefore 
accumulation of mitochondrial proteins that cannot be correctly imported, induced upregulation of 
proteasome activity (Wrobel et al., 2015). These results further underline the importance of the 
proteasome in mitochondrial quality control and suggest an adaptive regulation of proteasomal 
activity by mitochondrial dysfunction. 
The direct effect of mitochondrial dysfunction on proteasome activity was analyzed by some other 
studies by testing if inhibition of the mitochondrial respiratory chain could induce alterations in 
proteasome function. Indeed, treatment of HEK cells with rotenone (complex I inhibitor), antimycin A 
(complex III inhibitor) but not with KCN (complex IV inhibitor) decreased proteasomal degradation of 
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ubiquitin fused GFP (Chou et al., 2010). Similarly, in NT2 human carcinoma cells, the complex I 
inhibitors MPP+ or rotenone diminished proteasome activity measured by degradation of small 
peptidic proteasome model substrates (Domingues et al., 2008). These effects were attributed to an 
increase in mitochondrial ROS production upon respiratory chain inhibitor treatment (Chou et al., 
2010; Domingues et al., 2008). Additionally, a recent siRNA screen in C. elegans expressing 
ubiquitinated GFP as a proteasome reporter showed that knockdown of respiratory chain subunits or 
enzymes involved in mitochondrial metabolic processes decreases proteasome activity. This effect 
was attenuated by treatment with antioxidants such as N-acetyl cysteine (NAC) (Segref et al., 2014) 
showing its dependency on cellular ROS. A more detailed description of proteasomal alterations in 
response to respiratory chain inhibitors was provided by Livnat-Levanon et al. (2014). Treatment of 
yeast cells or hamster kidney cells with antimycin A led to disassembly of 26S proteasomes thereby 
decreasing proteasome activity and inducing accumulation of ubiquitinated proteasome substrates. 
Again, this effect could be partially reverted with DTT showing a dependency of oxidative 
modifications induced upon respiratory chain inhibition (Livnat-Levanon et al., 2014). This ROS-
dependent decrease of proteasomal activity in response to respiratory chain inhibition is well in 
accordance with the already known influence of ROS on the proteasome system (Aiken et al., 2011; 
Breusing and Grune, 2008; Wang et al., 2010). However, one caveat remains as it is unclear to which 
extent this effect is physiologically relevant. It was shown that under unstressed or mildly stressed 
conditions mitochondrial ROS acts as a signaling molecule in cells and is required for cellular 
homeostasis (Sena and Chandel, 2012). Pharmacologically inhibiting the respiratory chain, however, 
strongly and acutely increases mitochondrial ROS production to a level which is probably highly 
above normal ROS production in vivo (Murphy, 2009). Furthermore, much of the effect of 
mitochondrial ROS in vivo might be dependent on the balance between ROS and cellular antioxidant 
defenses (Sena and Chandel, 2012) and hence might not be well reflected by an acute outburst of 
ROS production. 
As the dependency of 26S proteasomes on ATP is well documented, decreased ATP levels in response 
to mitochondrial damage were suggested as another mechanism contributing to diminished 
proteasome activity. Indeed, Huang et al. showed that treatment of primary rat cortical neurons with 
antimycin A, rotenone or the complex V inhibitor oligomycin induces a decrease in 26S proteasome 
assembly and subsequent accumulation of ubiquitinated substrates. This correlated with decreased 
ATP levels in treated cells (Huang et al., 2013). However, as the treatment conditions in this study 
were associated with induction of necrosis and substantial loss in cell viability (Huang et al., 2013) it 
is not clear whether loss of proteasome function is causally linked to reduced ATP levels or rather to 
the induction of cell death or other confounding factors. Another study in primary rat neurons 
showed that rotenone or MPP+-induced decrease in proteasome activity could be reversed by 
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increased glucose supplementation to the cell culture medium which also partially reversed the 
decrease of ATP in response to inhibitor treatment. Importantly, in contrast to glucose 
supplementation, the antioxidant NAC was not able to rescue proteasome activity in this study 
(Höglinger et al., 2003). However, as ATP levels are usually tightly regulated in the cell, treatment 
with respiratory chain inhibitors induces an acute decrease in ATP production which probably might 
not reflect the physiological regulation. 
In summary, the effect of mitochondrial damage and dysfunction on the proteasome is differentially 
regulated depending on the nature of mitochondrial damage (Figure 1-5). Mitochondrial protein 
misfolding in the IMS or defective mitochondrial protein import is associated with increased 
proteasome activity. On the other hand inhibition of the respiratory chain impairs proteasomal 
function, which most probably due to highly increased mitochondrial ROS production or decreased 
ATP availability in the cell. However, the studies are sometimes contradictory, e.g. on whether 
antioxidants are protective or not. This might be due to differences in cell types or even organisms 
used in the studies or also due to different concentrations of the applied compounds. Additionally, 
while these results are strongly dependent on the acute chemical inhibition of the respiratory chain, 
the effect of more physiological triggers of respiratory chain dysfunction as it might occur in disease 
or in aging are not well characterized. Therefore, these results give important insights in potential 
mechanisms which can link mitochondrial dysfunction with proteasome function but they are not 
sufficient to fully explain the connection between these two systems, e.g. in situations without 
elevated ROS production. 
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Figure 1-5: Effect of mitochondrial dysfunction on proteasome activity 
Mitochondrial dysfunction has diverse effects on proteasome function. Mitochondrial protein misfolding in the 
mitochondrial intermembrane space or dysfunctional mitochondrial protein import induces an increase in proteasome 
activity. On the other hand, inhibition of the respiratory chain is associated with decreased proteasome activity and lower 
levels of assembled 26S and 30S proteasomes. Treatment of cells with respiratory chain inhibitors is signaled to the 
proteasome by acutely elevated mitochondrial ROS production or diminished ATP availability. 
Altogether, proteasomal and mitochondrial function are clearly interconnected as evident by the role 
of the proteasome system in mitochondrial quality control and also by the observed regulation of 
proteasomal activity in response to mitochondrial dysfunction. An additional important link is given 
by a close correlation of mitochondrial and proteasomal function during aging, as both mitochondrial 
and proteasomal function were described to decline during aging (López-Otín et al., 2013) and in 
some age-related diseases such as Alzheimer’s disease (Ross et al., 2015). 
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1.4 Lung aging 
1.4.1 Molecular mechanisms of aging 
Aging is usually defined as a progressive decline of cellular, tissue and organ function that leads to 
increased vulnerability to disease and eventually death (Kirkwood and Austad, 2000; López-Otín et 
al., 2013). Several theories have been developed to explain the evolution of aging such as the 
“mutation accumulation” or the “disposable soma” theory (Kirkwood and Austad, 2000; Ljubuncic 
and Reznick, 2009). Mechanistically, most theories link the aging process to accumulation of damage 
during an organism’s life span (Kirkwood and Austad, 2000; López-Otín et al., 2013).  
Within this framework, López-Otín et al. recently defined nine “hallmarks of aging” at the cellular 
level, i.e. genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, 
deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, altered intercellular 
communication and stem cell exhaustion, that are causally linked with the aging process and 
together contribute to the loss of function in aged tissues (López-Otín et al., 2013). Intervening with 
these pathways often extends lifespan in model organisms thereby proving their importance in the 
aging process (Kennedy and Pennypacker, 2014; López-Otín et al., 2013). Importantly, these 
interventions can also be used to delay or prevent many age-related diseases (Kennedy et al., 2014) 
thereby opening the possibility to use these concepts to better describe age-related pathologies 
(Meiners et al., 2015). Since both proteasomal and mitochondrial function are recognized as 
hallmarks of aging, this further argues for a close interconnection of mitochondria and the 
proteasome. However, the effect of aging on proteasomal and mitochondrial function has mostly 
been studied independently of each other. 
1.4.2 Proteasome activity in aging 
During aging, a decline in proteasome activity was described in several organisms and tissues such as 
in brain, liver, muscle, lymphocytes, and heart (Chondrogianni et al., 2014; Keller et al., 2000). 
Furthermore, overexpression of proteasome subunits in yeast and C. elegans was shown to increase 
lifespan, especially under mild stress conditions (Chen et al., 2006; Vilchez et al., 2012), while flies 
and mice with genetically decreased proteasome activity exhibited a premature aging phenotype 
(Tomaru et al., 2012; Tonoki et al., 2009). In addition, a very recent study reported on the particular 
correlation of immunoproteasome expression with maximum lifespan. Especially, 20S proteasome 
activity and immunoproteasome expression showed a particular correlation with the maximum 
lifespan in long-lived primate species and in rodent models with experimentally increased lifespan 
(Pickering et al., 2015).  
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1.4.3 Mitochondrial function in aging 
For mitochondria, it has long been recognized that mitochondrial function declines during aging 
(Bratic and Larsson, 2013). Indeed, basal as well as maximal mitochondrial oxygen consumption 
decreased with aging and electron leakage and ROS production by the respiratory chain is increased 
in aged organisms. Additionally, mitochondrial number and structure is altered in aging and 
mutations and deletions in mitochondrial DNA accumulate (Bratic and Larsson, 2013; Edgar and 
Trifunovic, 2009; López-Otín et al., 2013; Marzetti et al., 2013). The strong correlation of 
mitochondria and aging also placed mitochondria at the very center of the aging process in the 
so-called mitochondrial free radical theory of aging. According to this theory, oxidative metabolism in 
mitochondria induces mitochondrial ROS production which further induces damage to the mtDNA. In 
turn mtDNA damage results in expression of defective respiratory chain complexes which produce 
even more ROS leading to a vicious cycle of mitochondrial damage and ROS (Bratic and Larsson, 
2013; Marzetti et al., 2013). However, in the last few years the mitochondrial free radical theory of 
aging has been substantially challenged. First evidence was obtained from transgenic animals which 
accumulated mitochondrial DNA mutations and showed a premature aging phenotype, however, in 
the absence of increased ROS production (Trifunovic et al., 2004, 2005). Additionally, increasing 
antioxidant defense does not prevent aging (Pérez et al., 2009) and also genetic manipulations in 
mice that increase mitochondrial ROS and oxidative damage do not accelerate aging (Zhang et al., 
2009). In contrast, increased levels of ROS were even beneficial for organismal lifespan in some cases 
(Mesquita et al., 2010; Yun and Finkel, 2014). This new data argues for a more complex role of 
mitochondria in aging focusing on other signaling pathways of mitochondria.  
In summary, a decline of mitochondrial function and alterations of mitochondrial structure and 
mtDNA integrity are clearly associated with aging. Additionally, interventions that increase lifespan 
are also associated with improved mitochondrial function (Bratic and Larsson, 2013; López-Otín et 
al., 2013).  
However, despite the clear regulation of mitochondrial and proteasomal function in aging the 
connection of these two hallmarks of aging seems to be more complex than initially suggested. 
Furthermore, it remains unclear to which extent the different hallmarks contribute to the aging 
phenotype of different organs and tissues and to which degree they are affected in healthy or 
diseased aging. 
1.4.4 Healthy and diseased aging phenotypes of the lung 
In the lung, characteristic phenotypes of healthy aging and age-related diseases can be described. 
Lung morphology and physiology significantly changes over the lifetime of an organism and thereby 
can be used to analyze the effects of molecular mechanisms on the healthy aging process. 
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Lung function increases after birth when the lung matures and peaks at an age of 20-25 years. After 
this age, lung function progressively declines with aging (Janssens et al., 1999; Sharma and Goodwin, 
2006). This loss of function is linked to several structural and functional alterations of the respiratory 
system such as a decrease in chest wall compliance or loss of respiratory muscle strength (Sharma 
and Goodwin, 2006). An important structural change during aging is the progressive enlargement of 
the alveolar space leading to a decrease in the alveolar surface area necessary for gas exchange. In 
analogy to pathological airspace enlargement, this condition was called “senile emphysema” 
(Janssens et al., 1999). However, development of senile emphysema was shown to be 
mechanistically different from disease-related emphysema. Senile emphysema is generally described 
as “non-destructive” (Janssens et al., 1999; Tuder, 2006). It is thereby in sharp contrast to 
pathophysiologically altered, emphysematous lungs in which emphysema development is driven by 
protease/antiprotease imbalance in the extracellular space and hence by protease-induced 
destruction of connective tissue (Taraseviciene-Stewart and Voelkel, 2008). Emphysema 
development during healthy aging was not associated with increased extracellular protease activity 
and tissue destruction (Calvi et al., 2011; Janssens et al., 1999; Sueblinvong et al., 2012; Tuder, 2006) 
but is rather caused by intracellular factors such as increase in cellular senescence and decreased of 
extracellular matrix production (Calvi et al., 2011; Taraseviciene-Stewart and Voelkel, 2008). 
Importantly, these changes are not restricted to humans but can also be found in mice during healthy 
aging (Calvi et al., 2011) and can therefore be studied in mouse models. 
1.4.4.1 Age-related diseases of the lung 
Aging is an important risk factor for many chronic lung diseases. A strong increase in incidence with 
age has been described for chronic lung diseases such as chronic obstructive lung disease (COPD), 
idiopathic pulmonary fibrosis or lung cancer (Meiners et al., 2015; Thannickal et al., 2015).  
Especially COPD was described as a disease of accelerated lung aging (Lee et al., 2011; MacNee, 
2009; Mercado et al., 2015). COPD is characterized by progressive airflow limitation which is not fully 
reversible. Important features of the disease are chronic bronchitis, airway inflammation, increased 
mucus production and emphysema (Barnes, 2000; Ito, 2009; Tuder and Petrache, 2012). In contrast 
to senile emphysema in healthy aging, COPD-related emphysema is caused by alveolar wall 
destruction due to unopposed action of proteases in the alveolar space (Taraseviciene-Stewart and 
Voelkel, 2008; Tuder and Petrache, 2012). Since exposure to cigarette smoke is closely associated 
with COPD development it was suggested that exposure to cigarette smoke leads to increased 
accumulation of damage thereby causing accelerated aging in lung cells which then contributes to 
disease manifestation (Ito, 2009; Lee et al., 2011). Indeed, cigarette smoke induces alveolar epithelial 
cell senescence (Tsuji et al., 2004). Senescence of pulmonary cells has been proposed as a 
pathogenetic mechanisms for the progression of COPD (Müller et al., 2006; Tsuji et al., 2006) 
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probably due to attenuated tissue repair capacity of senescent cells (Lee et al., 2011; Mercado et al., 
2015). Additionally, prematurely aging mouse models with increased amounts of senescent cells are 
more susceptible to cigarette smoke-induced emphysema generation (Meiners et al., 2015; Sato et 
al., 2006; Yamada et al., 2015). In further support of the notion of COPD as a disease of accelerated 
aging, almost all of the molecular mechanisms which have been described as hallmarks of aging have 
similarly been described in COPD patients (Meiners et al., 2015; Mercado et al., 2015).  
Altogether, it is obvious that similar cellular processes that contribute to aging are also involved in 
the development of chronic lung diseases such as COPD. Environmental factors such as cigarette 
smoke accelerate the aging process thereby tipping the balance from moderate lung function decline 
during healthy aging to pathologic dysfunction. Further understanding of how the different hallmarks 
of aging are interconnected and how they are affected by environmental challenges will therefore 
deepen our understanding of disease pathogenesis. 
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2 Aims of the study 
Protein quality control in the cytosol and in mitochondria is essential to maintain cellular health and 
function especially during aging. However, limited knowledge is available on how mitochondrial 
function and proteasomal function are connected in the context of chronic perturbations of 
mitochondrial function which are not associated with an increased ROS generation or an acute drop 
in ATP levels. Furthermore, it is unknown to which extent impairments of mitochondrial or 
proteasomal functions contribute tissue-specifically to the aging processes in healthy aging of the 
lung and how they are altered in response to environmental insults to the lung. 
The main hypothesis of this work is that mitochondrial and proteasomal functions are interconnected 
and that chronic mitochondrial perturbations influence the function of the proteasome system. This 
connection of mitochondrial and proteasome function is signaled by mechanisms beyond acute and 
excessive ROS production. Furthermore, it is hypothesized, that alterations in mitochondrial and 
proteasomal function contribute to the aging process in the lung during healthy aging and add to the 
development of age-related lung disease in response to environmental challenges such as cigarette 
smoke. 
Therefore, this work aims to describe the interconnection between mitochondrial dysfunction and 
proteasomal activity in model systems related to chronic mitochondrial dysfunction and independent 
of acute, pharmacological inhibition of mitochondrial function. Furthermore, this study aims to 
provide insights in the regulation of proteasomal and mitochondrial functions during healthy aging of 
the lung and in response to cigarette smoke exposure (Figure 2-1).  
 
Figure 2-1: Connecting mitochondrial and proteasomal functions in the lung 
This study aims to analyze the interconnection between mitochondrial and proteasomal function in settings of chronic 
mitochondrial dysfunction and to analyze the effect of healthy aging or environmental stress such as cigarette smoke 
exposure on mitochondrial and proteasomal function in the lung. 
To this end, the interplay of mitochondrial and proteasomal function was evaluated in a first step 
using cells with chronic mitochondrial dysfunction based on mutations in genes of the respiratory 
chain complexes. Second, to assess mitochondrial alterations in response to environmental 
challenges in the lung, the effect of cigarette smoke exposure on mitochondrial function and quality 
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control was analyzed in lung epithelial cells. Finally, the effect of proteasomal activity and 
mitochondria function on healthy aging of the lung was analyzed. Therefore, proteasomal function 
during healthy aging of the lung was comprehensively analyzed in several mouse models. 
Additionally, it was examined whether mitochondrial dysfunction in a mouse model of premature 
aging has an effect on the aging phenotype of the lung.  
Altogether, these analyses aim to provide insight into how proteasomal and mitochondrial function 
are interconnected and to describe how proteasomal and mitochondrial function contribute to aging 
phenotypes in the lung. 
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3 Materials and methods 
3.1 Materials 
3.1.1 Reagents and chemicals 
The following reagents and chemicals were used during the study: 
Table 3-1: Reagents and Chemicals 
Reagent Solvent 
Stock 
concentration 
Manufacturer 
2,5-diphenyltetrazolium bromide (MTT) PBS 5 mg/ml 
Sigma-Aldrich 
(St. Louis, MO) 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES) 
- - 
AppliChem 
(Darmstadt, Germany) 
4′,6-Diamidin-2-phenylindol (DAPI) PBS 300 nM Sigma-Aldrich 
ABT-488 DMSO 10 mM 
Enzo Life Sciences 
(Farmingdale, NY) 
Adenosine triphosphate (ATP) - - 
Roche 
(Basel, Switzerland) 
Amidoblack staining solution H2O 2x Sigma-Aldrich 
Antimycin A DMSO 50 mM Sigma-Aldrich 
Boric acid - - Applichem 
Bortezomib H2O 2.6 mM 
Millennium 
(Cambridge, MA) 
Bovine serum albumin (BSA) - - Sigma-Aldrich 
Bromophenol blue - - AppliChem 
β-mercaptoethanol - - AppliChem 
Carbonyl cyanide 3-chlorophenylhydrazone (CCCP) DMSO 25 mM Sigma-Aldrich 
Citric acid monohydrate - - AppliChem 
Complete® protease inhibitor H2O 25x Roche 
Cycloheximide DMSO 100 mM Sigma-Aldrich 
DAKO mounting medium - - 
Dako 
(Hamburg, Germany) 
Dithiothreitol (DTT) H2O 1 M AppliChem 
Dimethyl sulfoxide (DMSO) - - 
Roth 
(Karlsruhe, Germany) 
Dodecyltrimethylammonium bromide (DTAB) H2O 20 % Sigma-Aldrich 
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ECL Plus Detection Reagent - - 
GE Healthcare 
(Chalfont St Giles UK) 
Ethylenediaminetetraacetate (EDTA) - - AppliChem 
Ethyleneglycoletetraacetate (EGTA) - - AppliChem 
Eukitt - - Sigma-Aldrich 
EX-527 DMSO 10 mM Sigma-Aldrich 
Fetal bovine serum (FBS) - - 
PAA Laboratories 
(Pasching, Austria) 
Glycerol H2O 87 % AppliChem 
GSH-magnetic beads - - GE Healthcare 
H2O2 H2O 30 % AppliChem 
HCl H2O 37 % AppliChem 
KCl - - AppliChem 
Ketamin - - 
Bela Pharm 
(Vechta, Germany) 
KH2PO4 - - Sigma-Aldrich 
K-lactobionate - - Sigma-Aldrich 
KOH - - AppliChem 
MACH 2 Rabbit AP-Polymer - - 
Biocare 
(Concord, CA) 
Mannitol - - Sigma-Aldrich 
May-Grünwald staining solution - - 
Merck 
(Whitehouse Station, NJ) 
MgCl2 - - AppliChem 
MitoSOX Red® DMSO 5 mM 
Life Technologies 
(Carlsbad, CA) 
M-MLV reverse transcriptase - - Sigma-Aldrich 
NaCl - - AppliChem 
NaN3 H2O 1 M AppliChem 
NaOH - - AppliChem 
Ni-NTA beads - - 
Thermo Fisher Scientific 
(Waltham, MA) 
Nonidet P-40 - - AppliChem 
Oligomycin DMSO 5 mM Sigma-Aldrich 
Paraformaldehyde (PFA) PBS 4 % AppliChem 
Penicillin - - Life Technologies 
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Propidium Iodide Staining Solution - - 
BD Biosciences 
( San Jose, CA) 
Random hexamers - 3 µg/µl Life technologies 
Rodent Block M - - Biocare 
Rotenone DMSO 50 mM Sigma-Aldrich 
Rotiblock H2O 10x Roth 
Roti-Immunoblock H2O 10x Roth 
Sodiumdeoxycholate - - Roth 
Sodiumdodecylsulfate (SDS) - - AppliChem, 
Streptomycin - - Life Technologies 
Succinyl-leucine-leucine-valine-tyrosine-
aminoluciferin (Suc-LLVY-aminoluciferin) 
DMSO 2 mM 
Promega 
(Madison, WI) 
Succinyl-leucine-leucine-valine-tyrosine-
aminomethylcoumarine (Suc-LLVY-AMC) 
DMSO 2 mM 
Bachem 
(Bubendorf, Switzerland) 
Sucrose - - Sigma-Aldrich 
Super Signal West Femto - - Thermo Fisher Scientific 
Taurine - - Sigma-Aldrich 
Tetramethylrhodamin-methylester 
perchlorate (TMRM) 
DMSO 1 mM Life Technologies 
Tris(hydroxymethyl)-aminomethane (Tris) - - AppliChem 
Triton X-100 - - Life Technologies 
Tween-20 - - AppliChem 
Uridine H2O 100 mM Sigma-Aldrich 
Vulcan Fast Red - - Biocare 
Xylazine - - Bela Pharm 
Z-leucine-arginine-arginine-aminoluciferin (Z-LRR-
aminoluciferin) 
DMSO 2 mM Bachem 
Z-norleucine-proline-norleucine-aspartate- 
aminomethylcoumarine (Z-nLPnLD-AMC) 
DMSO 2 mM Bachem 
Z-norleucine-proline-norleucine-aspartate-
aminoluciferin (Z-nLPnLD-aminoluciferin) 
DMSO 2 mM Bachem 
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3.1.2 Buffer formulations 
The following buffers were used in the study. All buffers were prepared with MiliQ™ water if not 
stated otherwise. 
Table 3-2: Buffer formulations 
Buffer Compounds Concentration 
Annexin V binding buffer (pH 7.4) HEPES 10 mM 
NaCl 140 mM 
CaCl2 2.5 mM 
Citrate buffer pH 6 Citric acid monohydrate 1.8 mM 
Sodium citrate tribasic 8.2 mM 
FACS Buffer (in PBS) FBS 2 % 
EDTA 20 µM 
Mitochondrial isolation buffer pH 7.4 Mannitol 220 mM 
Sucrose 70 mM 
HEPES 5 mM 
EGTA 1 mM 
Native gel running buffer  Tris 89 mM 
Boric acid 89 mM 
EDTA 2 mM 
MgCl2 5 mM 
ATP 2 mM 
DTT 1 mM 
Phosphate buffered saline (PBS) pH 7.4 NaCl 137 mM 
KCl 2.7 mM 
Na2HPO4 10 mM 
KH2PO4 2 mM 
Proteasome purification buffer HEPES 25 mM 
Glycerol 10 % 
MgCl2 5 mM 
ATP 1 mM 
DTT 1 mM 
Respiration buffer pH 7.4 EGTA 0.5 mM 
MgCl2 3 mM 
K-lactobionate 60 mM 
Taurine 20 mM 
KH2PO4 10 mM 
HEPES 20 mM 
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Mannitol 110 mM 
BSA 1 g/l 
RIPA Buffer pH 7.5 Tris 50 mM 
NaCl 150 mM 
Nonidet P-40 1 % 
Sodium deoxycholate 0.5 % 
SDS 0.1 % 
SDS PAGE running buffer Tris 25 mM 
Glycin 192 mM 
SDS 0.1 % 
Solubilisation buffer Na2CO3 66 mM 
SDS 2 % 
β-mercaptoethanol 1.5 % 
Tris buffered saline and Tween (TBST) pH 7.6 Tris 20 mM 
NaCl 135 mM 
Tween-20 0.02 % 
TSDG Buffer pH 7 Tris 10 mM 
KCl 25 mM 
MgCl2 1.1 mM 
EDTA 0.1 mM 
DTT 1 mM 
NaN3 1 mM 
Glycerol 10 % 
Western blot transfer buffer Tris 25 mM 
Glycine 192 mM 
Methanol 10 % 
5x native loading buffer Tris 250 mM 
Glycerol 50 % 
Bromophenol blue 0.01 % 
6x Laemmli buffer Tris 300 mM 
Gylcerol 50 % 
SDS 6 % 
Bromophenol blue 0.01 % 
DTT 600 mM 
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3.1.3 Cigarette smoke extract preparation 
Cigarette smoke extract (CSE) was prepared by bubbling smoke from 6 cigarettes (Research-grade 
cigarettes (3R4F); Kentucky Tobacco Research and Development Center at the University of 
Kentucky) through 100 ml of FBS-free cell culture medium at constant airflow. Smoked medium was 
sterile filtered through a 0.20 µm filter (Minisart; Satorius Stedim Biotech, Göttingen, Germany), 
divided into aliquots, stored at -20°C and served as the 100 % CSE stock solution. For treatment, CSE 
was supplemented with 1 % penicillin/streptomycin and diluted with treatment medium to the 
indicated concentrations directly before use. To assure comparable potency of CSE, each stock 
solution was tested by MTT assays for having similar cytotoxicity.  
3.2 Animal experiments 
Animal experiments were conducted in collaboration with Anne Caniard and Ilona Kammerl and with 
the research groups of Ali Önder Yildirim at the Comprehensive Pneumology Center Munich and the 
research group of Aleksandra Trifunovic at the University of Cologne. 
Lung function analysis, bronchoalveolar lavage and tissue extraction of young and aged Wildtype 
(WT), ODD-luc reporter and LMP2 or LMP7 knockout mice were performed by Anne Caniard and 
Ilona Kammerl in collaboration with the research group of Ali Önder Yildirim. Maintenance of mtDNA 
mutator mice and WT controls was performed by the research group of Aleksandra Trifunovic at the 
University of Cologne. In all other cases tissue extraction and subsequent analysis was performed by 
Korbinian Berschneider. 
3.2.1 Animals and maintenance 
Female C57BL/6J mice at the age of 2 months (young) or 18 months (aged) were obtained from 
Harlan Laboratories. LMP2-/- (Psmb9tm1Stl (Van Kaer et al., 1994)) or LMP7-/- (Psmb8tm1Hjf (Fehling et al., 
1994)) mice with C57BL/6J background were obtained by courtesy of Prof. Dr. Antje Voigt (Charité, 
Universitätsmedizin Berlin) and ODD-luc reporter mice (129S6-Gt(ROSA)26Sortm1(HIF1A/luc)Kael/J (Safran 
et al., 2006)) with FVB background were bought from Jackson Laboratory (Bar Harbor, ME) and 
housed at the Helmholtz Center Munich in rooms maintained at a constant temperature and 
humidity with a 12 h light cycle. Animals were allowed food and water ad libitum. All animal 
experiments were conducted under strict governmental and international guidelines and were 
approved by the local government for the administrative region of Upper Bavaria. MtDNA mutator 
mice and WT controls were provided by Aleksandra Trifunovic from the University of Cologne and 
housed according to the standards and rules of the University of Cologne. 
For protein and RNA preparation mouse lungs were perfused with PBS before extraction. All organs 
were shock-frozen in liquid nitrogen directly after extraction and kept at -80°C until processing. For 
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embedding into paraffin, mouse lungs were fixed by intratracheal instillation of 
4 % paraformaldehyde in PBS before extraction.  
3.2.2 Lung function analyses 
Pulmonary function in mice was measured using the flexiVent system (Scireq, Montréal, Canada). 
Mice were anesthetized with ketamine-xylazine, tracheostomized and connected to the flexiVent 
system. Mice were ventilated with a tidal volume of 10 ml/kg at a frequency of 150 breaths/min in 
order to reach a mean lung volume similar to that of spontaneous breathing. Testing of lung 
mechanical properties including dynamic lung compliance and resistance was carried out by a 
software-generated script that took four readings per animal. 
3.2.3 Bronchoalveolar lavage cell analysis 
Mouse lungs were lavaged by inserting a cannula into the trachea and instilling four times 1 ml of 
ice-cold sterile PBS into the lungs. Cells in bronchoalveolar lavage fluid were counted and 30,000 cells 
were used for cytospins. Cytospins were stained according to May-Grünwald and cellular 
composition was assessed by counting approx. 100 cells per slide. 
3.3 Cell culture 
3.3.1 Isolation of primary murine alveolar type II cells (pmATII) 
PmATII cells were kindly provided by Katrin Mutze after isolation according to the following protocol:  
pmATII cells were isolated from C57BL/6N mice (Charles River GmbH, Sulzfeld, Germany) at 8-14 
weeks of age as describes previously (Corti et al., 1996; Königshoff et al., 2009). Briefly, mouse lungs 
were lavaged with 500 µl of sterile PBS twice and perfused through the right heart using 0.9 % NaCl 
solution (B. Braun Melsungen AG, Melsungen, Germany). Lungs were subsequently inflated with 
1.5 ml dispase solution (BD Biosciences) and 300 µl of 1 % low melting point agarose (Sigma-Aldrich) 
and incubated for 45 min at room temperature (RT). Lungs were minced and consecutively filtered 
through 100 µm, 20 µm, and 10 μm nylon meshes (Sefar, Heiden, Switzerland). The resulting single 
cell suspension was centrifuged at 200 g for 10 min and the cell pellet was resuspended in DMEM. 
Incubation of the single cell suspension on petri dishes coated with antibodies against CD45 and 
CD16/32 (both BD Biosciences) for 30 min at 37°C was performed for depletion of macrophages and 
lymphocytes. Non-adherent cells were collected and negative selection for fibroblasts was 
performed by adherence for 25 minutes on cell culture dishes. Again, non-adherent cells were 
collected and cell viability was determined by trypan blue exclusion. Cell purity was assessed by 
immunofluorescence staining of cytospin preparations using antibodies for proSFTPC (Merck 
Millipore, Darmstadt, Germany), panCK (Dako), CD45 (BD Biosciences), and αSMA (Sigma Aldrich). 
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pmATII cells were resuspended in DMEM supplemented with 10 % FBS, 2 mM L-glutamine, 1 % 
penicillin/streptomycin (both Life Technologies), 3.6 mg/ml glucose (Applichem), and 10 mM HEPES 
(PAA Laboratories) and cells were cultured for 24 h to allow attachment. 
3.3.2 Cell growth and maintenance 
Cells were grown at 37°C in a humidified atmosphere containing 5 % CO2. Growth medium of the 
cells was changed every two to three days. All cell lines except human dermal fibroblasts were grown 
until 100 % confluency before passaging into a new cell culture flask. Human dermal fibroblasts were 
passaged after reaching 70% confluency. 
The following growth media were used. All growth media were obtained from Life Technologies. 
Table 3-3: Cell culture media 
Cell line Medium Supplementation 
Mouse lung epithelial cell line (MLE12) 
(growth medium) 
RPMI 10 % FBS 
1 % Penicillin/Streptomycin (P/S) 
MLE12 (treatment medium) RPMI 1 % Penicillin/Streptomycin (P/S) 
pmATII (growth medium) High Glucose DMEM 10 % FBS 
1 % Penicillin/Streptomycin (P/S) 
pmATII (treatment medium) High Glucose DMEM 1 % Penicillin/Streptomycin (P/S) 
Mouse embryonic fibroblasts (MEFs) High Glucose DMEM 10 % FBS 
1 % Penicillin/Streptomycin (P/S) 
Dermal fibroblasts High Glucose DMEM 10 % FBS 
1 % Penicillin/Streptomycin (P/S) 
200 µM Uridine 
3.3.3 Cytotoxicity testing (LDH release) 
Cytotoxicity was assessed using the cytotoxicity detection kit (Roche) according to the 
manufacturer’s instructions. Cells were seeded into 6-well plates, grown to approx. 80 % confluency 
and treated for the indicated times. 15 minutes before the end of the treatment, one well was 
treated with 2 % Triton X-100 to serve as the control for maximal cellular release of Lactate 
dehydrogenase (LDH). Supernatants were collected, cleared by centrifugation, and LDH content was 
measured in technical triplicates according to the manufacturer’s instructions using a Tristar LB 941 
plate reader (Berthold Technologies, Bad Wildbad, Germany). Data were normalized as follows: 
Untreated cells were set to 0 % cytotoxicity and 2 % Triton X-100-treated cells were set to 100 % 
cytotoxicity. 
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3.3.4 Metabolic activity assay (MTT reduction) 
Metabolic activity was measured using the 2,5-diphenyltetrazolium bromide (MTT) assay. Cells were 
seeded into 24-well or 96-well plates with each sample in at least three technical replicates. Cells 
were grown for 24 h and medium was changed to 500 µl (24-well plates) or 100 µl (96-well plates) 
treatment or control medium as indicated in the figures. After treatment 100 µl (24-well plates) or 
20 µl (96-well plates) of freshly prepared thiazolyl blue tetrazolium bromide solution (5 mg/ml in 
PBS) was added to each well and cells were incubated for 30 min at 37°C. The supernatant was 
aspirated, and blue crystals were dissolved in isopropanol + 0.1 % Triton X-100. Absorbance was 
measured at 570 nm using a Tristar LB 941 plate reader.  
3.3.5 Cell proliferation assay (BrdU incorporation) 
Cell proliferation was measured using the cell proliferation BrdU ELISA kit (Roche) according to the 
manufacturer’s instruction. Cells were seeded in 96-well plates and grown for 24 h. 10 µl of BrdU 
labeling solution were added to each well and cells were incubated for 2 h. Labeling medium was 
removed and cells were incubated with 200 µl fixation solution for 30 min at RT. Afterwards, fixation 
solution was replaced by anti-BrdU solution and incubated for 90 min at RT. Cells were washed three 
times with PBS and incubated with 100 µl substrate solution. After 15 min absorbance was measured 
at 370 nm and normalized to absorption at 492 nm using a Tristar LB 941 plate reader. 
3.3.6 Live/dead assay with Annexin V/PI 
Induction of apoptosis or necrosis was analyzed by staining cells with an Annexin V antibody and 
Propidium iodide (PI). Cells were seeded into 6-well plates and grown for 24 h. Cells were then 
treated with the indicated compounds. After the treatment, cells were trypsinized, washed twice 
with PBS and resuspended in 100 µl Annexin V binding buffer. 5 µl anti-Annexin V-FITC (BD 
Biosciences) and 10 µl PI staining solution were added and cells were incubated for 15 min at room 
temperature in the dark. After the incubation time, 400 µl Annexin V binding buffer were added and 
samples were measured by flow cytometry analysis using the Becton Dickinson LSRII and analyzed 
using FlowJo software (version 7.6.5). 
3.3.7 Measurement of cellular ATP levels 
Cellular ATP levels were measured using the CellTiter-Glo assay kit (Promega, Madison, WI). Cells 
were seeded in 6-well plates and grown for 24 h. If desired, cells were then treated with the 
indicated compounds. After the treatment cells were trypsinized and 40,000 cells/well were 
transferred to a white flat bottom 96-well plate. CellTiter-Glo reagent was added and the 
luminescent signal was measured after shaking the plate thoroughly in a Tristar LB 941 plate reader. 
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3.3.8 Analysis of cellular ROS production 
Cellular ROS generation was analyzed using H2DCFDA (Life Technologies). Cells were seeded in 6-well 
plates and grown for 24 h. Cells were then stained for 30 minutes in medium containing 25 µM 
H2DCFDA. Cells were washed with PBS, trypsinized, and resuspended in 500 µl FACS Buffer. Samples 
were then analyzed by flow cytometry and ROS production was measured as mean DCF fluorescence 
intensity. 
3.3.9 Measurement of cellular NAD+ and NADH levels 
Cellular NAD+ and NADH levels were measured using the NAD/NADH-Glo assay kit (Promega) 
according to the manufacturer’s introductions. Cells were harvested, washed twice with PBS and 
40,000 cells in 50 µl PBS were transferred to a 96-well plate. Cells were lysed by addition of 50 µl 
0.2 M NaOH with 1 % Dodecyltrimethylammonium bromide (DTAB). The sample was split into two 
wells and 25 µl 0.4 M HCl were added to one part constituting the acid-treated part. The plate was 
incubated for 15 min at 60°C thereby depleting NADH in the acid-treated wells and depleting NAD+ in 
the non-treated wells. After the incubation 25 µl of 0.5 M Tris solution was added to the acid-treated 
part. The other part was treated with 50 µl 0.25 M Tris, 0.2M HCl solution. 20 µl of each well were 
transferred to a white flat bottom 96-well plate and 20 µl of NAD/NADH Glo detection reagent were 
added. Luminescence was measured in a Tristar LB 941 plate reader. The luminescence signal of the 
acid-treated wells represents the NAD+ levels while the luminescence signal of the non-treated wells 
represents the NADH levels. 
3.4 Mitochondrial function analysis 
3.4.1 Mitochondrial membrane potential analysis 
Mitochondrial membrane potential was measured by TMRM fluorescence. Cells were seeded in 
6-well plates and grown for 24 h. Cells were then treated with the indicated compounds. After the 
treatment, cells were stained for 30 minutes in medium containing 5 nM TMRM. Cells were washed 
with PBS, trypsinized, and resuspended in 500 µl FACS Buffer. Samples were then analyzed by flow 
cytometry and mitochondrial membrane potential was measured as mean TMRM fluorescence 
intensity. To ensure total depolarization CCCP was added to the samples to a final concentration of 
100 µM and measurements were repeated after 15, 30 and 60 minutes. 
3.4.2 Analysis of mitochondrial superoxide production 
Mitochondrial superoxide generation was analyzed using MitoSOX Red®. Cells were seeded in 6-well 
plates and grown for 24 h. Cells were then treated with the indicated compounds. After the 
treatment, cells were stained for 30 minutes in medium containing 5 µM MitoSOX Red. Cells were 
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washed with PBS, trypsinized, and resuspended in 500 µl FACS Buffer. Samples were then analyzed 
by flow cytometry and superoxide production was measured as mean MitoSOX fluorescence 
intensity. 
3.4.3 Analysis of mitochondrial morphology  
For mitochondrial morphology analysis cells were grown on 15 mm glass coverslips to approx. 50 % 
confluency and treated for the indicated times. After the treatment, cells were fixed with 4 % PFA for 
10 minutes, permeabilized with 0.1 % Triton X-100 in PBS and unspecific binding sites were blocked 
with Roti-Immunoblock for one hour at RT. After blocking, cells were incubated with anti-cytochrome 
c antibody (1:1000, BD Bioscience (#556432), San Jose, CA) for 2 h at RT, washed and incubated with 
an Alexa Fluor® (AF)-488-coupled secondary antibody (1:750, Life Technologies) for one hour at RT. 
All subsequent steps were performed with minimal light exposure. Cells were washed twice for 
10 min with PBS and nuclei were stained with DAPI for 5 min. Finally, cells were mounted on 
microscopic slides with fluorescence mounting medium and imaged using confocal laser-scanning 
microscopy (Zeiss LSM710, Oberkochen, Germany). 
For quantification, cells were visually categorized into three classes according to their mitochondrial 
morphology: Cells displaying an intact network of tubular mitochondria were classified as normal. 
When the network was disrupted and mitochondria appeared predominantly spherical or rod-like, 
they were classified as fragmented. Cells with considerably elongated mitochondria, which were 
more interconnected, were classified as hyperfused (Figure 3-1). The mitochondrial morphology of 
on average 100 cells per condition was determined by a blinded observer. 
 
Figure 3-1: Mitochondrial morphology classification 
Representative images of mitochondrial staining of cells categorized in the three different groups. Cells with a fragmented 
mitochondrial network showed small spherical mitochondria. Cells with a normal mitochondrial network had short tubular 
mitochondria and cells with a hyperfused network displayed elongated and highly connected mitochondria. Scale bars: 
10 µm. 
3.4.4 Analysis of cellular oxygen consumption 
Oxygen consumption in MLE12 cells was measured in an Oxygraph chamber (Oroboros Instruments, 
Innsbruck, Austria). Cells were seeded in 10 cm dishes, grown to approx. 80 % confluency and treated 
with control medium or 25 % CSE-containing medium. After 24 h of treatment, cells were washed 
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with PBS, trypsinized, and 5x106 cells were transferred in respiration buffer and added into the 
Oxygraph chamber. Oxygen consumption was measured at basal conditions (basal respiration), after 
addition of 2.5 µM oligomycin (blocking proton backflow through complex V to measure proton 
leak), after addition of 1 µM CCCP (uncoupling the respiratory chain to enable unlimited proton flow 
through the mitochondrial membrane to induce maximum respiration) and after addition of 2.5 µM 
rotenone/antimycin A (blocking complex I and III to inhibit mitochondrial respiration). These 
concentrations were also previously shown to be suitable for measuring oxygen consumption rates in 
MLE12 cells (Das, 2013). 
Oxygen consumption in mtDNA mutator MEFs and human dermal fibroblasts was measured using a 
Seahorse XF analyzer (Seahorse Bioscience) and oxygen consumption values were normalized to cell 
number as assessed by the CyQuant assay kit (Life technologies). These experiments were performed 
by Jennifer Wettmarshausen for mtDNA mutator MEFs and by Laura Kremer for human dermal 
fibroblasts. 
3.5 Protein analysis 
3.5.1 Immunohistochemistry 
For immunohistochemistry analysis of LMP2 in lung tissue, 3 μm thick mouse lung sections were 
deparaffinized in Xylene and rehydrated. Slides were incubated in solution containing 80 % methanol 
and 1.8 % H2O2 for 20 min to quench endogenous peroxidase activity. Heat-induced antigen retrieval 
was performed in citrate buffer (pH 6). Slides were washed with TBST buffer, blocked with Rodent 
Block M for 30 min, washed again and incubated for 60 min with an LMP2 specific antibody (1:500, 
Abcam, Cambridge, UK). After another washing step, slides were incubated with MACH 2 Rabbit AP-
Polymer for 30 min and washed again. Slides were incubated with Vulcan Fast Red for 12 min. 
Hematoxylin counterstaining was performed, and slides were dehydrated and mounted in Eukitt. 
Slides were evaluated using a MIRAX scanning system (Zeiss, Oberkochen, Germany). 
3.5.2 Immunofluorescence staining 
Mouse lung sections (3 μm) were deparaffinized in Xylene, rehydrated and heat-induced antigen 
retrieval was performed in citrate buffer (pH 6). Slides were washed with PBS and lungs were 
permeabilized in 0.2 % Triton X-100 in PBS for 15 minutes, blocked in Roti-Immunoblock for 1 h and 
stained over night with anti-LMP2 antibody (1:500) at 4°C. Slides were then washed again, incubated 
with an AF-647-coupled secondary antibody (1:750, Life technologies) for 1 h and with DAPI for 
30 min. Slides were mounted using DAKO immunofluorescence mounting medium and imaged using 
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confocal laser-scanning microscopy (Zeiss LSM710, Oberkochen, Germany). Images were analyzed 
using the Imaris Software (Version 8.0.3, Bitplane, Zürich, Switzerland).  
3.5.3 Preparation of protein lysates 
Prior to protein extraction, cells were trypsinized, washed with PBS and cell pellets were stored 
at -20°C until further processing. 
For disintegration of frozen mouse tissue, samples were dismembrated using a Mikro-
Dismembrator S. Tissue samples were transferred into dismambrating tubes containing a metal 
grinding ball and shaken two times using frequency of 3000 RPM for 30 seconds.  
For preparation of denatured protein lysate, cell pellets or dismembrated tissue were lysed by 
incubation in RIPA buffer supplemented with Complete® protease inhibitor cocktail for 20 minutes at 
4°C. This method was used for Western blots depicted in Figure 5-5A, Figure 5-14A, Figure 5-15A and 
Figure 5-7A. 
For preparation of native protein lysates, cell pellets or dismembrated tissue were lysed in TSDG 
buffer supplemented with Complete® protease inhibitor cocktail by subjecting them to seven cycles 
of freezing in liquid nitrogen and subsequent thawing at room temperature. This method was used 
for all protein lysates if not stated otherwise. 
Debris was removed from the protein lysate by centrifugation at 14000 rpm at 4°C for 20 min. The 
supernatant containing the protein lysate was stored at -20°C until use. Protein content was assessed 
using the Bio-Rad Quick Start Bradford protein assay (Bio-Rad, Hercules, CA) or the Pierce BCA 
protein assay kit (Thermo Fisher Scientific). 
3.5.4 Preparation of mitochondrial fractions 
Mitochondria were isolated by ultracentrifugation after cellular lysis using a cell disruption bomb 
(Parr Instruments, Moline, IL). In short, cells were seeded in 15 cm dishes, grown to 80 % confluency, 
and treated. After the treatment, cells were scraped, pelleted, and resuspended in mitochondrial 
isolation buffer supplemented with Complete® protease inhibitor cocktail. Cells were lysed by stirring 
for 15 min in a cell disruption bomb at 800 psi nitrogen pressure and subsequent rapid 
depressurizing. Cell lysates were then centrifuged at 600 g for 10 min to remove nuclei. The 
supernatant was centrifuged at 8000 g for 10 min to obtain a crude mitochondrial pellet. The 
supernatant was removed and kept as the cytosolic fraction. Light colored ER membranes were 
removed from the pellet and the mitochondrial pellet was resuspended in mitochondrial isolation 
buffer to serve as the mitochondrial fraction. Protein content in the different fractions was 
determined using the Pierce BCA protein assay kit. 
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3.5.5 Western blot analysis 
For Western blot analysis, 10-20 µg of protein lysates were mixed with 6x Laemmli buffer and 
incubated at 95°C for 5 minutes. After the incubation, samples were subjected to electrophoresis on 
7.5 % - 12 % SDS-PAGE gels and blotted onto polyvinylidenedifluoride (PVDF) membranes. 
Electrophoretic separation in SDS gels was performed at 90-130 V at room temperature and transfer 
to PVDF membranes was performed at 250 mA for 90 min at 4°C. Membranes were blocked using 
Rotiblock (Roth) and treated with antibodies using standard Western blot techniques. The ECL Plus 
Detection Reagent and Super Signal West Femto were used for chemiluminescent detection and 
membranes were analyzed using X-Omat LS films (Carestream, Rochester, NY) in a Curix 60 developer 
(Agfa, Mortsel, Belgium). Densitometry analysis was performed using the ImageLab Software (Biorad, 
Hercules, CA). 
Antibodies used were:  
Table 3-4: Antibodies used for western blotting 
Antibody Dilution Host Manufacturer Product No. 
Primary Antibodies: 
Anti-AMPKα  1:1000 Rabbit (Rb) Cell Signaling (Cambridge, UK) 5831 
Anti-AMPKβ  1:1000 Rb Cell Signaling 4150 
Anti-ATP5A  1:1000 Mouse (Ms) Abcam (Cambridge, UK) Ab14748 
Anti-Calreticulin  1:1000 Rb Cell Signaling  2891 
Anti-cleaved Caspase3 1:1000 Rb Cell Signaling 9661 
Anti-DRP1  1:1000 Rb Cell Signaling  5391 
Anti-HSP60 1:1000 Rb Cell Signaling 4870 
Anti-HSP70 1:1000 Rb Cell Signaling 4872 
Anti-HSP90 1:1000 Rb Cell Signaling 4877 
Anti-K48-Ub 1:3000 Rb Merck Millipore 05-1307 
Anti-LMP2  1:500 Rb Abcam Ab3328 
Anti-LMP7  1:500 Rb Abcam Ab3329 
Anti-MFN1 1:1000 Ms Abcam Ab57602 
Anti-MFN2 1:1000 Rb Abcam  Ab124773 
Anti-OPA1 1:5000 Rb GeneTex (Irvine, CA) GTX48589 
Anti-PA28α 1:1000 Rb Abcam Ab155091 
Anti-PA28γ 1:1000 Ms Santa Cruz Biotechnology (Dallas, TX) Sc-136025 
Anti-phospho-4EBP1 
(Thr37/46) 
1:1000 Rb Cell Signaling 2855 
Anti-phospho-AMPKα 
(Thr172) 
1:1000 Rb Cell Signaling 2535 
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Anti-phospho-AMPKβ 
(Ser108) 
1:1000 Rb Cell Signaling 4181 
Anti-phospho-DRP1 
(Ser637) 
1:1000 Rb Cell Signaling 6319 
Anti-phospho-S6 
(Ser235/236) 
1:1000 Rb Cell Signaling 4858 
Anti-PINK1 1:500 Rb Novus Biologicals (Littleton, CO) NBP1-49678 
Anti-PSMA3 1:1000 Rb Cell Signaling 2456 
Anti-PSMD11 1:1000 Rb Novus Biologicals NBP1-46191 
Anti-PSMD7  1:1000 Rb Abcam Ab11436 
Anti-S6  1:1000 Rb Cell Signaling 2317 
Anti-Sirt1 1:1000 Rb Santa Cruz Biotechnology Sc-15404 
Anti-TBP1 (Rpt5) 1:2000 Rb Bethyl Laboratories (Montgomery, TX) A303-538A 
Anti-VCP 1:1000 Rb Novus Biologicals NB100-1558 
Anti-VMS1 1:1000 Rb Cell Signaling 5937 
Anti-α1-7  1:1000 Ms Abcam  Ab22674 
Anti-α-Tubulin 1:1000 Ms GeneTex GTX628802 
Anti-β1 1:1000 Rb Santa Cruz Biotechnology Sc-67345 
Anti-β5  1:1000 Rb Santa Cruz Biotechnology  Sc-135011 
HRP conjugated anti-
GAPDH 
1:30000 Rb Cell Signaling 3683 
HRP conjugated anti-
β-Actin  
1:40000 – 
1:80000 
Ms Sigma-Aldrich A5228 
Secondary antibodies: 
HRP conjugated anti-
mouse IgG 
1:40000 Sheep  GE Healthcare NA931 
HRP conjugated anti-
mouse IgG 
1:30000-
1:50000 
Goat (Gt) Cell Signaling 7076 
HRP conjugated anti-
rabbit IgG 
1:40000 Donkey GE Healthcare NA934 
HRP conjugated anti-
rabbit IgG 
1:30000-
1:50000 
Gt Cell Signaling 7074 
 
When total protein levels were used for normalization of protein content, amidoblack staining of 
membranes was used to determine total protein amount. Therefor, membranes were incubated with 
Amidoblack staining solution (Sigma-Aldrich) for 5 min and washed with H2O until blue background 
staining disappeared. Membranes where then air dried and imaged using the ChemiDoc XRS system 
(Biorad).  
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3.5.6 Detection of oxidatively damaged proteins 
Oxidatively modified proteins were detected using the OxyBlot Protein Oxidation Detection Kit 
(Merck Millipore). 5 µl protein lysate were denatured by adding an equal volume of 12 % SDS and 
derivatized by adding 10 µl 1x 2,4-Dinitrophenylhydrazine (DNPH) solution and incubating for 15 min 
at room temperature. The derivatization reaction was stopped by adding 7.5 µl neutralization 
solution and the samples were loaded on a polyacrylamide gel. Separation by electrophoresis and 
transfer to PVDF membranes was performed using standard Western blot techniques.  
3.5.7 Proteasome activity assay 
Proteasome activity was measured with the Proteasome-Glo™ Assay System (Promega) according to 
the manufacturer’s instructions. 1-5 µg protein in native lysates were diluted to a total volume of 20 
µl and incubated with 20 µl reaction buffer containing luminescent proteasome substrates. 
Substrates used for determination of proteasome chymotrypsin-like (CT-L), trypsin-like (T-L), and 
caspase-like (C-L) activities were Succinyl-leucine-leucine-valine-tyrosine-aminoluciferin, Z-leucine-
arginine-arginine-aminoluciferin, and Z-norleucine-proline-norleucine-aspartate-aminoluciferin, 
respectively. Luminescence was measured every 5 min for 1 h in white flat bottom 96-well plates in a 
Tristar LB 941 plate reader. Blank luminescence values using substrate only were subtracted from 
each well. 
3.5.8 Native-gel proteasome analysis 
Individual proteasome complexes were separated using native gel electrophoresis. 10-20 µg protein 
were mixed with 5x native loading buffer, loaded on precast 3-8 % Tris-acetate gels (Life 
Technologies) and separated at 150 V for 4 h at 4°C. For overlay activity assay, gels were incubated 
for 30 min in 50 mM Tris containing 1 mM ATP, 10 mM MgCl2, 1 mM DTT and 0.05 mM Suc-LLVY-
AMC (for CT-L activity) or Z-nLPnLD-AMC (for C-L activity). 
For immunoblotting, gels were incubated 15 min in solubilisation buffer and blotted on PVDF 
membranes using standard Western blot techniques.  
3.5.9 Activity based probe analysis of proteasome activity 
Analysis of proteasome subunit activity was monitored by using activity based probes (ABP). The 
fluorescent compound MV151 (Verdoes et al., 2006) was used to specifically label active proteasome 
subunits in native TSDG cell lysates. Proteasome subunits were labeled by incubating protein lysates 
with 0.5 µM MV151 in 50 mM HEPES Buffer at 37°C in the dark for 1 h while shaking at 600 rpm. The 
labeling reaction was stopped by the addition of 6x SDS Laemmli buffer to a final 1x concentration. 
Samples were then subjected to a SDS gel electrophoresis and active proteasome subunits were 
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imaged using a Typhoon TRIO+ fluorescent scanner (GE Healthcare). Images were taken at 450 PTM 
and 50 μm resolution in the Cy3/TAMRA fluorescent channel and analyzed using the ImageJ 
software. To ensure equal protein loading Gels were stained with Coomassie Blue staining by 
incubation with PageBlue staining solution (Thermo Fisher Scientific) overnight. 
3.5.10 Isolation of 26S proteasomes 
26S proteasomes were isolated according to Besche et al. (2009). 300 µl of native protein lysates 
with > 2 µg/µl protein concentration were incubated with 60 µl magnetic GSH beads and 0.2 mg 
GST-UBL for 2 h at 4°C. After the incubation time, beads were captured with a magnet and the 
supernatant was removed and stored as flow through (FT). The beads were then washed four times 
with proteasome purification buffer. After the washing, 26S proteasomes were eluted from the 
beads by incubating 15 min at 4°C with 100 µl proteasome purification buffer containing 0.2 mg 
His10-UIM. The beads were captured and the eluate was kept for further purification. The elution step 
was repeated and remaining His10-UIM was cleared from the combined eluates by incubation with 
80 µl of Ni-NTA beads for 20 min at 4°C. Beads were removed by centrifuging the sample through a 
0.22µM filter (Merck Millipore) and the cleared eluates containing purified 26S proteasomes were 
used directly or stored at -20°C after supplementing with 40 % glycerol. Protein content in the 
isolated fractions was assessed using the Bio-Rad Quick Start Bradford protein assay. 
Purity of 26S isolations was analyzed by Western blot analysis and silver gel analysis of input, FT and 
26S fractions. For silver gel analysis samples were subjected to electrophoresis on 12 % SDS-PAGE 
gels (90-120 V, 1.5 h). Gels were then fixed by incubation in fixation buffer (50 % Methanol, 12 % 
Acetic acid, 0.175% Formaldehyde) washed three times for 20 min in 50 % Ethanol, incubated for 1 
min in sensitizing buffer (0.02 % Na2S2O3-solution), washed three times for 20 seconds in H2O and 
stained by incubation for 20 min in staining solution (0.2 % AgNO3, 0.028% Formaldehyde). The gel 
was then washed again three times for 20 seconds in H2O and bands were developed by incubating 
the gel in developing buffer (6 % Na2CO3, 0.0004% Na2S2O3, 0.0185 % Formaldehyde) for approx. 30 
min. Afterwards gels were washed with H2O and imaged using the ChemiDoc XRS system (Biorad). 
Appearance of distinct band patters specific for 26S proteasomes was used as control for purity of 
the isolations. 
3.5.11 Analysis of nascent protein synthesis 
Nascent protein synthesis was analyzed using the Click-iT Plus OPP Protein Synthesis Assay Kit (Life 
Technologies). Cells were seeded in black clear-bottom 96-well plates and left over night to attach to 
the plate. Cells were then treated with control medium or with medium containing 100 µM 
cycloheximide for 4 h at 37°C. After the treatment, medium was removed and cells were incubated 
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with growth medium containing 20 µM Click-iT O-propargyl-puromycin (OPP) reagent for 30 min at 
37°C. Next, medium was removed, cells were washed with PBS and fixed with 4 % PFA for 15 min at 
RT. After fixation, cells were permeabilized in 0.5 % TritonX-100 in PBS for 15 min, washed twice with 
PBS and stained by adding 50 µl AF-647 picolyl azide containing Click-iT Plus OPP reaction cocktail per 
well and incubating for 30 min at RT. Afterwards, cells were washed with PBS and nuclei were stained 
by incubation with HCS NuclearMask Blue Stain in PBS for 30 min. Cells were washed again twice 
with PBS and fluorescence was measured using the LSM710 fluorescence microscope (Zeiss). Protein 
synthesis was measured as the mean intensity of the red signal and normalized to cell number 
assessed by the blue NuclearMask signal. 
3.6 Quantitative real-time RT-PCR analysis 
Total RNA from tissue was isolated using Roti-Quick-Kit (Roth) and peqGOLD Total RNA Kit (Peqlab, 
Erlangen, Germany). Total RNA from cells was isolated using Roti-Quick-Kit. 100-1000 ng per sample 
of total RNA were reverse transcribed using random hexamers and M-MLV reverse transcriptase. 
Quantitative PCR was performed using the SYBR Green LC480 System (Roche Diagnostics, Mannheim, 
Germany). The following gene-specific primers were used: 
Table 3-5: Mouse primers for qPCR 
Gene name Forward Primer (5‘-3‘) Reverse Primer (5‘-3‘) 
DRP1 AGGAGATGCAGAGGATCATTCAG ATCAGCAAAGTCGGGGTGTT 
MFN1 TGTGTTCGGATTTTCAAGAGGACA CTCCTGGGCTGCATTATCCG 
MFN2 CATGTCCACGATGCCCAAC GACAAAGTGCTTGAGAGGGG 
OPA1 ATGATTGGGCCAGACTGGAA AGGTAAGCTGGGTGCTCATC 
P16 TCGTGAACATGTTGTTGAGGC CTACGTGAACGTTGCCCATC 
P21 CGGTGTCAGAGTCTAGGGGA AGAGACAACGGCACACTTTG 
PSMA3 TGAAGAAGGCTCCAATAAACGTCT AACGAGCATCTGCCAGCAA 
PSMB10 GAAGACCGGTTCCAGCCAA CACTCAGGATCCCTGCTGTGAT 
PSMB5 TGCTCGCTAACATGGTGTATCAGTA GGCCTCTCTTATCCCAGCCA 
PSMB6 AGACGCTGTCACTTACCAACTTGG AAGAGACTGGCGGCTGTGTG 
PSMB7 TGCCTTATGTCACCATGGGTTC TTCCTCCTCCATATCTGGCCTAA 
PSMB8 TGCTTATGCTACCCACAGAGACAA TTCACTTTCACCCAACCGTC 
PSMB9 GTACCGTGAGGACTTGTTAGCGC GGCTGTCGAATTAGCATCCCT 
PSMC2 TCCTAAGATCGACCCAACAGTTACC TTCCTTACAGCCACCAACATCA 
PSMC3 AAGCTGAGCAAGATGGCATT TTCATGGGTGACTCGCAATA 
PSMD11 GAATGGGCCAAATCAGAGAA TGTACTTCCACCAAAAGGGC 
PSME1 AGGCTTCCACACGCAGATCT ACCAGCTGCCGATAGTCACC 
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PSME2 CCAGATCCTCCACCCAAGGA CCGGGAGGTAGCCACACTTA 
PSME3 TAGCCACGATGGACTGGATG CACAAACACCTTGGTTCCTTGAA 
PSME4 CATCCTTCAAATAATGGGCG AAGCTTATGGCTTTCAGGCA 
 
3.7 Statistical analysis 
One-way ANOVA with Dunnett’s multiple comparison test or student’s t-test was used for statistical 
analysis of mitochondrial membrane potential, mitochondrial superoxide production or ATP levels. 
Two-way ANOVA with Bonferroni multiple comparison test or one-way ANOVA with Dunnett’s 
multiple comparison test was used for statistical analysis of mRNA expression, protein synthesis or 
proteasome activity. Differences in lung function were evaluated using student’s t-test. Differences in 
protein expression data were evaluated using t-test or one-way ANOVA with Dunnett’s multiple 
comparison test or two-way ANOVA with Bonferroni multiple comparison test. Alterations in 
mitochondrial morphology were analyzed using the chi-square test. All statistical analysis was 
performed using GraphPad Prism software (version 5.00). Significance was indicated in the figures as 
*: p<0.05, **: p<0.01 or ***: p< 0.001. 
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4 The effect of mitochondrial dysfunction on proteasome 
activity and composition 
Parts of this chapter have been prepared for publication as:  
Berschneider K., Kremer L., Meul T., Kukat A., Wettmarshausen J., von Törne C., Hauck S., Geerlof A., 
Perrochi F., Trifunovic A., Eickelberg O., Prokisch H., Meiners S. (2016). Genetic dysfunction of the 
mitochondrial respiratory chain impairs proteasome activity. 
Berschneider K., Meul T., Kukat A., Eickelberg O., Trifunovic A., Meiners S. (2016). Loss of 26S 
proteasome activity induces resistance to proteasome inhibition independent of 19S subunit 
expression.  
4.1 Introduction 
Mitochondrial and proteasomal functions are important determinants of cellular health. Since both 
systems readily adapt to environmental stress and cellular alterations, it can be speculated that 
mitochondrial and proteasomal functions also adapt to changes in the respective other system. 
However, surprisingly little is known about how mitochondrial and proteasomal functions are 
connected especially in the context of chronic alterations of their function. As outlined in paragraph 
1.3, mitochondrial ROS production is a potential mechanism on how mitochondrial dysfunction 
affects proteasomal function. However, mitochondrial dysfunction does not necessarily induce an 
increase in cellular ROS burden. Especially, in the context of aging, cells of the premature aging 
mtDNA mutator mouse model show a prominent mitochondrial dysfunction without increased 
cellular or mitochondrial ROS production (Trifunovic et al., 2005). MtDNA mutator mice express a 
modified version of the mitochondrial DNA polymerase subunit γ (PolG) with an amino acid 
substitution in the second exonuclease domain of PolG (D257A). This amino acid substitution induces 
a proofreading deficiency of PolG without affecting its DNA synthesis capacity (Trifunovic et al., 
2004). Mice homozygous for the mtDNA mutator allele show a prominent premature aging 
phenotype with first signs of aging beginning at 25 weeks of age. These mice develop a plethora of 
aging phenotypes such as kyphosis, alopecia, greying of hairs, weight loss, anemia and die 
prematurely with a median lifespan of 48 weeks (Trifunovic et al., 2004). The premature aging 
phenotype was associated with a strongly increased mutation load in mtDNA and decreased 
respiratory chain activity in mtDNA mutator mice (Trifunovic et al., 2004). Importantly, accumulating 
mtDNA mutations did not induce increased mitochondrial ROS production despite pronounced 
respiratory chain dysfunction in mtDNA mutator mice cells and tissue (Trifunovic et al., 2005). 
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Therefore, this model can be used to assess ROS-independent effects of mitochondrial dysfunction 
on proteasome function.  
To understand how mitochondrial respiratory dysfunction affects the proteasome, the function of 
the proteasome system was assessed in embryonic fibroblasts from mtDNA mutator mice and in 
human dermal fibroblasts harboring mutations in respiratory chain subunits. Additionally, activation 
of several possible signaling pathways such as ROS, ATP, or NADH signaling was analyzed and its 
effect on proteasome activity was assessed.  
4.2 Results 
To investigate the effect of mitochondrial dysfunction on the proteasome system, first mitochondrial 
dysfunction was confirmed in mtDNA mutator MEFs (Mut). Mitochondrial oxygen consumption was 
almost completely abolished in mtDNA mutator MEFs indicating a pronounced respiratory chain 
dysfunction (Figure 4-1A&B). Indeed, mtDNA mutator MEFs are unable to use mitochondria for ATP 
production as shown by the strongly impaired mitochondrial ATP production as estimated by the 
decrease in oligomycin-sensitive respiration (Figure 4-1C). Beside the strong respiratory dysfunction, 
mitochondrial membrane potential was unchanged between wildtype (WT) and mtDNA mutator 
MEFs (Figure 4-1D) indicating that other mitochondrial functions such as protein import and export 
or mitochondrial fusion and fission might still be functional. The function of the mitochondrial 
membrane potential specific probe TMRM was confirmed by adding CCCP to the samples and 
measuring residual fluorescence after 15 and 30 min (Figure 4-1E). 
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Figure 4-1: Mitochondrial respiration is decreased in mtDNA Mutator MEFs 
(A) Cellular oxygen flux under basal conditions, after addition of oligomycin (proton leak), CCCP (maximum respiration), or 
antimycin A and rotenone (non-mitochondrial respiration) analyzed using the Seahorse XF analyzer. Curves show mean 
values from three independent wildtype (WT) or four independent mtDNA mutator (Mut) MEF lines. (B) Mean oxygen 
consumption rate in WT (n=3) and mtDNA mutator (n=4) MEFs. Significance was determined using two-way ANOVA with 
Bonferroni multiple comparison test. *:p< 0.05, ***:p< 0.001. (C) Mitochondrial ATP production (oligomycin-sensitive 
respiration) in WT (n=3) and mtDNA mutator (n=4) MEFs. Significance was determined using student’s t-test. ***:p< 0.001. 
(D) Mean fluorescence intensity of WT (n=3) and mtDNA mutator (n=4) MEFs stained with TMRM for assessment of 
mitochondrial membrane potential measured by flow cytometry analysis. (E) Representative measurement of TMRM 
fluorescence before and after addition of CCCP to ensure specificity for mitochondrial membrane potential. Values are 
displayed as mean+SEM. Analysis of mitochondrial oxygen consumption was performed in collaboration with Jennifer 
Wettmarshausen. 
In accordance with unaltered mitochondrial fusion and fission dynamics, as indicated by the stable 
membrane potential of mtDNA mutator MEFs, no significant differences in mitochondrial 
morphology were observed between WT and mtDNA mutator MEFs (Figure 4-2). 
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Figure 4-2: Mitochondrial morphology is not altered in mtDNA mutator MEFs 
Representative immunofluorescence pictures of WT and mtDNA mutator MEFs stained with anti-cytochrome c antibody. 
To further characterize mtDNA mutator MEFs, cellular growth and metabolic activity as well as 
cellular protein homeostasis were analyzed. Interestingly, mtDNA mutator MEFs showed no reduced 
growth or overall metabolic activity as analyzed by BrdU incorporation or MTT reduction, 
respectively (Figure 4-3A&B). Moreover, no broad proteostasis failure was observed in mtDNA 
mutator MEFs as expression of the chaperones HSP70 and HSP90 was not affected by the mutator 
phenotype (Figure 4-3C). Similarly, no accumulation of polyubiquitinated proteins was observed in 
mtDNA mutator MEFs (Figure 4-3D). 
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Figure 4-3: Cellular growth and protein homeostasis are not altered in mtDNA mutator MEFs 
(A) BrdU incorporation and (B) MTT assay of WT (n=3) and mtDNA mutator (n=4) MEFs. (C) Representative Western blot 
analysis of HSP70 and HSP90 expression in WT and mtDNA mutator MEFs. Actin was used as a loading control. 
Densitometric analysis shows mean+SEM of three independent WT and four mutator MEFs lines. Values are displayed as 
fold changes relative to WT. (D) Representative Western blot analysis of K48-linked ubiquitin levels in WT and mtDNA 
mutator MEFs. Densitometric analysis shows mean+SEM of three WT and four mutator MEF lines and was normalized to 
total protein levels as determined by amidoblack staining. 
4.2.1 Proteasome activity is decreased in mtDNA mutator MEFs 
To analyze the effect of respiratory chain failure on the proteasome, the activity of the catalytic 
active sites of the proteasome was measured by cleavage of luminogenic model substrates. Activity 
of all three active sites of the proteasome was significantly attenuated in mtDNA mutator MEFs 
compared to WT MEFs indicating a pronounced effect of mitochondrial dysfunction on the 
proteasome in this model (Figure 4-4). 
 
Figure 4-4: Proteasome activity is decreased in mtDNA mutator MEFs 
Cleavage of luminogenic model substrates specific for the CT-L, C-L, or T-L active site of the proteasome in WT (n=3) and 
mtDNA mutator (n=4) MEFs. Bar graphs show mean fold change relative to WT. Significance was determined using two-way 
ANOVA with Bonferroni multiple comparison test. *:p< 0.05. 
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To assess whether the decreased proteasome activity is associated with decreased proteasome 
levels, expression of total proteasome subunits was analyzed. In contrast to the changes in 
proteasome activity, no significant alterations were observed for mRNA or protein expression of 
subunits of the 20S core particle and the 19S regulatory particle (Figure 4-5). 
 
Figure 4-5: Proteasome expression is not altered in mtDNA mutator MEFs 
(A) Representative Western blot analysis of 20S (α1-7, β5) and 19S (Rpn6, Rpn8) subunit expression in WT and mtDNA 
mutator MEFs. Actin was used as a loading control. Densitometric analysis shows mean+SEM from three WT or four mtDNA 
mutator MEF lines. (B) RT-qPCR analysis of proteasome subunit mRNA expression levels in WT (n=3) and mtDNA mutator 
(n=4) MEFs. Bar graphs show mean+SEM relative to WT. 
4.2.2 Assembly of 26S and 30S proteasome complexes is decreased in 
mtDNA mutator MEFs 
Proteasomal activity is mainly regulated by attachment of the 19S regulatory particle to the 20S 
proteasome core. To test whether 26S or 30S proteasome assembly is impaired in mtDNA mutator 
MEFs, native gel analysis of proteasome complexes was performed. Interestingly, 20S proteasome 
activity and complex levels were unaltered in mtDNA mutator MEFs (Figure 4-6A-C). 20S complex 
levels even tended to be increased in mtDNA mutator MEFs which was, however, not statistically 
significant. In contrast, attachment of the 19S regulatory particle to one or both ends of the 20S core 
particle was significantly reduced in mtDNA mutator MEFs, resulting in decreased levels and activity 
of assembled 26S and 30S proteasome complexes (Figure 4-6A-C). 
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Figure 4-6: 26S and 30S proteasome assembly is impaired in mtDNA mutator MEFs 
(A) Representative native gel analysis of proteasome complexes activity in cell lysates from WT and mtDNA mutator MEFs. 
Panels show CT-L activity overlay of native gels and α1-7 immunostaining after immunoblotting of the native gels. 
(B) Quantification of CT-L activity and (C) α1-7 immunostaining in native gel assays. Bar graphs show mean+SEM. 
n=3(WT) - 4(Mut). Significance was determined using student’s t-test comparing WT vs. Mut cells. *:p< 0.05, ns: non-
significant. 
To assess whether association with alternative regulators is altered in mtDNA mutator MEFs, levels 
of PA28α and PA28γ in whole cell lysates and in association with isolated 26S proteasomes were 
analyzed. Purity of isolated 26S fractions was confirmed by silver gel and western blot analysis. 
Isolated 26S preparations showed a 26S specific band pattern in the silver gel analysis (Figure 4-7A) 
and were strongly enriched for both 20S as well as 19S subunits (Figure 4-7B). While no significant 
expressional changes of PA28α or PA28γ were observed in total cell lysate (Figure 4-8A), PA28γ levels 
were significantly decreased in fractions of isolated 26S proteasome (Figure 4-8B). Decreased 
association of PA28γ with proteasome complexes was further confirmed by immunoblotting of 
native gels for PA28γ (Figure 4-8C). 
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Figure 4-7: Isolation of 26S proteasomes 
(A) Representative silver gel analysis of input, flow through (FT) or isolated 26S fractions showing a distinct band pattern for 
isolated 26S proteasomes. Molecular weight (MW) is given according to a molecular weight standard. (B) Representative 
western blot analysis for 20S (α1-7), 19S (Rpt5) or cytosolic (GAPDH) marker proteins in 26S isolations.  
 
Figure 4-8: Decreased association of proteasome complexes with PA28γ in mtDNA mutator MEFs 
Representative Western blot analysis and quantification of PA28α and PA28γ in (A) whole cell lysates and (B) 26S isolations 
from WT (n=3) and mtDNA mutator (n=4) MEFs. Actin was used as loading control in whole cell lysates and Rpt5 was used 
in 26S preparations. Significance was determined using two-way ANOVA with Bonferroni multiple comparison test. 
*:p< 0.05 (C) Representative immunoblot and quantification of PA28γ in native gel assays. Bar graphs show mean+SEM. 
n=3(WT) - 4(Mut). Significance was determined using student’s t-test comparing WT vs. Mut cells. *:p< 0.05, **:p< 0.01. 
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In summary, mtDNA mutator MEFs show pronounced dysfunction of the mitochondrial respiratory 
chain which is associated with reduced assembly and activity of 26S and 30S proteasomes and PA28γ 
containing alternative proteasome complexes. Importantly, as the amount of active 20S proteasome 
complexes is not increased in mtDNA mutator MEFs, diminished 26S and 30S formation is not due to 
disassembly of these complexes. Moreover, it is not dependent on expressional regulation of 20S or 
19S proteasome subunits. 
4.2.3 Mitochondria to proteasome signaling in mtDNA mutator MEFs 
Attachment of regulatory particles to the proteasome core particle is suggested to be dynamically 
regulated to allow the cell to adapt proteasome activity to cellular needs (Meiners et al., 2014). To 
assess the underlying mechanisms of mitochondria to proteasome signaling several signaling 
pathways were analyzed for being affected by mitochondrial dysfunction and affecting proteasome 
activity in mtDNA mutator MEFs. As outlined in paragraph 1.3.2, mitochondrial damage can result in 
elevated leakage of electrons in the respiratory chain and thereby increased generation of ROS. 
However, as also published previously, mtDNA mutator MEFs do not show increased mitochondrial 
ROS production (Trifunovic et al., 2005). These data were confirmed in this study: No change was 
found in the levels of mitochondrial superoxide (Figure 4-9A) or overall cellular ROS (Figure 4-9B) in 
mtDNA mutator MEFs compared to WT MEFs. Accordingly, the amount of proteins containing 
oxidative modifications was not significantly changed in mtDNA mutator MEFs as assessed by oxyblot 
analysis (Figure 4-9C). Furthermore, treatment of mtDNA mutator MEFs with the antioxidant N-
acetylcysteine did not have any effect on proteasome activity in these cells (Figure 4-9D&E). These 
data support the notion that impaired proteasome activity is not due to ROS-mediated signaling in 
mtDNA mutator MEFs.  
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Figure 4-9: No elevated ROS production in mtDNA mutator MEFs 
Flow cytometry analysis of WT and mtDNA mutator MEFs stained with (A) MitoSOX Red for detection of mitochondrial 
superoxide generation, n=3 (WT) - 4(Mut) +SEM, or (B) H2DCFDA for detection of cellular ROS. n=2+SEM. (C) Representative 
Oxyblot image and quantification of oxidatively modified proteins from WT (n=3) and mtDNA mutator (n=4) MEFs. (D) CT-L 
proteasome activity in WT (n=3) and mtDNA mutator (n=4) MEFs after treatment with control or 5 mM NAC-containing 
medium for 2 h. Bars show mean+SEM. Values were displayed as fold change relative to WT. (E) CT-L proteasome activity in 
5 mM NAC treated WT (n=2) and mtDNA mutator MEFs (n=2) over a time-course of 24 h.  
26S and 30S proteasome activity is dependent on the availability of ATP and disassembly of 19S and 
20S particles was observed in the absence of ATP (Liu et al., 2006a). However when ATP levels were 
analyzed in WT and mtDNA mutator MEFs no change in total cellular ATP was observed indicating 
absence of an obvious difference in ATP availability (Figure 4-10A). Since measurement of total ATP 
levels only reflects the steady state in the cells, additionally activation of the cellular ATP sensor 
AMPK was analyzed. AMPK is the major energy sensing molecule in the cell and is activated by 
increased phosphorylation in response to low ATP availability (Hardie et al., 2012). Hence, AMPK 
activation reflects a low energy status in the cell and low availability of ATP. Thereby it would reflect 
the physiological situation much more than the measurement of steady state ATP levels. However, 
no difference in phosphorylation of the AMPK α or β subunits was observed in WT and mtDNA 
mutator MEFs (Figure 4-10B) indicating absence of AMPK activation. 
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Figure 4-10: No alterations in ATP availability in mtDNA mutator MEFs 
(A) Relative ATP levels in WT and mtDNA mutator MEFs. (B) Representative Western blot analysis for phosphorylated and 
total AMPKα and AMPKβ and quantification of phosphorylated/total AMPKα or AMPKβ levels in WT (n=3) and mtDNA 
mutator (n=4) MEFs. 
Beside ATP, also the metabolic mediator NADH was shown to affect proteasome function (Tsvetkov 
et al., 2014). Since NADH is the main substrate for the mitochondrial respiratory chain and 
mitochondria are the major producer of NADH in the cell (Nunnari and Suomalainen, 2012), it was 
analyzed if changes in NAD+ or NADH occur in mtDNA mutator MEFs and whether these might be 
responsible for mitochondria to proteasome signaling. While no changes in NAD+ levels were 
observed in mtDNA mutator MEFs, NADH levels were significantly increased compared to WT cells 
(Figure 4-11). Accordingly, the NAD+/NADH ratio was significantly decreased in mtDNA mutator 
MEFs. 
 
Figure 4-11: NADH levels are increased in mtDNA mutator MEFs 
NAD+ and NADH levels and the resulting NAD+/NADH ratio in WT (n=3) and mtDNA mutator (n=4) MEFs. Significance was 
determined using student’s t-test comparing WT vs. Mut cells. *:p< 0.05. 
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To analyze whether the alteration in NADH levels is responsible for the observed change in 
proteasome activity in mtDNA mutator MEFs, NAD+ and NADH levels were modified by treating the 
cells with the NAD+ precursor nicotinamide (NAM) or with the NAD+ salvage pathway inhibitor FK866. 
NAD+ can be biosynthetically generated by the cell using NAM as a precursor, while FK866 inhibits 
this biosynthetic pathway (Stein and Imai, 2014). Hence, treatment with NAM is expected to increase 
NAD+ and NADH levels while FK866 is expected to reduce NAD+ and NADH levels. Indeed, treatment 
of cells with NAM increased NAD+ and NADH levels, while FK866 treatment reduced NAD+ and NADH 
levels both in WT and mtDNA mutator MEFs (Figure 4-12A) indicating that NAD+ and NADH levels can 
be experimentally modified in these cells. However, neither treatment with FK866 nor with NAM 
induced any changes in proteasome activity of WT or mtDNA mutator MEFs (Figure 4-12B) indicating 
that reduced proteasome activity is independent of NAD+ or NADH levels. 
 
Figure 4-12: Alterations in NAD+ or NADH levels do not affect proteasome activity 
(A) NAD+ and NADH levels in WT (n=2) and mtDNA mutator (n=2) MEFs in response to treatment with 5 mM NAM or 5 nM 
FK866 for the indicated times. Values are displayed as fold change relative to untreated WT or mtDNA mutator MEFs, 
respectively. (B) CT-L proteasome activity in WT (n=2) and mtDNA mutator (n=2) MEFs after treatment with NAM or FK866 
for the indicated times. Bar graphs show mean+SEM. Values are displayed as fold change relative to WT Ctrl. 
NAD+ is the main cofactor for enzymes of the Sirtuin deacetylase family and the poly(ADP-
ribose)polymerase (PARP) family. Hence, it was additionally investigated whether Sirtuin or PARP 
activity might be changed by alterations in NAD+/NADH ratios, which might thereby indirectly affect 
proteasome function in mtDNA mutator MEFs. To analyze the effect of altered Sirtuin or PAPR 
activity on proteasome activity, WT and mtDNA mutator MEFs were treated with the PARP inhibitor 
ABT-488 or the Sirtuin inhibitor EX-527 and proteasome activity was assessed in response to the 
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treatment. However, proteasome activity did neither change in WT nor in mtDNA mutator MEFs 
upon treatment with ABT-488 or EX-527 (Figure 4-13) indicating that reduced proteasome activity in 
mtDNA mutator MEFs is not dependent on PARP or Sirtuin activity. 
 
Figure 4-13: Inhibition of Sirtuin or PARP activity does not affect proteasome activity 
CT-L proteasome activity in WT (n=2) and mtDNA mutator (n=2) MEFs after treatment with 10 µM ABT-488 (PARP inhibitor) 
or 10 µM EX-527 (Sirtuin inhibitor) for the indicated times. Bar graphs show mean+SEM. Values are displayed as fold change 
relative to WT Ctrl. 
In summary, impaired 26S and 30S proteasome activity in mtDNA mutator MEFs is most probably not 
mediated by changes in ROS signaling, ATP signaling or NADH signaling since no differential activation 
of ROS or ATP signaling was found between WT and mtDNA mutator MEFs. Furthermore, 
experimentally modulation of ROS- or NAD+/NADH-dependent signaling pathways did not show any 
effect on proteasome activity in both WT and mtDNA mutator MEFs.  
4.2.4 Increased resistance against proteasome inhibition in mtDNA 
mutator MEFs 
To analyze whether the impairment of proteasome function in mtDNA mutator MEFs decreases the 
spare proteolytic capacity of the cells and renders the cells more susceptible to further proteotoxic 
stress, WT and mtDNA mutator MEFs were treated with the proteasome inhibitor bortezomib and 
the dose-dependent effects on cell viability were analyzed. Unexpectedly, mtDNA mutator MEFs 
showed an increased resistance to bortezomib, as higher doses of bortezomib were necessary to 
decrease mtDNA mutator MEF viability to a similar extent as in WT cells (Figure 4-14A). Furthermore, 
similar doses of bortezomib induced less apoptosis in mtDNA mutator MEFs compared to WT MEFs 
as revealed by Annexin V/PI staining (Figure 4-14B&C). 
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Figure 4-14: Increased resistance to bortezomib in mtDNA mutator MEFs 
(A) MTT assay of WT (n=3) and mtDNA mutator (n=4) MEFs treated with the proteasome inhibitor bortezomib for 24 or 
48 h. Values were normalized to the control-treated group (0 nM bortezomib) and are displayed as mean+SEM. Significance 
was determined using two-way ANOVA with Bonferroni multiple comparison test. *:p< 0.05, **:p< 0.01, ***:p< 0.001. 
(B) Representative flow cytometry analysis of Annexin V and PI staining of 24 h 25 nM bortezomib (Bz) or control-treated 
WT and mtDNA mutator MEFs. (C) Quantification of healthy (Annexin V-/PI-), early apoptotic (Annexin V+/PI-), late apoptotic 
(Annexin V+/PI+), or necrotic (Annexin V-/PI+) cells after 24 h of 25 nM Bz or control treatment in WT (n=3) and mtDNA 
mutator (n=4) MEFs. Bar graphs show mean+SEM. Significance was determined using student’s t-test. *:p< 0.05. 
Importantly, the increase in bortezomib resistance was not due to a generally increased resistance to 
apoptosis as cellular viability in response to H2O2 treatment did not differ between WT and mtDNA 
mutator MEFs (Figure 4-15). 
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Figure 4-15: No change in cell viability of WT and mtDNA mutator MEFs in response to H2O2-induced apoptosis 
MTT assay of WT (n=3) and mtDNA mutator (n=4) MEFs treated with H2O2 for 24 h or 48 h. Values were normalized to the 
control-treated group (0 µM H2O2) and are displayed as mean+SEM.  
Altogether, these data show that despite decreased 26S and 30S proteasome activity, mtDNA 
mutator MEFs are less sensitive to proteotoxic stress as induced by bortezomib-mediated 
proteasome inhibition. This effect is specific to proteasome inhibitor-induced apoptosis and does not 
account for a generally altered susceptibility to apoptosis. 
4.2.5 Protein synthesis is decreased in mtDNA mutator MEFs 
Proteasomal activity is coupled to cellular protein synthesis (Kalapis et al., 2015; Zhang et al., 2014; 
Zhao et al., 2015) and a large fraction of newly synthesized polypeptides are directly degraded by the 
proteasome (Schubert et al., 2000). Furthermore, attenuation of general protein synthesis is a 
common part of the cellular stress response, e.g. during oxidative stress or ER stress (Grant, 2011; 
Logue et al., 2013). Therefore, it was analyzed if decreased protein degradation in mtDNA mutator 
MEFs is also coupled with protein synthesis. Indeed, the overall level of protein synthesis was 
reduced in mtDNA mutator MEFs while the protein synthesis inhibitor cycloheximide effectively 
abolished protein synthesis in both WT and mtDNA mutator MEFs (Figure 4-16). 
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Figure 4-16: Protein synthesis is reduced in mtDNA mutator MEFs 
(A) Representative fluorescent images showing nascent protein synthesis (OPP+-AF-647 fluorescence: red) and nuclear 
staining (blue) of WT and mtDNA mutator MEFs after 4h control (Ctrl) or 100 µM cycloheximide (CHX) treatment. Scale 
bars: 100 µm. (B) Quantification of protein synthesis in WT (n=3) and mtDNA mutator (n=4) MEFs after 4h control or 
100 µM CHX treatment. Bar graphs show mean+SEM. Values are displayed as fold change relative to WT controls. 
Significance was determined using two-way ANOVA with Bonferroni multiple comparison test. *:p< 0.05. 
The mTOR complex is a major metabolic sensor in mammalian cells with the mTOR complex 1 
(mTORC1) being a master regulator of protein synthesis (Laplante and Sabatini, 2009). Accordingly, it 
was analyzed if mTORC1 signaling is changed in mtDNA mutator MEFs by analyzing phosphorylation 
of the mTORC1 downstream target proteins 4EBP1 or S6 ribosomal protein. However, despite 
decreased protein synthesis, no significant change was observed in the level of phosphorylated 
4EBP1 (Figure 4-17). Additionally, even though total levels of S6 ribosomal protein were decreased in 
WT cells, changes in the ratio of phosphorylated to total S6 between WT and mutator cells did not 
reach statistical significance (Figure 4-17). 
 
Figure 4-17: mTORC1 signaling is not altered in mtDNA mutator MEFs 
(A) Representative Western blot analysis for phosphorylated 4EBP1 and phosphorylated- or total S6 ribosomal protein. 
(B) Quantification of phospho-4EBP1/Actin and phosphor-S6/S6 levels in WT (n=3) and mtDNA mutator (n=4) MEFs. 
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4.2.6 Human dermal fibroblasts harboring mutations in single respiratory 
chain genes show differentially altered proteasome activity 
To investigate whether impaired proteasome activity is also observed in patients who suffer from 
mitochondrial mutations in respiratory chain genes and to analyze if also single mutations in the 
mitochondrial respiratory chain caused alterations in proteasomal function, human dermal 
fibroblasts from patients with mitochondrial disorders were analyzed. These human fibroblasts 
harbor mutations in single mitochondrial genes, which were encoded either in nuclear DNA or in 
mtDNA. Two independent cell lines without any mutations (Control), one cell line with an 
uncharacterized mutation (unknown) and one cell line with a mutation in the Tango2 gene which is 
not involved in the mitochondrial respiratory chain were used as controls. The respective gene 
mutations of the obtained fibroblast lines are displayed in Table 4-1. 
Table 4-1: Mitochondrial gene mutations in human dermal fibroblasts lines used in the study 
Gene name Protein name Molecular function Location 
NDUFB3 NADH:ubiquinone oxidoreductase subunit B3 
Subunit of respiratory 
chain complex I 
Nuclear DNA 
ND5 
Mitochondrially encoded NADH 
dehydrogenase 5 
Subunit of respiratory 
chain complex I 
mtDNA 
unknown uncharacterized unknown unknown 
Tango2 Transport and golgi organization 2 homolog β-oxidation Nuclear DNA 
 
Mitochondrial oxygen consumption was strongly decreased in fibroblasts with mutations in NDUFB3 
and ND5. Fibroblasts with other mutations and also control cells showed no reduction in oxygen 
consumption (Figure 4-18A). Mitochondrial superoxide generation was significantly increased in 
fibroblasts with mutations in the NDUFB3 gene but not in any other cell line independent of the 
respective mitochondrial respiratory chain dysfunction. Treatment of control fibroblast with 
antimycin A induced a strong increase of superoxide production reaching levels which were 
additionally elevated compared to NDUFB3 fibroblasts (Figure 4-18B). 
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Figure 4-18: Mitochondrial function in human dermal fibroblast lines 
(A) Relative rotenone-sensitive oxygen consumption rate in human dermal fibroblast lines. n=8+SEM. (B) Flow cytometry 
analysis of MitoSOX Red fluorescence for detection of mitochondrial superoxide generation in human dermal fibroblasts. 
Control cells treated with 50 µM antimycin A for 30 min (C + AMA) were used as a positive control. n=3-6. Bar graphs show 
mean+SEM. Values are displayed relative to control cells. Analysis of mitochondrial oxygen consumption was performed by 
Laura Kremer. Significance was determined using one-way ANOVA with Dunnett’s multiple comparison test comparing all 
groups vs. control group. **:p< 0.01, ***: p< 0.001. 
Proteasome activity was slightly but significantly decreased in NDUFB3 and ND5 cells as determined 
by analysis of the cleavage of CT-L specific luminescent probes (Figure 4-19A). These results were 
confirmed by activity based profiling of overall proteasome activity which also showed a trend 
towards decreased activity in NDUFB3 and ND5 cells (Figure 4-19B).  
 
Figure 4-19: Proteasome activity in human dermal fibroblast lines 
(A) Cleavage of luminogenic model substrates specific for the chymotrypsin-like active site of the proteasome in human 
dermal fibroblasts. n=10(Control) - 5(Mutants) +SEM. (B) Representative ABP gel of human dermal fibroblasts resolving 
individual bands for β2 and β2i and overlapping bands for β1 and β5i as well as for β1i and β5. Coomassie staining was used 
to ensure equal loading. Quantification shows combined proteasome activity of all active sites. Bar graphs show mean fold 
change relative to control. n=6(Control) - 3(Mutants) +SEM. Significance was determined using one-way ANOVA with 
Dunnett’s multiple comparison test comparing all groups vs. control group. *:p< 0.05, **: p< 0.01. 
Native gel analysis of proteasome activity in human dermal fibroblasts showed a significant decrease 
in 30S activity of NDUFB3 cells, while no significant change was observed in the other fibroblast lines. 
Furthermore, for NDUFB3, ND5 and also for Tango2 cells and cells with an uncharacterized mutation 
activity of the 26S proteasome appeared to be slightly reduced (Figure 4-20).  
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Figure 4-20: Activity of proteasome complexes in human dermal fibroblast lines 
Representative native gel analysis of proteasome complex activity in cell lysates from human dermal fibroblasts and 
quantification of CT-L activity in the overlay assay. Bar graphs show mean fold change relative to control. 
n=8(Control) - 4(Mutants) +SEM. Significance was determined using one-way ANOVA with Dunnett’s multiple comparison 
test comparing all groups vs. control group. *: p< 0.05. 
Furthermore, similar to mtDNA mutator MEFs expression of proteasome subunits was not changed in 
human dermal fibroblast lines (Figure 4-21). 
 
Figure 4-21: Proteasome expression is not changed in human dermal fibroblast lines 
Representative Western blot analysis of 20S (α7, β5) and 19S (Rpt5) subunit expression in human dermal fibroblast lines. 
Actin was used as a loading control. Densitometric analysis shows mean+SEM. n=8(Control) - 4(Mutants). 
In summary, human dermal fibroblasts with single mutations in the complex I genes NDUFB3 and 
ND5 show a reduction in basal respiratory chain activity which is accompanied by a slight decrease in 
proteasome activity. The decrease in proteasome activity appears to be due to a minor reduction in 
30S and maybe 26S proteasome complexes. In human dermal fibroblasts with an uncharacterized 
mutation or a mutation in the β-oxidation gene Tango2 no reduction of respiratory chain activity and 
no significant reduction in proteasome activity were observed. 
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4.3 Discussion 
Mitochondrial function and protein degradation by the proteasome seem to be closely 
interconnected. However, little is known on how mitochondrial dysfunction directly affects the 
proteasome especially in settings of chronic genetic respiratory chain dysfunction. Here, MEFs of the 
mtDNA mutator mouse were used to analyze the effect of severe and chronic dysfunction of the 
respiratory chain on proteasomal activity. Proteasomal activity and particularly activity and assembly 
of the 26S and 30S proteasome complexes were adversely influenced by mitochondrial dysfunction. 
Importantly, this effect was independent of mitochondrial ROS production, ATP availability or levels 
of the signaling molecules NAD+ and NADH. Furthermore, diminished 26S and 30S proteasome 
assembly in mtDNA mutator MEFs was associated with increased resistance towards proteasome 
inhibition and decreased cellular protein synthesis rates. Similar to mtDNA mutator MEFs, human 
dermal fibroblasts from patients with single mutations in respiratory chain genes also showed a 
correlation between decreased respiratory chain activity and proteasome activity. 
4.3.1 Dysfunction of the mitochondrial respiratory chain is associated with 
decreased 26S and 30S proteasome assembly and activity 
Regulation of proteasomal activity in the cell can mainly be mediated by expressional changes of 
proteasome subunits or by altered association of proteasomal activators with the proteasome 
(Paragraph 1.1.1.2) (Meiners et al., 2014; Schmidt and Finley, 2013). In mtDNA mutator MEFs, overall 
proteasomal activity towards peptidic substrates was decreased in the absence of expressional 
changes of 19S or 20S proteasome subunits. While activity of 20S proteasome complexes was not 
changed, activity of 26S and 30S proteasomes was significantly reduced in mtDNA mutator MEFs. 
This decreased activity was associated with reduced levels of assembled 26S and 30S proteasomes 
indicating that the observed overall decrease in proteasome activity is mainly caused by diminished 
assembly of the 19S activator with the 20S core proteasome. Similar to mtDNA mutator MEFs, 
human dermal fibroblasts from patients with decreased respiratory chain activity also showed 
decreased proteasome activity which might also be caused by reduced assembly of 26S and 30S 
proteasomes. 
In addition, formation of alternative 20S or 26S proteasome complexes containing PA28γ was 
reduced in mtDNA mutator MEFs, while expression levels of the alternative proteasome activators 
PA28α and PA28γ were not altered. Hence, impaired proteasome activity in mtDNA mutator MEFs is 
based on decreased association of proteasomal activators with the 20S proteasome core particle and 
independent of proteasome subunit expression. Furthermore, since levels and activity of free 20S 
proteasomes did not change in mtDNA mutator MEFs, impaired proteasome activity is not due to 
disassembly of existing 26S or 30S proteasomes but rather due to decreased assembly of newly 
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formed proteasome complexes. This finding further underlines the importance of association with 
regulatory particles as a specific way of regulating proteasome activity (Meiners et al., 2014). 
Mitochondria have several functions in the cell such as ATP production in the respiratory chain or 
biosynthesis of several essential molecules. Furthermore, mitochondria are central mediators of 
cellular signaling, e.g. in apoptosis initiation (Chandel, 2014). Therefore, it is important to delineate 
which of the diverse functions of mitochondria are associated with alterations of proteasomal 
function. In mtDNA mutator MEFs, mutations specifically occur in the mtDNA which encodes only 
few proteins which are all subcomplexes of the respiratory chain while the vast majority of 
mitochondrial proteins is encoded in the nucleus (Trifunovic et al., 2004). Hence, specifically the 
respiratory chain complexes are destabilized in mtDNA mutator mice and show increased turnover 
(Edgar et al., 2009). Accordingly, it is shown here that while respiratory chain function is almost 
completely abolished in mtDNA mutator MEFs, mitochondrial morphology and mitochondrial 
membrane potential did not differ between mtDNA mutator MEFs and WT MEFs and also apoptosis 
is not significantly increased at baseline. Furthermore, cellular growth or overall metabolic activity 
was not altered in mtDNA mutator MEFs indicating that these cells do not miss any essential 
biosynthetic products produced in mitochondria. Moreover, other functions of the mitochondria, 
such as protein import and export which utilizes the mitochondrial membrane potential as a driving 
force (Schmidt et al., 2010) or mitochondrial apoptosis induction are preserved in mtDNA mutator 
MEFs. Thereby, the decreased proteasome activity and assembly in mtDNA mutator MEFs is likely to 
be dependent on the prominent respiratory chain failure in these cells.  
4.3.2 Mitochondria to proteasome signaling in mtDNA mutator MEFs 
Several pathways are known to regulate the association of proteasomal regulatory particles with the 
20S core complex (Paragraph 1.1.1.2). This signaling enables rapid adaptation of proteasomal activity 
to the cellular state by regulating proteasomal complex formation (Meiners et al., 2014). 
Furthermore, it is well known that mitochondrial function can communicate to the cell and to the 
proteasome in several ways (Paragraph 1.3.2).  
One prominent example for mitochondrial signaling is mitochondrial ROS, which is a very versatile 
signaling mediator and often associated with mitochondrial damage (Sena and Chandel, 2012). 
Mitochondrial ROS production was previously associated with mitochondria to proteasome signaling 
(Branco, 2010; Chou et al., 2010; Livnat-Levanon et al., 2014; Segref et al., 2014). Importantly, a 
recent study by Livnat-Levanon et al. observed that decreased proteasome assembly was associated 
with increased mitochondrial ROS production following acute respiratory chain inhibition, which was 
partially reversible by addition of antioxidants (Livnat-Levanon et al., 2014). However, in contrast to 
these findings the mtDNA mutator mouse provides a model of mitochondrial dysfunction which is 
The effect of mitochondrial dysfunction on proteasome activity and composition  
72 
not associated with increased mitochondrial ROS production (Trifunovic et al., 2005). Indeed, 
mitochondrial superoxide production, cellular ROS production and the amount of oxidatively 
modified proteins did not differ between WT and mtDNA mutator MEFs. Furthermore, antioxidant 
treatment had no effect on the proteasome function in mtDNA mutator MEFs. Hence, the signaling 
mechanism between mitochondria and the proteasome in mtDNA mutator MEFs is clearly 
independent of altered mitochondrial ROS production and thereby differs from the mechanisms 
described previously. One reason for this discrepancy might be that in most studies mitochondrial 
dysfunction was induced by treatment of cells with mitochondrial inhibitors or by siRNA-mediated 
knockdown of respiratory chain subunits. This leads to acute mitochondrial stress, which is in 
contrast to the chronic mitochondrial failure in mtDNA mutator MEFs. Acute ROS generation, 
however, leaves the cell less time to adapt to altered conditions. Furthermore, acute inhibition of 
mitochondrial respiratory chain complexes might induce ROS production which is higher than 
mitochondrial ROS production under physiological conditions (Murphy, 2009). Accordingly, in human 
dermal fibroblasts harboring mutations in mitochondrial genes, mitochondrial superoxide production 
did not reach similar high ROS levels as induced in control cells treated with antimycin A.  
As mitochondria are best known for producing ATP and 26S and 30S proteasome function is 
dependent on ATP (Kim et al., 2012; Liu et al., 2006a), it seems plausible that mitochondrial and 
proteasomal function might be connected by the availability of ATP. Indeed, it was previously shown 
that a decrease in proteasome activity caused by treatment with mitochondrial respiratory chain 
inhibitors could be reversed by increased glucose supplementation to cell culture medium (Höglinger 
et al., 2003). Additionally, acute ATP depletion in response to oligomycin treatment was also 
associated with 26S proteasome disassembly (Huang et al., 2013). However, in mtDNA mutator MEFs 
steady state levels of cellular ATP did not differ from WT cells. Additionally, no change was observed 
in AMPK activation between WT and mtDNA mutator MEFs. Since AMPK is the major energy sensor 
in the cell and becomes phosphorylated upon low ATP/ADP ratios (Hardie et al., 2012) a decrease in 
ATP availability should be associated with AMPK activation. These data indicate that mtDNA mutator 
MEFs are able to maintain their ATP production via mitochondria-independent pathways. Since in 
this study MEFs were cultured in DMEM containing a high concentration of glucose, mtDNA mutator 
MEFs are most probably able to meet their energy requirements by performing glycolysis. 
Accordingly, increased reliance of mtDNA mutator MEFs on glycolysis has been reported previously 
(Trifunovic et al., 2005). These data therefore indicate that decreased 30S and 26S assembly in 
mtDNA mutator MEFs is not caused by reduced availability of ATP. 
Beside ATP also the metabolic mediator NADH has the ability to affect proteasome function. 
Mitochondria are the major cellular source for NADH which is used as a substrate in the 
mitochondrial respiratory chain (Nunnari and Suomalainen, 2012). In mtDNA mutator MEFs NADH 
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accumulates, which might be based on decreased utilization of NADH due to impaired respiratory 
chain activity. In line with this finding, it has previously been shown that in rho0 cells, which are 
devoid of mtDNA, NADH accumulates in the cytosol due to a defective mitochondrial respiratory 
chain (Olgun and Akman, 2007).  
Altered NADH levels and alterations in the NAD+/NADH ratio might signal to the proteasome in 
different ways. On the one hand, altered NADH levels might affect proteasome activity by direct 
binding of NADH to proteasome subunits. Indeed, NADH was shown to be able to directly bind Rpt2 
and stabilize 26S and 30S proteasome complexes (Tsvetkov et al., 2014). On the other hand, 
alterations in the NAD+/NADH ratio might be signaled to the proteasome by an altered activity of 
NAD+ consuming enzymes such as poly(ADP-ribose)polymerases (PARP) or Sirtuin deacetylases. PARP 
activation and subsequent proteasome polyADP-ribosylation was shown to enhance the activity of 
20S proteasomes in response to acute oxidative stress (Ullrich et al., 1999; Luo and Kraus, 2012). 
Additionally, assembly of 26S proteasomes was decreased after treatment with an inhibitor of the 
PARP family member TNKS revealing an additional effect of PARylation on 26S activity (Cho-Park and 
Steller, 2013). Furthermore, although little is known directly about the regulation of proteasomal 
activity by Sirtuins, decreased Sirtuin activity is associated with decreased protein homeostasis 
(Tomita et al., 2015) as well as with aging and mitochondrial dysfunction (Imai and Guarente, 2014; 
Lin, 2004; Mouchiroud et al., 2013; Sack and Finkel, 2012). Hence, altered NAD+ or NADH levels as a 
consequence of mitochondrial dysfunction might signal directly to the proteasome by binding to 
proteasomal subunits or indirectly by affecting PARP or Sirtuin activities. 
However, experimentally manipulation of NADH levels in this study did not change proteasome 
activity neither in WT MEFs nor in mtDNA mutator MEFs indicating that direct regulation of 
proteasome activity by NADH levels does not play a prominent role in this setting. Importantly, a 
direct regulation of the proteasome by NADH due to its binding to Rpt2 was only effective in the 
absence of ATP (Tsvetkov et al., 2014), indicating that this effect might only be relevant under 
specific conditions. Furthermore, inhibiting PARP or Sirtuin activity with the specific inhibitors ABT-
888 and EX-527, respectively, also did not alter proteasome activity in WT or mtDNA mutator MEFs, 
thereby suggesting the absence of indirect regulation of proteasome activity via NAD+/NADH-
dependent pathways. Therefore, while NADH levels are significantly increased in mtDNA mutator 
MEFs, this does not obviously relate to proteasomal regulation and rather seems to be a parallel 
effect based on mitochondrial dysfunction. In support of this notion, it was found that tumor cells, 
which switch from mitochondrial respiration to glycolytic ATP production, i.e. the Warburg effect, 
also have increased NADH levels (Santidrian et al., 2013) which are, however, associated with 
increased proteasome activity and a particular sensitivity to proteasome inhibition (Arlt et al., 2009; 
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Chen and Madura, 2005). Hence, increased NADH levels do not appear to be canonically associated 
with decreased proteasome activity.  
In summary, mitochondrial dysfunction-induced decrease in proteasome activity and 26S assembly in 
mtDNA mutator MEFs is not dependent on alterations in cellular ROS, ATP, or NADH signaling and is 
hence signaled by a yet undescribed novel mechanism. Beside the described signaling pathways, 
regulation of proteasome complex assembly can also take place by introduction of posttranslational 
modifications to proteasome subunits (Meiners et al., 2014; Schmidt and Finley, 2013) such as 
recently shown for phosphorylation of Rpn6 (Lokireddy et al., 2015). Hence, future work to identify 
the mechanistic steps involved in decreased proteasome assembly should involve analysis of 
posttranslational modifications in 20S or 19S proteasome subunits. 
4.3.3 Decreased proteasome activity does not induce proteostasis 
imbalance in mtDNA mutator MEFs 
The proteasome is one of the major protein degradation pathways in the cell and impaired 
proteasome function has been shown to induce proteostatic imbalance (Goldberg, 2003). 
Accordingly, inhibition of proteasomal activity induces a manifold cell stress response in order to 
maintain proteostasis. This cellular response includes induction of cell cycle arrest, attenuation of 
protein synthesis, initiation of the unfolded protein response, upregulation of heat shock protein 
expression and proteasome biosynthesis and, in case of prolonged proteasome inhibition, induction 
of apoptosis (Bush et al., 1997; Frankland-Searby and Bhaumik, 2012; Kawazoe et al., 1998; 
Kubiczkova et al., 2014; Meiners et al., 2006). Furthermore, reduced activity of the proteasome is 
associated with accumulation of polyubiquitinated proteins and protein aggregate formation 
(Heinemeyer et al., 1991; Hipp et al., 2012; Meiners et al., 2006). However, despite decreased 
proteasome activity in mtDNA mutator MEFs no pronounced proteostasis imbalance was detected as 
indicated by the fact that expression levels of the heat shock proteins HSP70 and HSP90 as well as 
cellular growth and viability remained stable. Furthermore, levels of ubiquitinated proteins did not 
change between WT and mtDNA mutator MEFs. In conclusion, these data show that despite 
decreased proteasome activity cellular protein homeostasis remains functional in mtDNA mutator 
MEFs. These findings accord with recently published data which showed the absence of a protein 
stress response upon mild knockdown of 19S proteasome subunits (Tsvetkov et al., 2015). 
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4.3.4 mtDNA mutator MEFs are less sensitive to bortezomib-induced cell 
death 
While cellular proteostasis did not appear to be imbalanced in mtDNA mutator MEFs the spare 
proteolytic capacity of the proteasome might be reduced in these cells. To investigate if 
mitochondrial dysfunction-induced reduction of 26S and 30S proteasome levels indeed decreases the 
spare proteolytic capacity in mtDNA mutator MEFs and thereby renders the cells more vulnerable to 
a second hit, MEFs were treated with the proteasome inhibitor bortezomib. Paradoxically, WT MEFs 
were significantly more sensitive to proteasome inhibition than mtDNA mutator MEFs. Although it 
seems counterintuitive that reduced proteasome activity and decreased 26S proteasome assembly 
protects the cell from further inhibition of the proteasome system, this finding is in line with two 
recent publications which were utilizing mutational screens or shRNA libraries to assess mechanisms 
of resistance against proteasome inhibitors. These studies screened for protein mutations or shRNAs 
which provide survival advantages to cells under conditions of proteasome inhibition. Importantly, 
mutations in 19S subunits or mild knockdown of 19S subunits, which concordantly reduced 26S and 
30S proteasome levels, were protective against proteasome inhibitor treatment. This effect was very 
specific for proteasome regulator subunits as knockdown of almost any of the 19S subunits mediated 
protection, while knockdown of 20S core subunits sensitized to proteasome inhibition (Acosta-Alvear 
et al., 2015; Tsvetkov et al., 2015). Hence, very similar to results obtained with the knockdown of 19S 
subunits, the observed reduction in assembly of 26S and 30S proteasomes in mtDNA mutator MEFs is 
associated with increased resistance to proteasome inhibitor treatment.  
The present study reveals that decreased assembly of 26S and 30S proteasome is sufficient to induce 
resistance towards proteasome inhibitors even in the absence of expressional changes of 19S 
subunits. Hence, loss of 26S proteasome activity is probably mechanistically downstream of the 
reduced 19S subunit expression applied in the previous studies. Furthermore, this study shows that 
physiological triggers such as mitochondrial dysfunction can induce proteasomal dysfunction in an 
extent which contributes to decreased sensitivity to proteasome inhibitors. These results are of 
especial importance in the light of the therapeutic use of proteasome inhibitors as anti-cancer drugs. 
Due to increased sensitivity of tumor cells to proteasome inhibition, proteasome inhibitors are used 
as anti-cancer drugs (Adams, 2004; Kisselev et al., 2012). However, the acquisition of resistance to 
proteasome inhibitors in tumors is a major problem during therapy (Buac et al., 2013). Importantly, 
also decreased mitochondrial metabolism and increased aerobic glycolysis – the so-called Warburg 
effect – is a common feature of tumor cells (Denko, 2008). Furthermore, it was recently shown that 
in multiple myeloma cells metabolic shifts towards increased glycolysis are also associated with 
increased resistance to bortezomib (Maiso et al., 2015). Taken together, these data on mitochondrial 
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dysfunction-mediated proteasome impairment might thus reveal a novel mechanism for resistance 
to proteasome inhibition in tumor cells.  
Several mechanisms may contribute to the increased resistance against proteasome inhibition upon 
impaired 26S proteasome activity. First, a mild decrease in proteasome activity could induce a 
hormetic response by upregulation of other stress response pathways thereby providing an already 
stress-adapted surrounding (Bieler et al., 2009; Meiners et al., 2006). However, in this study as well 
as in the study of Tsvetkov et al., no induction of the protective heat shock response was observed 
under baseline conditions (Tsvetkov et al., 2015). Second, redundant proteolytic systems such as the 
autophagy pathway could take over tasks from an attenuated proteasome system. However, it has 
previously been described that autophagy is rather suppressed than enhanced in mtDNA mutator 
MEFs (Li-Harms et al., 2014). Third, it was suggested that decreased protein synthesis and hence a 
reduced need of protein turnover might be responsible for resistance to proteasome inhibition. 
Indeed, knockdown of mediators of protein translation also desensitized cells towards proteasome 
inhibition (Acosta-Alvear et al., 2015). Additionally, increased resistance to proteasome inhibitors 
was associated with a decreased rate of protein synthesis in cells after knockdown of 19S subunits 
(Tsvetkov et al., 2015). Accordingly, overall protein synthesis was attenuated in mtDNA mutator 
MEFs compared to WT MEFs. Since a substantial fraction of proteins is ubiquitinated and targeted for 
degradation by the proteasome directly after synthesis (Schubert et al., 2000), a reduction of protein 
synthesis rates would also well accord with the absence of accumulation of polyubiquitinated 
proteins in mtDNA mutator MEFs. However, while protein synthesis is significantly reduced in mtDNA 
mutator MEFs and correlates with reduced 26S activity, it is unclear whether decreased protein 
synthesis is cause or consequence of impaired 26S and 30S assembly in mtDNA mutator MEFs or 
whether it might be regulated independently. 
To analyze regulation of protein synthesis in mtDNA mutator MEFs activity of the mTORC1 pathway, 
which is a master regulator of protein synthesis (Laplante and Sabatini, 2009), was analyzed in 
mtDNA mutator MEFs. However, the downstream mediators of mTORC1 signaling 4EBP1 or S6 
ribosomal protein did not show significant alteration in mtDNA mutator MEFs.  
In summary, these results confirm the paradoxical resistance to proteasome inhibition first described 
by Acosta-Alvear et al. and Tsvetkov et al. and further extend their relevance in the context of 
physiologically decreased 26S complex assembly. Additionally, it was shown that changes in 26S 
proteasome activity are sufficient to induce resistance to proteasome inhibitors and do not require 
transcriptional alterations of 19S regulatory particle subunits. While decreased protein synthesis 
might contribute to decreased sensitivity towards proteasome inhibitor-induced cell death a detailed 
mechanism downstream of reduced 26S and 30S assembly still has to be elucidated. Furthermore, 
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the possibility that 26S proteasome assembly is impaired upon metabolic switches in tumor cells and 
might contribute to resistance to proteasome inhibition in tumor cells requires further investigation. 
4.3.5 Reduced proteasome activity in human mitochondrial disorders 
To analyze whether decreased proteasome activity also manifests in humans with mitochondrial 
disorders, proteasome activity was analyzed in human dermal fibroblasts that harbor specific 
mutations in genes of the respiratory chain. Dysfunctions in respiratory chain complexes in humans 
are associated with heterogeneous disease conditions with a large variety of clinical symptoms 
(Haack et al., 2012; Munnich and Rustin, 2001). These diseases are associated with a broad spectrum 
of clinical manifestations for which direct genotype to phenotype correlations are missing (Haack et 
al., 2012). A mitochondrial disorder is usually suspected in patients presenting neuromuscular 
disorders in a combination with other non-neuromuscular disorders. These disorders usually have a 
progressive course and involve seemingly unrelated organs. Furthermore, the number of organs 
involved frequently increases over the course of the disease (Munnich and Rustin, 2001). However, 
as the main function of the mitochondrial respiratory chain is production of ATP it is not surprising 
that mitochondrial disorders are most evident in tissues with high energy demand such as the 
nervous system, the heart or skeletal muscle (Kanabus et al., 2014). 
Here, dermal fibroblasts from control subjects without disease relevant mutations were used as well 
as patient fibroblasts harboring mutations in NDUFB3 (complex I, nuclear DNA encoded) or ND5 
(complex I, mtDNA encoded). Furthermore, patient fibroblasts with a mutation in the non-respiratory 
chain gene Tango2 (β oxidation, nuclear DNA encoded) or with an uncharacterized mutation were 
analyzed (See also Table 4-1). 
Proteasome activity was reduced in cells with NDUFB3 and ND5 mutations and thereby correlated 
well with the decrease in respiratory chain functions. In contrast, cells with an uncharacterized 
mutation or a mutation in Tango2 which did not show decreased oxygen consumption were able to 
maintain their proteasome activity on a similar level as control cells. Additionally, while mutations in 
NDUFB3 were associated with increased production of mitochondrial superoxide, generation of 
mitochondrial superoxide was not different between control cells and cells with ND5 mutations. 
Hence, dysfunction of the respiratory chain induced loss of proteasome activity in human dermal 
fibroblasts from patients with mitochondrial disorders independent of an accompanying change in 
mitochondrial superoxide production.  
Reduced proteasomal protein degradation was previously described in cells from patients with a 
mutation in the human IVD gene which leads to a defect in mitochondrial leucine metabolism and a 
disease called isovaleric acidemia (IVA) (Segref et al., 2014; Tanaka et al., 1966). In this case 
proteasomal dysfunction correlated with increased mitochondrial superoxide production in patient 
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cells (Segref et al., 2014). However, since the in vitro activity of respiratory chain complexes was 
unchanged in an animal model of IVA (Ribeiro et al., 2007) the described effect on the proteasome is 
probably not caused by altered mitochondrial respiratory chain activity. These data indicate that 
different regulatory mechanisms are present which signal from mitochondria to the proteasome. 
In addition to a different extent of respiratory chain inhibition in the different patient fibroblasts, the 
specific mutations are located in mtDNA or nuclear DNA encoded genes. Hence, in addition to 
analyze whether reduced proteasome activity also manifests in patients with mitochondrial disorders 
it was analyzed if the reduction of proteasome activity is dependent on the localization of the 
mutated genes. 
Proteasome activity was decreased in cells with mutations in the nuclear DNA encoded NDUFB3 gene 
as well as in the mtDNA encoded ND5 gene. Hence, mitochondrial dysfunction-induced attenuation 
of proteasomal activity appears to be independent of nuclear or mitochondrial location of the 
mutated gene. NDUFB3 and ND5 are both subunits of complex I. A reduction of proteasome activity 
was only observed in NDUFB3 and ND5 mutants but not in other mutants. However, other mutants 
also showed a milder phenotype without reduction in basal oxygen consumption rates. Hence, it 
cannot be distinguished whether the observed decrease in proteasome activity is dependent on the 
location or the extent of the mitochondrial dysfunction. However, as chemical inhibition of different 
complexes such as complex I, III or V was capable to induce decreased proteasome activity (Chou et 
al., 2010; Huang et al., 2013; Livnat-Levanon et al., 2014) it seems more likely that the extent but not 
the molecular basis of the respiratory chain dysfunction is responsible for the loss of proteasome 
activity.  
In summary, reduced proteasome activity also manifests in fibroblasts from patients with 
mitochondrial disorders. Decreased proteasome activity was clearly associated with reduced 
respiratory chain activity while it did not correlate with mitochondrial superoxide production. 
Furthermore, it was not dependent on the localization of the mutation in nuclear or mtDNA encoded 
genes. These results indicate that indeed the extent of respiratory chain dysfunction is the 
determinant for decreased proteasome activity in cases of genetic mitochondrial dysfunction. 
4.3.6 Differential adaptation of proteasomal function to mitochondrial 
dysfunction 
This study confirms a strong connection between mitochondrial and proteasomal function. This was 
evident in the context of respiratory chain dysfunction without elevated ROS generation in a model 
of premature aging and in the context of disease relevant mutations in genes of single respiratory 
chain subunits. However, the mechanism of signaling between mitochondria and proteasome differs 
The effect of mitochondrial dysfunction on proteasome activity and composition 
79 
from previous studies and is probably depending to the acuteness and cause of mitochondrial 
dysfunction. Reduced proteasome activity in response to acute mitochondrial dysfunction caused by 
treatment with respiratory chain inhibitors was mediated by an increase in ROS production or 
decreased ATP availability (Paragraph 1.3.2). In contrast, decreased proteasome assembly based on 
chronic respiratory chain dysfunction in mtDNA mutator MEFs was independent of cellular ROS or 
ATP production. Therefore, a model can be proposed in which proteasome activity is differentially 
regulated by mitochondrial functions depending on the nature of mitochondrial perturbation: Acute 
respiratory chain inhibition, generating high amounts of mitochondrial ROS, can induce ROS-
dependent 26S disassembly (Chou et al., 2010; Livnat-Levanon et al., 2014; Segref et al., 2014). 
Similarly, acute ATP depletion by mitochondrial inhibition impairs proteasome activity (Höglinger et 
al., 2003; Huang et al., 2013). In contrast, chronic mitochondrial dysfunction in the mtDNA mutator 
MEFs leads to decreased levels of assembled 30S and 26S proteasomes by an mechanism 
independent of increased ROS production or ATP depletion. Furthermore, in human dermal 
fibroblasts mutations in mitochondrial respiratory genes, which induce decreased oxygen 
consumption, are associated with decreased proteasome activity which is similarly not dependent on 
mitochondrial superoxide production.  
Furthermore, as outlined in paragraph 1.3.2, mitochondrial perturbations which are not associated 
with respiratory chain failure such as malfunction of the mitochondrial protein import machinery or 
excessive accumulation of misfolded proteins in the mitochondrial intermembrane space have 
opposite effects on proteasomal function as they were shown to increase proteasomal activity (Papa 
and Germain, 2011; Wrobel et al., 2015). Hence, while respiratory chain deficiency induces a 
decrease in proteasomal activity via diverse mechanisms, mitochondrial protein misfolding is 
associated with increased proteasome activity.  
In summary, this study confirms the finding that mitochondrial respiratory chain dysfunction is 
associated with decreased activity of 26 and 30S proteasomes and shows that regulation of 
proteasome function in response to mitochondrial respiratory chain dysfunction seems to be much 
more versatile than usually suggested and reaches beyond ROS generation and ATP depletion 
especially in settings of chronic mitochondrial dysfunction (Figure 4-22). 
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Figure 4-22: Mitochondrial respiratory chain dysfunction is associated with decreased 26S and 30S proteasome activity 
which is mediated by distinct mechanisms 
Mitochondrial protein misfolding in the IMS or dysfunctional protein import increases proteasome activity. In contrast, 
respiratory chain dysfunction is associated with decreased proteasome activity. Different mechanisms such as 
mitochondrial ROS signaling or ATP availability can signal between mitochondria and the proteasome. In case of chronic 
respiratory chain dysfunction due to mutations in respiratory chain genes, impaired 26S and 30S proteasome activity is 
mediated by yet unknown mechanisms which are independent of ROS or ATP signaling.  
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5 Mitochondrial function in response to cigarette smoke 
extract exposure 
Parts of this chapter have previously been published as: Ballweg K., Mutze K., Königshoff M., 
Eickelberg O., and Meiners S. (2014). Cigarette smoke extract affects mitochondrial function in 
alveolar epithelial cells. Am. J. Physiol. Lung Cell Mol. Physiol. 307, L895–L907. 
5.1 Introduction 
Mitochondrial and proteasomal functions are linked together as dysfunction of mitochondria signals 
to the proteasome and proteasomal function is required for the maintenance of mitochondrial 
protein homeostasis (Paragraphs 1.3 and 4). However, it is widely unknown, how mitochondrial 
function and mitochondrial proteostasis change in response to disease-relevant stimuli in lung cells.  
As the lung is directly exposed to air and constantly in contact with the environment, exposure of the 
lung to noxious environmental agents, such as pollutants or cigarette smoke (CS), is an important 
determinant for developing chronic lung diseases (Meiners et al., 2015). This is especially evident for 
chronic obstructive pulmonary disease, for which cigarette smoke is the main risk factor in the 
western world (Barnes, 2000; Tuder and Petrache, 2012). Cigarette smoke is a complex mixture of 
different combustion products. It contains thousands of injurious agents and has strong oxidative 
capacities (Bowler et al., 2004; Nyunoya et al., 2014). Exposure of lung epithelial cells to cigarette 
smoke initiates an adaptive cellular response which involves proinflammatory and oxidative stress 
responses (Nyunoya et al., 2014; Bowler et al., 2004). As such, it was recently suggested that 
cigarette smoke might also induce mitochondrial alterations in lung epithelial cells, which might 
further contribute to COPD pathogenesis. Additionally, cigarette smoke-induced mitochondrial stress 
could require the activation of mitochondrial proteostasis systems in order to maintain mitochondrial 
function. However, a number of studies on the effect of cigarette smoke on mitochondria provide 
rather conflicting data on mitochondrial function and activation of mitochondrial proteostasis 
pathways. Mitochondrial fragmentation (Hara et al., 2013) as well increased branching and 
mitochondria elongation (Hoffmann et al., 2013) have been described in cigarette smoke extract 
(CSE)-treated cells and in cells isolated from COPD patients. Additionally, decreased mitochondrial 
membrane potential and induction of mitophagy on the one hand (Mizumura et al., 2014) or 
increased cellular ATP levels on the other hand (Hoffmann et al., 2013) have been reported. The 
potentially conflicting results on mitochondrial alterations in response to cigarette smoke in these 
studies therefore clearly emphasize the need of further studies to fully understand how cigarette 
smoke affects mitochondrial function. 
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Importantly, in addition to mitochondrial alterations, cigarette smoke was already shown to affect 
cellular proteostasis such as autophagy and proteasomal function (Chen et al., 2010; Nyunoya et al., 
2014; van Rijt et al., 2012). Hence, both mitochondrial and proteasomal function might be altered in 
alveolar cells upon exposure to cigarette smoke and thereby might contribute to the development of 
COPD. 
This part aims to identify alterations in mitochondrial morphology, mitochondrial network dynamics 
and mitochondrial function as well as mitochondrial proteostasis and activation of quality control 
pathways in a cell culture model of cigarette smoke exposure. To fulfill these aims, lung epithelial 
cells were treated with low and nontoxic cigarette smoke extract. Nontoxic doses of CSE were 
considered to more closely resemble a physiologically relevant situation than toxic doses. Cells were 
thereafter analyzed for mitochondrial morphology, mitochondrial function and for expression and 
intracellular localization of genes involved in mitochondrial network dynamics or mitochondrial 
proteostasis.  
5.2 Results 
In order to analyze the effect of cigarette smoke on mitochondrial function of alveolar epithelial cells, 
murine lung epithelial (MLE) 12 cells were treated with nontoxic doses of cigarette smoke extract. 
CSE doses up to 25 % CSE were nontoxic as assessed by the absence of caspase 3 cleavage and LDH 
release in treated cells (Figure 5-1A&B).  
MLE12 cells are a cell line established from pulmonary tumors of a transgenic mouse (Wikenheiser et 
al., 1993). To also analyze a model which is more closely associated with the physiological situation, 
additionally primary mouse alveolar epithelial type II cells (pmATII) were analyzed. Importantly, these 
primary cells were more resistant to CSE and doses up to 50 % CSE did not induce pronounced 
cytotoxicity (Figure 5-2). 
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Figure 5-1: Low-doses of CSE are nontoxic in MLE12 cells 
(A) Western blot analysis of caspase 3 cleavage in MLE12 cells treated with low dose CSE for 6, 24 or 48 h. Each lane 
corresponds to lysates from an independent experiment. 24 h 75 % CSE and 6 h 75 % CSE-treated MLE12 cells were used as 
a positive control for all experimental timepoints. (B) LDH assay of CSE-treated MLE12 cells after 6, 24, and 48 h. n=3. Bar 
graphs show mean+SEM. 
 
Figure 5-2: CSE doses up to 50 % CSE are nontoxic for pmATII cells 
LDH assay of 24 h CSE-treated pmATII cells. n=3. Bar graphs show mean+SEM. Significance was determined using one-way 
ANOVA with Dunnett’s multiple comparison test. **:p< 0.01. 
5.2.1 Cigarette smoke extract induces mitochondrial hyperfusion in mouse 
alveolar epithelial cells 
To analyze the effect of nontoxic CSE on mitochondria, mitochondria were stained using a 
cytochrome c antibody and mitochondrial morphology was analyzed using immunofluorescence 
microscopy. CSE treatment induced a pronounced elongation of mitochondria and increased 
mitochondrial network connectivity (Figure 5-3A). In order to quantify CSE-induced changes, 
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mitochondrial morphology was categorized into three types: “fragmented”, “normal”, or 
“hyperfused” (see also paragraph 3.4.3). Treatment with CSE significantly increased the proportion of 
hyperfused mitochondria compared to control treatment after 6, 24 or 48 h (Figure 5-3B). CCCP, 
which is known to induce mitochondrial fragmentation (Duvezin-Caubet et al., 2006; Tanaka et al., 
2010), was used as a positive control. Indeed, CCCP treatment significantly increased the fraction of 
fragmented cells in a time-dependent manner (Figure 5-3B). 
 
Figure 5-3: CSE treatment leads to mitochondrial hyperfusion in MLE12 cells.  
(A) Representative immunofluorescence pictures of MLE12 cells treated with control medium, 25 % CSE, or 10 µM CCCP for 
48 h. Scale bars: 10 µm (B) Quantification of mitochondrial morphology in MLE12 cells after 6, 24, and 48 h of treatment. 
n=3. Bars show mean percentage + SEM. Significance was determined using the chi-square test. ***:p< 0.001. 
Similar to MLE12 cells, primary alveolar type II cells treated with 50 % CSE for 24 h showed 
pronounced mitochondrial hyperfusion with a strong increase in mitochondrial network connectivity 
(Figure 5-4). 
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Figure 5-4: CSE induces mitochondrial hyperfusion in pmATII 
(A) Representative immunofluorescence pictures of pmATII cells treated with control medium, 50 % CSE, or 10 µM CCCP for 
24 h. Scale bars: 10 µm (B) Quantification of mitochondrial morphology in 24 h control, CCCP, 25 % or 50 % CSE-treated 
pmATII cells. n=3. Bars show mean percentage + SEM. Significance was determined using the chi-square test. ***:p< 0.001. 
Mitochondrial morphology is regulated by expression, localization and activity of several 
mitochondrial fusion and fission proteins. Protein and mRNA expression levels of the outer 
membrane fusion proteins MFN1 and MFN2 as well as the inner membrane fusion protein OPA1 and 
the mitochondrial fission protein DRP1 were analyzed in total cell lysates of MLE12 cells. MFN2 
expression was transiently increased on mRNA and protein level after 24 h of CSE treatment. No 
significant changes with CSE treatment were observed for expression of MFN1, DRP1 or OPA1 (Figure 
5-5 and Figure 5-6). Again, CCCP was used as a positive control and, in accordance with published 
data (Duvezin-Caubet et al., 2006; Tanaka et al., 2010), induced cleavage of long OPA1 isoforms (a, b) 
and degradation of MFN2 at early times after treatment (Figure 5-5). 
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Figure 5-5: MFN2 expression is increased in response to CSE treatment in MLE12 cells 
(A) Representative Western blot analysis of mitochondrial fusion (MFN2, MFN1 and OPA1) and fission protein (DRP1) 
expression in MLE12 cells. Tubulin was used as a loading control. Letters indicate the different isoforms recognized by the 
respective antibody (OPA1 long: a-b; OPA1 short: c-e; DRP1: a-b). (B) Densitometric analysis of MFN2, MFN1, OPA1 and 
DRP1 expression in MLE12 cells, n=3-5. Bar graphs show mean+SEM. Values are displayed as fold change relative to time-
matched controls. Significance was determined using one-way ANOVA with Dunnett’s multiple comparison test comparing 
treated groups vs. time-matched controls. *:p<0.05, ***p<0.001. 
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Figure 5-6; mRNA expression of fusion and fission proteins in CSE-treated MLE12 cells 
mRNA expression of MFN1, MFN2, DRP1 and OPA1 in MLE12 cells, n=3+SEM. Values are displayed as fold change relative to 
time-matched control cells. Significance was determined using one-way ANOVA with Dunnett’s multiple comparison test 
comparing treated groups vs. time-matched controls. *:p<0.05. 
In addition to data obtained in MLE12 cells, the fusion protein MFN2 was also upregulated in CSE-
treated pmATII cells. The other fusion and fission mediators, MFN1, DRP1, or OPA1 showed no 
significant changes upon CSE treatment of pmATII cells (Figure 5-7). 
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Figure 5-7: MFN2 expression is elevated in 24 h CSE-treated pmATII 
(A) Representative western blot analysis of mitochondrial fusion (MFN2, MFN1, and OPA1) and fission protein (DRP1) 
expression in 24 h CSE-treated pmATII cells. Actin was used as a loading control. Letters indicate the different isoforms 
recognized by the respective antibody (OPA1 long: a-b; OPA1 short: c-e; DRP1: a-b). (B) Densitometric analysis of MFN2, 
MFN1, OPA1 and DRP1 expression in pmATII cells, n=3+/-SEM. Values are displayed as mean fold change relative to 
untreated cells. Significance was determined using one-way ANOVA with Dunnett’s multiple comparison test comparing Ctrl 
vs. CSE-treated groups. *:p<0.05. 
Fission activity of DRP1 requires translocation of DRP1 from the cytosol to mitochondria (Gomes and 
Scorrano, 2013). Hence, DRP1 levels in response to CSE treatment were analyzed in mitochondrial 
fractions of MLE12 cells. To this end, a crude mitochondrial isolation was prepared to enrich for 
mitochondria and associated proteins. Mitochondrial fractions were strongly enriched for 
mitochondrial proteins such as ATP5A while cytosolic (Actin) or ER-resident proteins (Calreticulin) 
had decreased abundance (Figure 5-8). No consistent changes in response to CSE treatment were 
observed for DRP1 levels in the different mitochondrial fractionations indicating absence of DRP1 
translocation to mitochondria (Figure 5-9).  
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Figure 5-8: Mitochondrial proteins are enriched in mitochondrial fractionations 
Representative western blot of mitochondrial fractionation of MLE12 cells treated with 25 % CSE or control (Ctrl) medium 
for 24 h. Calreticulin was used as marker for ER, ATP5A for mitochondria and Actin as cytosolic marker. 
 
Figure 5-9: No DRP1 translocation to mitochondria in response to CSE treatment 
Western blot analysis and densitometric quantification of DRP1 protein levels in four independently prepared 
mitochondrial fractions of MLE12 cells treated with 25 % CSE or control medium for 24 h. ATP5A was used as loading 
control. Letters confer to the different isoforms recognized by the respective antibody (DRP1: a-b).  
Taken together, these data indicate that nontoxic doses of CSE induce an adaptive response of the 
mitochondrial network including transient upregulation of MFN2, which results in a pronounced 
mitochondrial hyperfusion phenotype. Furthermore, these data show that mitochondrial hyperfusion 
is conserved between MLE12 and pmATII cells as a response to exposure to nontoxic doses of 
cigarette smoke extract. 
5.2.2 Cigarette smoke extract-induced mitochondrial hyperfusion is 
associated with increased mitochondrial oxygen consumption and 
ATP production 
Mitochondrial hyperfusion has previously been described as a protective stress response which 
increases mitochondrial ATP production. Several parameters of mitochondrial function were 
analyzed in response to CSE treatment. Metabolic activity was increased in low dose CSE-treated 
MLE12 cells as shown in the MTT assay. Importantly, higher doses which are usually associated with 
cell death significantly decreased metabolic activity (Figure 5-10A). The increase of metabolic activity 
at low doses was not related to increased cellular proliferation, as CSE treatment rather reduced 
cellular proliferation even at low doses (Figure 5-10B). 
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Figure 5-10: Low doses of CSE enhance metabolic activity in MLE12 cells 
(A) MTT assay of MLE12 cells after treatment with 10, 25, 50, or 75 % CSE for 6, 24 and 48 h. n=4-6. Data points are 
presented as mean +/- SEM relative to untreated control cells. Significance was determined using one-way ANOVA with 
Dunnett’s multiple comparison test comparing treated groups vs. time-matched controls. **:p<0.01, ***p<0.001. (B) BrdU 
incorporation in 24 h CSE-treated MLE12 cells. n=2. Bar graphs show mean+SEM. Values are displayed as fold change 
relative to untreated cells.  
To further assess mitochondrial function, mitochondrial membrane potential was analyzed in 
response to low dose CSE treatment. Nontoxic doses of CSE significantly increased mitochondrial 
membrane potential. CCCP treatment was used as a positive control and, as expected, induced a 
decrease in mitochondrial membrane potential (Figure 5-11).  
 
Figure 5-11: CSE treatment increases mitochondrial membrane potential in MLE12 cells 
Flow cytometry analysis of MLE12 cells stained with TMRM for assessment of mitochondrial membrane potential after 6, 
24, or 48 h of treatment with CCCP, or 10, 15 and 25 % CSE. n=2-5. Bar graphs show mean+SEM. Values are displayed as 
fold change relative to untreated cells. Significance was determined using one-way ANOVA with Dunnett’s multiple 
comparison test comparing treated groups vs. time-matched controls. *:p<0.05, **p< 0.01, ***p<0.001. 
Increased mitochondrial membrane potential is often associated with increased production of 
mitochondrial superoxide by the respiratory chain (Sena and Chandel, 2012). Therefore, 
mitochondrial superoxide production after CSE treatment was assessed with the mitochondria-
specific probe MitoSOX red. Superoxide production by the mitochondrial respiratory chain was not 
altered upon CSE treatment (Figure 5-12A). The function of the probe was confirmed by adding 
antimycin A, a commonly used inducer of mitochondrial superoxide (Mukhopadhyay et al., 2007), 
which markedly increased MitoSOX-specific fluorescence (Figure 5-12B). 
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Figure 5-12: Mitochondrial superoxide production is not changed in response to CSE treatment 
(A) Flow cytometry analysis of MLE12 cells stained with MitoSOX Red for detection of mitochondrial superoxide generation 
after 6, 24, or 48 h of treatment with 10, 15, and 25 % CSE. n=3-6. Bar graphs show mean+SEM. (B) Representative flow 
cytometry analysis for MitoSOX fluorescence before and after addition of antimycin A. Values are displayed as fold change 
relative to untreated control cells.  
To directly assess mitochondrial ATP production and function of the respiratory chain cellular oxygen 
consumption was analyzed. Basal oxygen consumption was slightly increased in CSE-treated cells 
(Figure 5-13A&B). Reduction of oxygen requires activity of complex I-IV of the respiratory chain 
which builds up a proton gradient across the inner mitochondrial membrane, which is then used by 
complex V to generate ATP. These reactions are usually coupled. Therefore, inhibition of proton flow 
through the mitochondrial inner membrane via complex V also decreases electron flow and oxygen 
consumption by the respiratory chain complexes I-IV. Residual oxygen consumption after complex V 
inhibition accounts for proton leak through the mitochondrial membrane and is not contributing to 
mitochondrial ATP production (Brand and Nicholls, 2011). Proton leak through the mitochondrial 
membrane was not affected by low dose CSE treatment of MLE12 cells (Figure 5-13A&B). Usually, 
mitochondria possess a spare respiratory capacity which is not used during baseline respiration. 
Enabling uncontrolled proton flow across the mitochondrial membrane by using a protonophore 
such as CCCP leads to uncoupling of respiratory chain activity from ATP production and thereby 
induces maximal respiratory activity (Brand and Nicholls, 2011). Similar to basal levels, maximal 
oxygen consumption was significantly increased in CSE-treated cells (Figure 5-13A&B). Finally, after 
blockade of complex I and III using rotenone and antimycin A only non-mitochondrial respiration 
remains, which proves dependency of oxygen consumption on mitochondrial activity (Figure 5-13A). 
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Importantly, these analyses reveal that mitochondrial ATP production, estimated as oligomycin-
sensitive respiration, is increased in CSE-treated cells (Figure 5-13C). Accordingly, steady state levels 
of cellular ATP were slightly increased after CSE treatment (Figure 5-13D). 
 
Figure 5-13: Mitochondrial oxygen consumption is increased in CSE-treated cells 
(A) Representative curve of one oxygraph experiment depicting the assessment of the various parameters of mitochondrial 
oxygen consumption rates. Outliers caused by reagent injection were excluded for better visibility. (B) Oxygen consumption 
rate in MLE12 cells after 24 h of 25 % CSE treatment. n=5. Bars show mean+SEM. Non-mitochondrial oxygen consumption 
was subtracted from all values. Significance was determined using two-way ANOVA with Bonferroni multiple comparison 
test comparing Ctrl vs. CSE-treated cells. *:p<0.05. (C) Mitochondrial ATP production (oligomycin-sensitive respiration) in 
24 h CSE-treated MLE12 cells. n=5. Bars show mean+SEM. Significance was determined using one-sample t-test. *:p< 0.05 
(D) Cellular ATP levels in MLE12 cells after treatment with 10 or 25 % CSE for 24 h relative to untreated control. Significance 
was determined using one-way ANOVA with Dunnett’s multiple comparison test comparing Ctrl vs. CSE-treated groups. 
*:p< 0.05, **:p< 0.01 
In summary, these data demonstrate increased mitochondrial activity and ATP production in 
response to CSE-induced mitochondrial hyperfusion in MLE12 cells. 
5.2.3 Low dose cigarette smoke extract treatment does not activate a 
protein stress response at mitochondria 
Mitochondrial damage induces activation of mitochondrial proteostasis pathways such as the mtUPR, 
MAD or disposal of damaged mitochondria via mitophagy. To analyze if low dose CSE induces a 
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protein stress response at mitochondria, expression of the mitochondrial chaperone HSP60 (a marker 
for mtUPR) and the respiratory chain complex V gene ATP5A (a marker for mitochondrial mass) was 
analyzed. HSP60 and ATP5A expression was not altered in response to low dose CSE (Figure 
5-14A&B) indicating the absence of mtUPR or mitophagy induction. Furthermore, levels of full-length 
PINK1, which accumulates at the mitochondrial outer membrane as a signal for mitochondrial 
degradation via the mitophagy pathway, were assessed in mitochondrial fractionations. A double 
band for full-length PINK1 with a molecular weight of 67 kDa and a single band for cleaved PINK1 at 
55 kDa were detected at mitochondria of CSE-treated MLE12 cells. Levels of full-length PINK1 were 
not altered in response to CSE (Figure 5-14C). 
 
Figure 5-14: CSE does not induce mtUPR or mitophagy activation 
(A) Representative Western blot analysis for expression of HSP60 and ATP5A in MLE12 cells treated with CCCP, 10, or 25 % 
CSE for 6, 24, or 48 h. Tubulin was used as a loading control. (B) Densitometric analysis of HSP60 and ATP5A expression in 
MLE12 cells. n= 3. Bar graphs show mean+SEM. Values are displayed as fold change relative to untreated cells. (C) Western 
blot analysis and densitometric quantification of PINK1 protein levels in four independently prepared mitochondrial 
fractions of MLE12 cells treated with 25 % CSE or control medium for 24 h. ATP5A expression was used as loading control. 
Two bands were detected for full-length (FL) and one band for cleaved (CL) PINK1.  
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Taken together, these data indicate that the applied conditions of CSE treatment do not activate a 
mitochondrial protein stress response. This does not exclude the possibility that retro-translocation 
of proteins via MAD or proteasomal recruitment to mitochondria are induced to cope with an 
increased demand for mitochondrial protein turnover upon CSE treatment. 
To analyze for the induction of mitochondria-associated degradation, levels of the MAD mediators 
VCP and VMS1 were analyzed in whole cell lysates. Intriguingly, VMS1 was significantly increased 
upon 24 h of 10 % CSE treatment, while in other conditions the increase in VMS1 expression did not 
reach statistical significance (Figure 5-15A&B). Total VCP levels remained unchanged upon CSE or 
CCCP treatment (Figure 5-15A&B).  
 
Figure 5-15: Mitochondria-associated degradation is only slightly activated in response to CSE 
(A) Representative Western blot analysis of VMS1 and VCP expression in MLE12 cells treated with CCCP, 10 %, or 25 % CSE 
for 6, 24, or 48 h. Tubulin was used as a loading control. (B) Densitometric analysis of VMS1 and VCP expression in MLE12 
cells. n=3. Bar graphs show mean+SEM. Values are displayed as fold change relative to untreated cells. Significance was 
determined using one-way ANOVA with Dunnett’s multiple comparison test comparing treated groups vs. time-matched 
controls. *:p< 0.05. 
To analyze whether the proteasome directly associates with mitochondria, recruitment of 
proteasomes to mitochondria was analyzed in crude mitochondrial fractions. No significant change in 
20S or 19S proteasome subunits at mitochondria was observed in response to CSE treatment (Figure 
5-16A). Of note, occurrence of VMS1 in mitochondrial fractions, which would argue in favor of MAD 
activation, could not be detected in control or CSE-treated cells (data not shown). Additionally, 
proteasome activity was analyzed in cytosolic and mitochondrial fractions. Proteasome activity was 
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reduced in response to CSE treatment in the cytosolic fraction but not in the mitochondrial fractions. 
However, these changes were not statistically significant (Figure 5-16B). 
 
Figure 5-16: No recruitment of proteasomes to mitochondria in response to CSE 
(A) Western blot analysis and densitometric quantification of proteasome subunit levels in four independently prepared 
mitochondrial fractions of MLE12 cells treated with 25 % CSE or control medium for 24 h. ATP5A was used as loading 
control. (B) CT-L proteasome activity in cytosolic and crude mitochondrial fractions of MLE12 cells treated with 25 % CSE or 
control medium for 24 h. 
In summary, a slight increase in VMS1 expression and, hence, maybe proteasome-mediated 
mitochondria-associated degradation is seen. However, the absence of induction of the mtUPR, 
mitophagy, or recruitment of proteasomes to mitochondria indicates that under conditions of low 
dose CSE treatment, mitochondrial protein homeostasis is not grossly altered and therefore no broad 
activation of mitochondrial proteostasis pathways is induced. 
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5.3 Discussion 
Exposure of the lung to cigarette smoke is known to be involved in the pathogenesis of chronic lung 
diseases and contributes to accelerated aging of the lung (Mercado et al., 2015). Exposure of cells to 
cigarette smoke extract is a commonly used model to study the effect of cigarette smoke in the lung 
(Nyunoya et al., 2014). Here, low and nontoxic doses of cigarette smoke extract were used. Absence 
of toxicity was clearly shown by absence of LDH release as an indicator for necrotic cell death and of 
caspase 3 cleavage as a marker for apoptotic cell death in CSE-treated cells. Moreover, nontoxic 
doses of CSE did not severely disturb protein homeostasis in mitochondria as induction of 
mitochondrial quality control pathways was not evident. Nontoxic CSE treatment, however, induced 
an adaptive response of alveolar epithelial cell mitochondria involving hyperfusion of the 
mitochondrial network, increased mitochondrial oxygen consumption and a transient increase in 
MFN2 expression.  
5.3.1 Nontoxic doses of cigarette smoke extract induce mitochondrial 
hyperfusion in alveolar epithelial cells 
Exposure of alveolar epithelial cells to low doses of cigarette smoke extract induced mitochondrial 
hyperfusion as evident by elongated and highly connected mitochondria and increased levels of the 
mitochondrial fusion protein MFN2. Mitochondrial network dynamics are dependent on a tight 
balance of the activity of mitochondrial fusion and fission proteins (Youle and van der Bliek, 2012). 
Mitochondrial hyperfusion can therefore result either from increased fusion activity or from 
decreased fission activity. Initially, stress-induced mitochondrial hyperfusion was described to be 
dependent on OPA1 and MFN1, but not on MFN2 (Tondera et al., 2009). In that case, the effect was 
related to altered activity of the fusion machinery as no expressional changes in fusion proteins 
occurred (Tondera et al., 2009). Another study described that during oxidative stress mitochondrial 
hyperfusion is dependent on increased oligomerization and thereby activation of the fusion proteins 
MFN1 and MFN2. Again, no changes in absolute levels of fusion and fission proteins were observed 
(Shutt et al., 2012). In contrast to increased fusion in stress-induced mitochondrial hyperfusion, 
starvation-induced mitochondrial hyperfusion was dependent on phosphorylation of the fission 
protein DRP1 and its decreased translocation to mitochondria (Gomes et al., 2011).  
In this study the fusion protein MFN2 was found to be upregulated in response to low dose CSE 
exposure, while expression of the mitochondrial mass marker ATP5A, the fusion protein MFN1, the 
inner membrane fusion protein OPA1, and the mitochondrial fission protein DRP1 were not altered. 
Importantly, also no change in DRP1 translocation to mitochondria was found in response to CSE. 
Hence, mitochondrial hyperfusion in this setting is most probably different to starvation-induced 
hyperfusion and not a result of decreased fission activity.  
Mitochondrial function in response to cigarette smoke extract exposure 
97 
As expressional changes in fusion or fission proteins were not observed in any of the three 
aforementioned studies, expressional changes are clearly not necessary to trigger mitochondrial 
hyperfusion (Gomes et al., 2011; Shutt et al., 2012; Tondera et al., 2009). Rather altered activity of 
the fusion and fission machinery contributes to mitochondrial hyperfusion. Accordingly, CSE-induced 
mitochondrial hyperfusion was evident already after 6 h of CSE treatment when no changes in 
Mitofusin levels are present and hyperfusion lasted up to 48 h when MFN2 levels were already 
declining to baseline. This argues that changes in activity and not in expression are the decisive factor 
also for CSE-induced hyperfusion. 
Since all mitochondrial fusion proteins are expressed in alveolar epithelial cells, it cannot be 
delineated whether activity changes in specific fusion or fission proteins are the underlying reason 
for the observed hyperfusion. However, the observed upregulation of MFN2 speaks in favor of a role 
of MFN2 in CSE-induced hyperfusion. Several published data indicate that changes in mitochondrial 
morphology can be associated with endogenous changes of single mitochondrial fusion proteins. 
Downregulation of MFN2 was associated with mitochondrial fragmentation without changes in 
MFN1 level (Martorell-Riera et al., 2014). Furthermore, upregulation of MFN1 but not MFN2 was 
correlated with elongated mitochondria in the brain of ME7-prion-infected mice (Choi et al., 2014). 
Additionally, a transient endogenous upregulation of MFN2 was found in senescence-induced 
hyperfusion. This effect was, however, also coupled with decreased activity of the fission machinery 
(Yoon et al., 2006). Moreover, overexpression of MFN2 in neurons or in pulmonary artery smooth 
muscle cells also induced mitochondrial elongation (Cagalinec et al., 2013; Ryan et al., 2013). These 
data show that altered expression levels of single fusion proteins indeed have the capability to 
functionally influence mitochondrial hyperfusion. Hence, while expressional changes in MFN2 are 
obviously not the sole reason for the observed mitochondrial hyperfusion, MFN2 upregulation might 
contribute in addition to changes in fusion protein activity. Thus, changes in fusion protein activity 
may account for the early induction of hyperfusion with upregulation of MFN2 levels representing an 
adaptive response which happens in addition to the previously described stress-induced hyperfusion 
pathways. As levels and activity of mitochondrial fusion and fission proteins need to be tightly 
balanced, elevated MFN2 levels are probably not maintained over longer periods but decline to 
baseline. 
These results on CSE-induced mitochondrial hyperfusion in alveolar epithelial cells differ from data 
obtained for bronchial epithelial cells. In one study, mitochondrial fragmentation was observed in 
primary human bronchial epithelial cells treated with CSE for 48 h. Mitochondrial fragmentation was 
associated with increased localization of the fission protein DRP1 to mitochondria without any 
changes for MFN2 or other mitochondrial fusion proteins (Hara et al., 2013). In contrast, another 
study described elongated and branched mitochondria in bronchial epithelial cells after chronic 
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exposure to cigarette smoke extract for six months and in primary bronchial epithelial cells isolated 
from COPD patients (Hoffmann et al., 2013). As these studies were performed in bronchial epithelial 
cells there is probably a strong cell type dependency for triggering an adaptive mitochondrial 
hyperfusion response of lung epithelial cells to cigarette smoke extract.  
5.3.2 Mitochondrial hyperfusion is associated with increased 
mitochondrial function 
Mitochondrial morphology is closely connected with mitochondrial function. Especially, 
mitochondrial hyperfusion was reported to be connected with an increased efficiency of ATP 
production (Gomes et al., 2011; Tondera et al., 2009). Accordingly, CSE-induced mitochondrial 
hyperfusion was associated with enhanced metabolic activity, increased cellular ATP levels, 
augmented mitochondrial membrane potential, and elevated oxygen consumption rates in MLE12 
cells. These observations are well in agreement with the concept of stress-induced mitochondrial 
hyperfusion as a protective response to increase the cell’s ability to repair damage. Mitochondrial 
hyperfusion was previously shown to be beneficial in response to a variety of stressors including 
amino acid starvation, UV exposure, actinomycin, or cycloheximide treatment (Gomes et al., 2011; 
Tondera et al., 2009). As mitochondrial hyperfusion can also be induced by oxidative stress (Shutt et 
al., 2012; Yoon et al., 2006), it seems plausible that this survival response is also part of the oxidative 
stress response to cigarette smoke extract.  
While mitochondrial hyperfusion was observed in MLE12 and pmATII cells, the increase in 
mitochondrial function was only measured in MLE12 cells. This was mainly due to the cumbersome 
work of culturing sufficient numbers of primary mouse ATII cells for mitochondrial analyses. 
However, the results obtained for the MLE12 cells might well be extrapolated to pmATII cells as 
previous studies also observed a clear association between mitochondrial hyperfusion and metabolic 
activity using different cell types (Gomes et al., 2011; Tondera et al., 2009). In addition, an increase in 
mitochondrial respiration in response to cigarette smoke exposure was previously shown in pmATII 
cells. Agarwal et al. showed that in pmATII cells respiring on the mitochondria-dependent substrates 
pyruvate or palmitate, oxygen consumption rates were significantly increased after CSE or cigarette 
smoke exposure (Agarwal et al., 2013, 2014). Therefore, although mitochondrial function in pmATII 
was not directly measured in this study, one can speculate that cigarette smoke-induced 
mitochondrial hyperfusion, which is shown here to occur in different types of alveolar epithelial cells, 
also might influence metabolic activity in these cells. Additionally, mitochondrial hyperfusion in CSE-
treated bronchial epithelial cells was associated with increased cellular ATP levels (Hoffmann et al., 
2013), which further supports the notion of increased mitochondrial respiratory chain activity in 
response to cigarette smoke. 
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In summary, cigarette smoke-induced mitochondrial hyperfusion is associated with increased 
mitochondrial oxygen consumption and ATP production. Therefore, this adaptive mitochondrial 
response to nontoxic doses of cigarette smoke exposure might be useful for the cell in order to 
provide ATP for the removal of cigarette smoke-induced damage to cellular functions and structures. 
5.3.3 Nontoxic cigarette smoke exposure does not induce activation of 
mitochondrial proteostasis pathways 
Cigarette smoke is well known to induce damage in the cell such as DNA damage or protein oxidation 
(Bowler et al., 2004; Nyunoya et al., 2014). Additionally, it is known that cigarette smoke induces 
protein stress responses in the cytosol and in the ER (Kelsen et al., 2008; van Rijt et al., 2012; Wei et 
al., 2013). We did not, however, observe any alteration in mitochondrial proteostasis in response to 
CSE treatment of alveolar epithelial cells. Accumulation of misfolded proteins in the mitochondrial 
matrix, which exceeds the folding capacity of mitochondrial chaperones, triggers the mitochondrial 
unfolded protein response. Increased expression of HSP60 is one hallmark of mtUPR induction 
(Jovaisaite et al., 2013; Pellegrino et al., 2013; Zhao, 2002). However, in the case of low dose CSE 
exposure, no changes in HSP60 expression were observed indicating absence of a pronounced 
accumulation of damaged mitochondrial proteins.  
Irreparable damage to mitochondria induces degradation of whole organelles via mitophagy. The 
PINK1/Parkin pathway constitutes one major mitophagy pathway in response to mitochondrial 
damage. Under baseline conditions, PINK1 is rapidly degraded in mitochondria while it is stabilized 
upon mitochondrial damage (Jin and Youle, 2012; Narendra et al., 2010). No changes in 
mitochondrial PINK1 levels were observed which indicates absence of PINK1/Parkin-dependent 
mitophagy. Furthermore, levels of ATP5A as a general marker for mitochondrial mass remained 
stable upon nontoxic CSE treatment. It can thus be concluded that nontoxic doses of CSE do not 
broadly activate mitophagy.  
Protein damage at mitochondria can also be resolved by degradation of proteins by the cytosolic 
ubiquitin proteasome system. Degradation of mitochondrial proteins by the proteasome can be 
mediated by VMS1/VCP-dependent translocation of mitochondrial proteins or by direct association 
of proteasomes at mitochondria (Heo and Rutter, 2011; Livnat-Levanon and Glickman, 2011). No 
change in expression was observed for total VCP levels. However, VCP is involved in a plethora of 
cellular processes including DNA damage responses or ERAD and its function is regulated by several 
adaptor proteins (Meyer et al., 2012). VMS1 is the adaptor protein of VCP which is specifically 
involved in MAD (Heo et al., 2010; Meyer et al., 2012). Indeed, VMS1 levels were increased in 
response to CSE treatment. However, this increase was only found to be significant for 24 h of 10 % 
CSE treatment. Additionally, recruitment of proteasomes to mitochondria was analyzed by assessing 
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the presence of proteasome subunits in crude mitochondrial isolations. However, no consistent 
changes in proteasome levels at mitochondria were observed indicating no increased recruitment of 
proteasomes to mitochondria. 
Altogether, no changes in mitophagy, the mtUPR or in proteasomal recruitment to mitochondria 
occur upon treatment of MLE12 cells with low doses of CSE. A small increase in VMS1 expression 
points towards slightly increased MAD which is however not a pronounced effect as it is only 
significant after 24 h of 10 % CSE treatment. Therefore, nontoxic CSE treatment does not induce a 
broad mitochondrial protein stress response. Indeed, nontoxic CSE treatment also induced only mild 
oxidative stress to mitochondria as indicated by the finding that mitochondrial superoxide 
production was not increased by CSE treatment. 
The mild and nontoxic doses of CSE used in this study have different effects on cellular physiology 
and mitochondrial function than higher, toxic doses. Another study, which reported induction of 
necrotic cell death by cigarette smoke extract in primary bronchial epithelial cells also observed 
mitochondrial damage such as decreased membrane potential (van der Toorn et al., 2007). 
Furthermore, a recent study showed increased PINK1 expression and mitophagy in CSE-treated 
bronchial epithelial cells and in cigarette smoke-exposed mice. In this study, mitophagy was an 
upstream event of necrotic cell death which clearly indicates a different outcome of the cigarette 
smoke treatment (Mizumura et al., 2014). A different mitochondrial response towards toxic CSE 
doses is plausible since mitochondria are an integral component of apoptosis and necroptosis 
pathways (Liesa et al., 2009; Vandenabeele et al., 2010). Therefore, the effect of cigarette smoke on 
pulmonary epithelial cell mitochondria might strongly depend on the dose. Low doses might induce a 
pro survival response while higher, toxic doses involve mitochondrial damage as well as activation of 
mitochondrial and non-mitochondrial cell death pathways. In addition to dose and maybe cell type 
specific effects of smoke on mitochondria, a time-dependent effect has also been observed in wood 
smoke-treated guinea pigs. Wood smoke exposure led to an initial decrease of mitochondrial 
function which, however, was fully recovered and even overcompensated at later timepoints 
(Granados-Castro et al., 2013). 
5.3.4 A hyperfused mitochondrial network poses a threat to cellular health 
Although nontoxic doses of CSE do not directly harm mitochondria, cigarette smoke-induced 
mitochondrial hyperfusion might pose a threat to cellular health. While short term mitochondrial 
hyperfusion is reported as a pro survival response (Blackstone and Chang, 2011; Tondera et al., 2009) 
a chronically hyperfused mitochondrial network might be detrimental as it slows mitochondrial 
dynamics and thereby attenuates mitochondrial quality control. This would render the cell more 
vulnerable to additional stress (Figge et al., 2013). Furthermore, hyperfused mitochondria are spared 
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from removal via mitophagy (Gomes and Scorrano, 2013). Therefore, sustained mitochondrial 
hyperfusion, e.g. in response to continuous exposure to nontoxic cigarette smoke, might reduce 
mitophagy activity and thereby also attenuate its important function for mitochondrial quality 
control. This mechanism was suggested to account for the occurrence of hyperfused dysfunctional 
mitochondria in aging muscles (Marzetti et al., 2013). In accordance with this hypothesis, sustained 
mitochondrial elongation has also been associated with cellular senescence (Lee et al., 2007) and vice 
versa, induction of cellular senescence is accompanied by mitochondrial elongation (Yoon et al., 
2006). Cigarette smoke is known to induce cellular senescence and accelerate aging (Tsuji et al., 
2004). Furthermore, induction of senescence in pulmonary cells has been proposed as a pathogenic 
mechanisms for COPD progression (Mercado et al., 2015; Müller et al., 2006; Tsuji et al., 2006). 
Therefore, it can be speculated that cigarette smoke extract-induced mitochondrial hyperfusion - 
although being part of a beneficial adaptive stress response in the first place - contributes to age-
related COPD pathogenesis by promoting diminished mitochondrial quality control, impaired cellular 
stress resistance, and cellular senescence. Importantly, a recent study showed that mitochondrial 
elongation is found in senescent fibroblasts after 10-15 days of CSE treatment. This study also 
confirmed impaired mitophagy and increased MFN2 expression in CSE-treated lung fibroblasts 
(Ahmad et al., 2015). Hence, mitochondrial elongation seems to be an important step in cigarette 
smoke-induced cellular senescence during COPD development.  
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6 Regulation of proteasomal function during healthy aging of 
the lung 
Parts of this chapter have previously been published as: Caniard A.*, Ballweg K.*, Lukas C., Yildirim 
A.Ö., Eickelberg O., and Meiners S. (2015). Proteasome function is not impaired in healthy aging of 
the lung. Aging (Albany NY) 7, 776–792. 
6.1 Introduction 
In addition to direct exposure to environmental hazards, aging is another major risk factor for the 
development of chronic lung diseases. Additionally, especially in the lung a prominent phenotype of 
“healthy”, disease-free aging is described with a decline in lung function and the development of 
senile emphysema as outlined in paragraph 1.4.4. 
Generally, aging is characterized as the progressive loss of cellular, tissue and organ function that 
leads to increased susceptibility to disease and eventually death. On the cellular level several 
mechanisms have been identified which contribute to loss of function in aged tissues. López-Otín et 
al. recently defined nine “hallmarks of aging” that are causally linked with the aging process (López-
Otín et al., 2013). Loss of proteostasis has been recognized as one of these hallmarks of aging. As 
described in paragraph 1.4, proteasome function was shown to decline in several tissues during aging 
and genetically attenuating or increasing proteasome activity in model organisms was able to 
shorten or increase lifespan, respectively. However, surprisingly little is known about proteasome 
function during healthy aging of the lung. So far, only two studies reported a decrease in 
proteasomal activity in the lungs of aging rats (Breusing et al., 2009; Keller et al., 2000). However, 
these studies only assessed cleavage of the peptidic probe Suc-LLVY-AMC in whole lung lysates and 
do not provide further insights in the regulation of proteasomal activity such as changes in 
proteasome subtypes. To better understand proteasomal regulation during healthy aging of the lung, 
proteasome expression and activity was comprehensively analyzed in lungs of healthy aged WT mice, 
proteasome reporter mice and LMP2 or LMP7 knockout mice. Additionally, lung aging and 
proteasome function in the premature aging mtDNA mutator mouse model was analyzed to assess 
the effect of mitochondrial dysfunction on the aging phenotype in the lung. 
6.2 Results 
Lung aging is accompanied by a decrease in lung function and the development of senile emphysema 
(Janssens et al., 1999). This is also evident in mice lungs (Calvi et al., 2011). As a first step, 
development of senile emphysema and the concomitant decrease in lung function in the lungs of 18 
months old C57Bl/6J mice was confirmed. Indeed, histological sections of aged mice showed a 
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pronounced increase in alveolar space (Figure 6-1A) when compared to two months old mice. 
Similarly, decreased lung function parameters were observed in aged mice (Figure 6-1B). 
 
Figure 6-1: Aged mice have senile emphysema and decreased lung function 
(A) Representative H&E staining of lung from young (2 months old) and aged (18 months old) wildtype C57Bl/6J mice. 
Images from two individual animals are depicted per group. H&E stainings were performed by Anne Caniard. (B) Resistance, 
dynamic elastance and dynamic compliance of lungs of young and aged C57Bl/6J wildtype mice. Significance was 
determined using student’s t-test. ***:p< 0.001. Lung function analysis was performed by the lab of Ali Önder Yildirim. 
6.2.1 Immunoproteasome expression is increased in lungs of aged mice 
To investigate proteasome function in the aged lungs, mRNA and protein expression levels of 
proteasome subunits were analyzed. Protein expression of the proteasome α-subunits was found to 
be significantly increased in whole lung lysates of aged mice while the catalytic subunits β1 and β5 
showed a trend towards increased expression which was, however, not statistically significant (Figure 
6-2B). The mRNA expression levels of the subunits of the standard proteasome similarly showed a 
trend towards increased levels, which was only significant for PSMB5 mRNA (Figure 6-2A). Of note, 
expression of the subunits of the immunoproteasome was significantly upregulated on both mRNA 
and protein level (Figure 6-2A&B).  
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Figure 6-2: Immunoproteasome expression is increased in lungs of aged mice 
(A) RT-qPCR analysis of proteasome subunit mRNA expression in young and aged WT mice. n=8. Bar graphs show 
mean+SEM. (B) Western blot analysis of proteasome subunit expression in young and aged wildtype mice and 
quantification of protein expression relative to the actin loading control. Bar graphs show mean+SEM. Values are displayed 
as fold change relative to young mice. Significance was determined using two-way ANOVA with Bonferroni multiple 
comparison test. *:p< 0.05, **:p< 0.01. 
Increased immunoproteasome levels can either result from increased expression of 
immunoproteasomes in the resident cells of the lung or from increased infiltration of cells expressing 
high levels of immunoproteasomes such as macrophages. Analysis of the bronchoalveolar lavage 
(BAL) fluid containing the loosely attached immune cells in the bronchoalveolar space, however, 
showed no changes in the immune cell composition in young and aged mice (Figure 6-3A&B). 
Furthermore, immunofluorescence staining of the immunoproteasome subunit LMP2 in lung sections 
of young and aged mice revealed no change in the relative number of LMP2 positive cells indicating 
absence of increased immune cell infiltration into aged lungs (Figure 6-3AC&D). To further analyze 
which cell types are responsible for the observed increase in LMP2 expression, lung slices of young 
and aged mice were immunohistochemically stained for LMP2 expression. Immunohistochemistry 
staining for the immunoproteasome subunit LMP2 revealed elevated staining mainly in resident cells 
of the lung (Figure 6-4) which mostly appear to be alveolar macrophages. Alveolar macrophages have 
previously been shown to be the most prominent immunoproteasome-expressing cell type in the 
lung (Keller et al., 2015). In addition, some dispersed staining was apparent in epithelial cells of the 
lung (Figure 6-4, marked by arrows). 
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In summary, these data suggest that the increase in immunoproteasome levels in the aged lung is 
due to elevated expression levels in resident cells of the lung with the highest expression in alveolar 
macrophages but also increased expression in non-immune cells of the lung. 
 
Figure 6-3: No change in immune cell count in the aged lung 
(A) Total cell number in 1 ml BAL fluid from young and aged C57Bl/6J wildtype mice. (B) Cellular composition of BAL cells in 
young and aged wildtype mice. n=8-9. Bar graphs show mean+SEM. (C) Quantification of LMP2-positive cells in lung tissue 
sections of young and aged mice in relation to total cell number (DAPI) using the IMARIS software. n=7-9. Bar graphs show 
mean+SEM. (D) Representative immunofluorescence images from young and aged C57Bl/6J wildtype mice. Staining show 
nuclei (DAPI, blue channel), LMP2 (red channel) and tissue auto-fluorescence (green channel). Scale bar: 100 µm. 
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Figure 6-4: LMP2 expression is mainly increased in macrophages in the aged lung 
(A) Representative staining of lung sections of young and aged C57Bl/6J wildtype mice. Lung sections were stained with an 
LMP2 antibody (red) and subsequently counterstained with hematoxylin staining. LMP2 staining was mainly detected in 
macrophages, with increased intensity in lungs of aged mice. However, in aged mice some positive staining of alveolar 
epithelial structures was also observed (Arrows). Scale bars: 50 µm (B) Representative immunohistochemistry control 
staining using an IgG control antibody.  
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6.2.2 26S proteasome-dependent protein degradation is not altered during 
healthy aging of the lung 
The catalytic activity of the proteasome is not only regulated by the expression of proteasomal 
subunits but depends on the assembly of standard or immunoproteasome subunits into the 20S 
catalytic core complex and is further regulated by attachment of regulatory particles (Paragraph 
1.1.1). To assess the influence of altered proteasome subunit expression on proteasome activity in 
aged mice, proteasome activity was measured with small peptidic substrates specific for the different 
proteasome active sites. Only the caspase-like activity of the proteasome was decreased in aged mice 
while the chymotrypsin-like and trypsin-like activities did not change during aging (Figure 6-5A). This 
finding was further confirmed in another mouse strain using lung tissue lysates from FVB mice 
(Figure 6-5B). Importantly, a decrease in caspase like activity is characteristic for replacement of the 
standard subunit β1 by the immunoproteasome subunit LMP2 (Ferrington and Gregerson, 2012; Van 
Kaer et al., 1994). 
 
Figure 6-5: Caspase-like proteasome activity is decreased in lung tissue of aged mice 
Cleavage of luminogenic model substrates specific for the caspase-like, chymotrypsin-like or trypsin-like active site of the 
proteasome in lung tissue lysate of (A) C57Bl/6J mice (n=8) and in (B) lung tissue lysate of FVB mice (n=6-7). Values are 
displayed as fold change relative to young mice. Bar graphs show mean+SEM. Significance was determined using two-way 
ANOVA with Bonferroni multiple comparison test. **:p< 0.01. The proteasome activity assay in FVB mice was conducted by 
Anne Caniard.  
To confirm this specific decrease in proteasome activity and to assign the activity to the distinct 
proteasome complexes, lung tissue lysates from young and aged mice were subjected to in-gel 
proteasome activity assays after native electrophoretic separation of proteasome complexes. 
Intriguingly, the chymotrypsin-like activity of the 26S/30S and 20S proteasome complexes was very 
similar in young and aged lungs confirming the above results with the peptide substrates (Figure 
6-6A&B). The caspase-like activity, however, was again significantly decreased. This decrease was 
observed predominantly in 20S complexes and not in the assembled 26S or 30S proteasomes of aged 
lung tissue (Figure 6-6C&D).  
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Figure 6-6: Caspase-like activity is decreased in 20S but not in 26S/30S proteasome complexes of aged mice 
(A) Native gel analysis of proteasome complexes with activity overlay for the chymotrypsin-like proteasome activity in lung 
tissue lysates from young and aged C57Bl/6J mice and (B) quantification thereof. (C) Native gel analysis with activity overlay 
for the caspase-like proteasome activity and (D) quantification thereof. The appearance of 20S double bands is possibly due 
to the binding of alternative proteasome regulators such as PA28 family members (Hernebring et al., 2013). Bar graphs 
show mean+SEM. Values are displayed as fold change relative to young mice. Significance was determined using student’s 
t-test. *:p< 0.05. The native gel activity assays shown in this figure were performed by Anne Caniard. 
The 26S and 30S proteasomes are responsible for ubiquitin-mediated degradation of proteasome 
substrates while the 20S proteasome does not degrade ubiquitinated substrates (Finley, 2009). 
Accordingly, ubiquitin-mediated degradation was not impaired in the lungs of aged mice as indicated 
by the absence of accumulation of K48-polyubiquitinated proteins (Figure 6-7A). In line with this 
finding ubiquitin-dependent degradation of the ODD-luc reporter construct was not changed in lungs 
of aged proteasome reporter mice (Figure 6-7B). These mice express luciferase as a reporter gene 
fused to the oxygen-dependent degradation domain (ODD). Under normal conditions, luciferase is 
quickly degraded by the 26S proteasome resulting in a low background luminescent signal. At 
conditions of proteasome inhibition, however, luciferase accumulates leading to an increased 
luminescence signal (Goldman et al., 2011; Kimbrel et al., 2009). 
In summary, these data indicate that 26S and 30S proteasome activity and thereby ubiquitin-
mediated protein degradation is not affected in healthy aging of the lung. However, upregulation of 
immunoproteasome subunits and changes in the caspase-like activity of 20S proteasomes suggest 
increased assembly and activity of immunoproteasomes. 
Regulation of proteasomal function during healthy aging of the lung  
110 
 
Figure 6-7: Ubiquitin-mediated degradation is not changed in lungs of aged mice 
(A) Western blot analysis for lysin-48 (K48)-linked polyubiquitinated proteins in lung tissue lysates from young and aged 
C57Bl/6J mice. Actin was used as a loading control. (B) Relative luciferase activity in lung tissue of young and aged FVB-luc 
reporter mice. n=6-7. Bar graphs show mean+SEM. The ODD-luc activity assay was performed by Anne Caniard. 
6.2.3 LMP2 or LMP7 knockout mice have preserved proteasome activity 
but are not protected from lung aging 
As immunoproteasome subunits were upregulated in the aging lung, the relevance of the 
immunoproteasome in the development of senile lung emphysema was assessed by analyzing lung 
aging in mice deficient for the immunoproteasome subunits LMP2 or LMP7. LMP2 or LMP7 knockout 
mice exhibit no obvious phenotypic alterations under normal maintenance conditions (Fehling et al., 
1994; Van Kaer et al., 1994). Here, no obvious signs of accelerated or decelerated aging were 
observed in aged LMP2 or LMP7 knockout mice. Importantly, the lungs of aged knockout mice 
developed a senile emphysema phenotype just as WT mice, indicating that aging of the lung is not 
affected by deficiency for these immunoproteasome subunits (Figure 6-8A&B). Similar to senile 
emphysema development, the expressional changes of proteasome subunits in young and aged 
LMP2 or LMP7 knockout mice showed a very similar pattern as in WT mice. While expression of the 
standard subunits was unchanged, expression of LMP2 and LMP7 was increased compared to young 
mice in old LMP7 or LMP2 knockout mice, respectively (Figure 6-9A&B).  
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Figure 6-8: Senile emphysema development in the lung of aged LMP2 or LMP7 knockout mice 
Representative H&E staining of lungs from young and aged (A) LMP2-/- and (B) LMP7-/- mice. Images from two individual 
animals are depicted per group. Scale bar: 200 µm. H&E stainings of LMP2-/- mice were performed by Anne Caniard. 
 
Figure 6-9: Increased expression of remaining immunoproteasome subunits in LMP2 or LMP7 knockout mice 
Western blot analysis of proteasome subunit expression and quantification of protein expression relative to the actin 
loading control in (A) LMP2-/- and (B) LMP7-/- mice. Bar graphs show mean+SEM. Values are displayed as fold change relative 
to young mice. Significance was determined using two-way ANOVA with Bonferroni multiple comparison test. **:p< 0.01. 
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As described above, incorporation of immunoproteasome subunits, especially of LMP2, induces an 
decrease in the proteasome caspase-like activity (Van Kaer et al., 1994). According to the inability to 
incorporate LMP2 in proteasome complexes, the caspase-like activity in lungs of young and aged 
LMP2 knockout mice was significantly increased compared to WT mice. Notably, this effect was even 
more pronounced in lungs of aged animals (Figure 6-10A&B). Concordantly, and in contrast to WT 
mice, no changes in proteasome activity were observed between young and aged LMP2 or LMP7 
knockout mice using small peptidic substrates on whole lung lysates (Figure 6-11A&B) or in the 
native gel overlay assay (Figure 6-11C&D). Well in accordance with the lack of changes in 
proteasomal activity between young and aged animals, the levels of K48 polyubiquitinated proteins 
were not changed in LMP2 or LMP7 knockout mice during aging (Figure 6-11E&F). 
In summary, lungs of aged LMP2 or LMP7 knockout mice have a very similar aging phenotype as aged 
WT mice including development of senile lung emphysema. However, proteasome function is 
unchanged in aged LMP2 or LMP7 knockout mice. These results therefore strongly indicate that the 
immunoproteasome-mediated changes in proteasome activity in WT mice are not related to the 
development of an aging phenotype in the lung during healthy lung aging. 
 
 
Figure 6-10: Caspase-like proteasome activity is increased in young and aged LMP2 deficient mice 
Cleavage of luminogenic model substrates specific for the C-L, CT-L or T-L active site of the proteasome in lung tissue lysate 
of (A) young and (B) old WT and LMP2 knockout mice. n=5-8. Bar graphs show mean+SEM. Values are displayed as fold 
change relative to WT mice. Significance was determined using two-way ANOVA with Bonferroni multiple comparison test. 
**:p< 0.01, ***:p< 0.01. 
 
Regulation of proteasomal function during healthy aging of the lung 
113 
 
Figure 6-11: No change in proteasome activity in young and aged LMP2 or LMP7 knockout mice 
(A) Cleavage of luminogenic model substrates specific for the C-L, CT-L or T-L active site of the proteasome in lung tissue 
lysate of LMP2-/- (n=5-8) and (B) LMP7-/- (n=6-11) mice. Bar graphs show mean+SEM. (C) Native gel analysis of proteasome 
complexes with activity overlay for CT-L activity in lung tissue lysate of LMP2-/- or (D) LMP7-/- mice and quantification 
thereof. Bar graphs show mean+SEM. Values are displayed as fold change relative to young mice. (E) Western blot analysis 
for K48-linked polyubiquitinated proteins in lung tissue lysates from young and aged LMP2-/- and (F) LMP7-/-mice. Actin was 
used as a loading control. Native gel analysis of LMP2-/- mice was performed by Anne Caniard. 
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6.2.4 Absence of a lung aging phenotype in premature aging mtDNA 
mutator mice 
To assess the influence of mitochondrial dysfunction on lung aging and proteasomal function in the 
aging lung, the premature aging mtDNA mutator mouse model was analyzed for lung aging. Hence, 
to investigate whether the premature aging phenotype of mtDNA mutator mice also affects the lung, 
lung histology of prematurely aged mtDNA mutator mice was analyzed. Of note, lungs of ten months 
old mtDNA mutator mice did not show any obvious signs of histological alterations such as senile 
emphysema (Figure 6-12).  
 
Figure 6-12: Absence of senile emphysema in premature aging mtDNA mutator mice 
Representative H&E staining of lungs from ten month old WT and mtDNA mutator (Mut) mice. Images from two individual 
animals are depicted per group. Scale bar: 200 µm.  
Furthermore, molecular markers of aging such as Sirt1 protein and p16 and p21 mRNA expression 
were analyzed and only a slight decrease in Sirt1 levels but no changes in p16 or p21 expression were 
observed (Figure 6-13A&B). Similarly, no alterations in proteasome mRNA or protein expression 
(Figure 6-14A&B) and in proteasome activities were observed in these lungs (Figure 6-14C). 
Collectively, these data demonstrate that the accelerated aging phenotype of mtDNA mutator mice 
does not involve premature aging of lung tissue and altered proteasome function. 
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Figure 6-13: No alterations in aging markers in mtDNA mutator mouse lungs 
(A) Sirt1 expression in lung tissue lysates of ten month old WT and mtDNA mutator mice and quantification thereof. 
(B) mRNA expression levels of p16 and p21 in lung tissue of WT and mtDNA mutator mice. n=6-7. Bar graphs show 
mean+SEM. Significance was determined using student’s t-test. *:p< 0.05. 
 
Figure 6-14: No change in proteasome expression and activity in mtDNA mutator mouse lungs 
(A) RT-qPCR analysis of proteasome subunit mRNA expression in mtDNA mutator mice. n=6-7. (B) Western Blot analysis of 
proteasome subunit expression in mtDNA mutator mice and quantification thereof. (C) Cleavage of luminogenic model 
substrates specific for the CT-L, C-L or T-L active site of the proteasome in lung tissue lysate of mtDNA mutator mice. n=4-9. 
Bar graphs show mean+SEM. Values are displayed as fold change relative to WT mice. 
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6.3 Discussion 
Proteostasis failure is one of the hallmarks of aging. However, protein homeostasis during healthy 
aging of the lung still remains to be studied. Here, a comprehensive analysis of proteasome function 
in lung aging is shown using transgenic proteasome reporter and immunoproteasome knockout 
mice. Activity of the 26S proteasome and concordantly ubiquitin-mediated degradation of 
ubiquitinated proteins or a proteasome reporter substrate was not altered in lungs of aged mice. 
Specifically, only the caspase-like proteasome activity was diminished in lung tissues from aged mice 
which could be attributed to increased expression of the catalytic immunoproteasome subunits. 
Mice deficient for the immunoproteasome subunits LMP2 or LMP7 did not show any age-related 
downregulation of proteasome activity. However, these mice still displayed age-related 
emphysematous changes in the lung. This argues that single immunoproteasome subunits do not 
play a protective role for lung aging. Furthermore, no changes in proteasome activity and lung 
phenotype were observed in lungs of the premature aging mtDNA mutator mice.  
6.3.1 Proteasome function is not markedly impaired in aged lungs 
Proteasome function was found to decrease during aging in several tissues and species 
(Chondrogianni et al., 2014; Dahlmann, 2007; Farout and Friguet, 2006; Keller et al., 2000). 
Proteostasis dysfunction during aging is thought to contribute to tissue damage by decreased 
degradation of damaged proteins thereby inducing aggregate formation and protein toxicity 
(Breusing et al., 2009; Chondrogianni et al., 2014; Ding et al., 2006; Farout and Friguet, 2006; Keller 
et al., 2000). This comprehensive analysis of proteasome activity in the lungs of aged mice, however, 
revealed that proteasome activity is not substantially impaired during healthy aging. While 
development of senile emphysema and age-dependent impairment of lung function was observed in 
lungs of aged mice, the activity of the proteasome was preserved. Only the caspase-like activity of 
the proteasome was found to decline during aging. However, this specific change of the proteasomal 
activity in aged lungs did not affect overall ubiquitin-mediated protein degradation. Specifically, the 
proteasome reporter substrate ODD-luciferase did not accumulate in the lungs of reporter animals 
during aging. In accordance with this finding, it has been reported that the caspase-like activity has 
only a minor contribution to overall protein degradation by the proteasome. It rather determines 
degradation rates of specific substrates and the composition of the degradation products (Kisselev et 
al., 1999, 2006). Interestingly, a decrease in caspase-like activity was also consistently reported in 
other tissues during aging while results for the chymotrypsin and trypsin-like activity were not 
consistent (Dahlmann, 2007).  
These results are in contrast to results obtained for the lungs of aged rats in which an impairment of 
the chymotrypsin-like activity was observed in whole lung tissue of 18-24 months old rats (Breusing 
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et al., 2009; Keller et al., 2000). This discrepancy might be related to substantial differences in tissue 
preparation and proteasome activity assays in these studies or to species-related variance. However, 
the findings are in accordance with several reports that studied proteasome function in aging 
specifically in the brain: No impairment in ubiquitin-mediated protein degradation was detected by 
Cook et al using GFP-based proteasome reporter mice (Cook et al., 2009). Similarly, the degradation 
rate of polyubiquitinated model substrates was not changed in isolated 26S proteasomes from the 
brains of young and aged rats (Giannini et al., 2013). Additionally, 20S proteasome activity but not 
26S proteasome function, which is responsible for ubiquitin-mediated turnover, correlated with 
species lifespan (Pickering et al., 2015). These data thus suggest that in the course of healthy aging of 
the lungs not overall ubiquitin-mediated protein degradation is altered but possibly proteasome 
cleavage specificity. 
6.3.2 Immunoproteasome expression is elevated in aged lungs 
Immunoproteasome expression is increased in aged mice. Elevated expression of 
immunoproteasome subunits was found both on mRNA and on proteins levels in whole lung 
samples. Immunohistochemical analysis showed that increased LMP2 expression occurs in alveolar 
macrophages and also in alveolar epithelial cells. Increased immunoproteasome content in the lung 
is well in accordance with the observed decrease in caspase-like activity. Immunoproteasomes have 
an altered cleavage site specificity which has been attributed to their specific function for the 
generation of MHC class I epitopes. Immunoproteasomes preferentially generate peptides with 
hydrophobic C-termini that have a higher affinity for binding into the MHC class I binding groove 
thereby improving MHC class I epitope generation and subsequent adaptive immune responses 
(Groettrup et al., 2010). For this reason, immunoproteasomes generally show diminished caspase-
like activity (cleavage after acidic residues) compared to standard proteasomes while the other two 
active sites (cleavage after basic or hydrophobic residues) are not changed (Ferrington and 
Gregerson, 2012). Accordingly, when immunoproteasome expression was abolished in LMP2 or 
LMP7 knockout animals the caspase-like proteasome activity was restored to normal. The relative 
difference in caspase-like activity was already seen by directly comparing young WT and LMP2 
knockout mice but it was particularly evident when comparing aged mice. This further argues in favor 
of the dependence of the caspase-like activity on increased immunoproteasome subunit 
incorporation in aging. Altogether, these findings imply that, in the lung, the decrease in proteasome 
activity during aging is not based on a loss of function phenotype of the proteasome but rather on 
altered proteasome subunit composition. 
Induction of immunoproteasomes in aging has also been observed in other tissues such as muscle 
and brain (Ferrington, 2005; Giannini et al., 2013). Generally, it can be attributed either to enhanced 
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recruitment of immune cells to the aged tissue or increased formation of immunoproteasomes in 
resident cells. The immunohistochemical analysis in this study suggests increased LMP2 expression 
especially in macrophages in the aged lung. Macrophages are the main immunoproteasome-
expressing cell type in the lung (Keller et al., 2015) and immunoproteasome expression accounts for 
approximately 50 % of total proteasome content in macrophages of young mice (I. Kammerl: 
unpublished data). Although an increase in macrophage content in lungs of aged mice was reported 
before (Calvi et al., 2011), no changes in the immune cell count in the BAL and no obvious difference 
in the number of LMP2-positive cells in the lung were found in this study. Hence, elevated LMP2 
levels are most probably not due to increased recruitment of immune cells in the aged lung but 
rather based on increased expression of immunoproteasome subunits in resident cells. Increased 
expression of immunoproteasome in alveolar macrophages might affect macrophage polarization. 
Polarization towards anti-inflammatory M2 macrophages was recently described to be enhanced 
upon immunoproteasome ablation (Chen et al., 2016). Furthermore, altered immunoproteasome 
expression in non-immune cells might possibly affect immune responses in the lung as it is supposed 
to alter cleavage site specificity of the proteasome. This might affect epitope processing and thus 
MHC class I immune surveillance. Therefore, increased immunoproteasome expression might 
modulate immune responses and possibly add to the risk of autoimmunity (Basler et al., 2013; 
Eleftheriadis, 2012). Indeed, the prevalence of autoimmune diseases clearly rises with age (Hasler 
and Zouali, 2005). Alternatively, upregulation of immunoproteasomes might represent a response to 
increased oxidative stress during aging. Accordingly, oxidative stress increases during aging (López-
Otín et al., 2013; Stadtman, 2006) and immunoproteasomes have been suggested to be involved in 
the degradation of oxidatively modified proteins (Aiken et al., 2011; Ebstein et al., 2013; Nathan et 
al., 2013; Seifert et al., 2010). Hence, increased expression of immunoproteasomes might also arise 
from an increased need to degrade oxidatively damaged proteins.  
6.3.3 Immunoproteasome expression does not causally contribute to the 
aging phenotype of the lung 
The causal contribution of elevated immunoproteasome expression to aging has not been proven so 
far. In general, upregulation of immunoproteasome subunits during aging has been proposed as a 
compensatory mechanism for decreased activity of constitutive proteasomes (Chondrogianni et al., 
2014). As immunoproteasomes are not only upregulated during aging but also immunoproteasome 
expression correlates with species longevity (Pickering et al., 2015), it is most likely that the increase 
of immunoproteasome expression is a protective and compensatory effect during aging and not part 
of detrimental age-related changes. Therefore one would expect that LMP2 or LMP7 knockout mice 
suffer more from age-related alterations of lung structure and function than WT mice. However, no 
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aggravated changes in lung aging were found in LMP2 or LMP7 knockout mice. This implies that 
knockdown of singular immunoproteasome subunits does not influence lung aging. Moreover, in 
lungs of aged LMP2 or LMP7 mice overall proteasome activity was restored indicating that the 
change in caspase-like proteasome activity in wildtype mice during aging does not causally influence 
lung aging. Several types of “mixed proteasomes” exist containing partly constitutive subunits and 
partly immunosubunits (Ferrington and Gregerson, 2012; Meiners et al., 2014). Therefore, it cannot 
be excluded that double or even triple knockout mice for the immunoproteasome subunits might 
show altered behavior. However, since the immunoproteasome propeptides generally favor 
cooperative assembly (De et al., 2003) and the incorporation of MECL-1 requires LMP2 (Groettrup et 
al., 1997), at least several possibilities of mixed proteasomes are ruled out. 
In contrast to these data, another study observed diminished proteasome activity in liver and brain 
of 12 months old LMP2 knockout mice compared to four months old animals. However, already in 
this study, strong differences between the two analyzed tissues were observed (Ding et al., 2006). 
Furthermore, in retinal epithelial cells of aged LMP7 knockout mice, proteasome activity was 
unchanged and in LMP7 and MECL-1 double knockout mice it was even elevated with age (Hussong 
et al., 2010). These data therefore argue that in immunoproteasome knockout mice proteasome 
activity is regulated in a very tissue-specific manner during aging and is not generally related to 
detrimental age-related changes. 
6.3.4 Proteostasis in healthy aging of the lung 
Altogether, these findings indicate that healthy aging of the lung and progressive development of 
senile emphysema does not involve impairment of proteasome function. In support of this notion, a 
transgenic mouse model with decreased chymotrypsin-like proteasome activity had a preserved lung 
structure, although these mice developed age-related phenotypes in other organs and tissues and 
died prematurely (Tomaru et al., 2012; Yamada et al., 2015). As no significant alteration in lung 
proteasome function was observed here, it is tempting to speculate that protein homeostasis in the 
lung remains functional upon healthy aging. Damaged proteins tend to aggregate during aging 
thereby inducing impairment of proteasome function (Andersson et al., 2013; Walther et al., 2015). 
This leads to disability of the proteasome system to degrade misfolded proteins and thereby 
increases the load of damaged proteins, which induces a vicious cycle of diminished protein 
degradation and aggregate formation (Andersson et al., 2013; Bence et al., 2001; Hipp et al., 2012). 
This model, however, suggests that up to a specific protein damage threshold protein homeostasis 
may remain functional. In the light of these data it seems plausible to speculate that this threshold is 
not exceeded during healthy aging of the lung. Therefore, dysregulation of proteostasis as a hallmark 
of aging is probably of minor importance during lung aging under conditions of healthy aging.  
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6.3.5 Mitochondrial function in lung aging 
In addition to proteasome function, the involvement of mitochondrial dysfunction in lung aging was 
analyzed. Therefore, the aging phenotype of the lung in the premature aging mtDNA mutator mouse 
model was assessed. The mtDNA mutator mice accumulate mutations in the mtDNA which leads to 
mitochondrial dysfunction in aged mice, which was linked to an aging phenotype in several tissues 
(Trifunovic et al., 2004). However, no signs of senile emphysema were observed in old mtDNA 
mutator mice. This correlated well with a minor lung aging phenotype in these mice as assessed by 
molecular markers of aging. Generally, alterations of lung function and lung morphology are not well 
recapitulated in many premature aging mouse models (Meiners et al., 2015). While some premature 
aging mouse models, such as the Klotho mice, senescence-accelerated mice or senescence-marker-
protein30 deficient mice show airspace enlargement, no lung phenotype was observed e.g. in the 
telomerase RNA null mice (Alder et al., 2011; Kurozumi et al., 1994; Meiners et al., 2015; Sato et al., 
2007). Therefore, formation of senile emphysema is not necessarily associated with some aging 
factors. Hence, as diminished mitochondrial activity does not result in premature aging of the lung, 
mitochondrial dysfunction does not appear to be a driving pathway of lung aging. 
Together, these data suggest that premature aging based on mitochondrial dysfunction does not 
primarily affect the aging phenotype in the lung. This finding is parallel to a premature aging mouse 
model based on decreased proteasome activity. Mice with premature aging based on diminished 
proteasome activity did not develop a lung aging phenotype and senile emphysema under normal 
maintenance conditions (Yamada et al., 2015). However, although no signs of lung aging were 
observed at baseline, these mice were more susceptible for cigarette smoke-induced emphysema 
development (Yamada et al., 2015).  
In summary, these data show that alterations of both proteasomal as well as mitochondrial function 
are not directly linked to healthy aging of the lung. However, as shown in a premature aging mouse 
model based on proteasome dysfunction, decreased proteasome activity during aging might well 
influence the susceptibility to environmental factors during aging. This is well in accordance with the 
aforementioned concept of a damage threshold which needs to be exceeded. A decrease in the 
proteolytic capacity or mitochondrial function due to exposition to environmental hazards might 
exceed the damage threshold thereby tipping the balance towards loss of proteostasis. This process 
might then further augment age-related tissue damage leading to the development of age-related 
lung disease by a self-amplifying mechanism. Importantly, impairment of proteasome function has 
already been reported in response to cigarette smoke and diesel exhaust as well as in smoke- and 
age-related chronic obstructive diseases of the lung (van Rijt et al., 2012; Min et al., 2011; Baker et 
al., 2014; Kipen et al., 2010; Kammerl et al., 2016). 
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7 Concluding remarks 
The aim of this study was to analyze the connection between mitochondria and the proteasome 
system and to examine how mitochondrial and proteasomal functions are affected during healthy 
aging of the lung and in the development of age-related lung disease. Therefore, the interconnection 
of mitochondrial and proteasomal function was analyzed in cellular models of mitochondrial 
dysfunction. Furthermore, the effect of cigarette smoke exposure on mitochondrial function and 
proteostasis in lung epithelial cells was analyzed as well as the regulation of proteasomal function 
during healthy aging of the lung. 
The first part of this thesis confirms the hypothesis that mitochondrial function is closely 
interconnected with mitochondrial function. It is shown that strong and persistent dysfunction of the 
respiratory chain is associated with reduced proteasome activity and lower levels of assembled 26S 
and 30S complexes. Additionally, mild mitochondrial respiratory chain dysfunction was similarly 
associated with decreased proteasome activity in cells harboring specific mutations in subunits of the 
respiratory chain. Furthermore, it is shown that additional regulatory mechanism exist for signaling 
of mitochondrial dysfunction to the proteasome in addition to known regulation by acute ROS 
generation or ATP depletion. Together with the published data which shows that also proteasomal 
dysfunction is tightly associated with mitochondrial function (see paragraph 1.3.1), this study clearly 
indicates that mitochondria and the proteasome system are connected in a more complex manner 
than originally thought. 
The second part explores the effect of environmental hazards on mitochondrial function and quality 
control in the lung and shows that exposure of alveolar epithelial cells to nontoxic doses of cigarette 
smoke extract induces mitochondrial hyperfusion and elevated mitochondrial respiration in the 
absence of a protein stress response at mitochondria. Cigarette smoke extract-induced mitochondrial 
hyperfusion increased cellular metabolic activity and ATP production and thereby can be regarded as 
part of a protective stress response to acute cigarette smoke stress. However, despite being 
beneficial in the first place, this response might decrease the adaption capacity of mitochondrial 
dynamics and might thereby be detrimental under chronic stress settings. 
The third part of this thesis provides novel data on the regulation of proteasomal function during 
healthy aging and in mitochondrial dysfunction-induced premature aging of the lung. It is shown that 
immunoproteasome expression is increased in the aging lung which is associated with a concomitant 
change in the proteasomal cleavage specificities. However, as the aging phenotype is not influenced 
in immunoproteasome knockout mice, this effect is not a decisive factor for the development of 
senile emphysema during healthy lung aging. Similarly, as shown in the prematurely aging mtDNA 
mutator mice, mitochondrial dysfunction does not seem to be the decisive factor during lung aging. 
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However, since the proteasome system shows adaptive changes during healthy aging, these adaption 
processes might reduce the additional adaption capacity of the proteasome system to further insults. 
Altogether, healthy aging or exposure to nontoxic doses of cigarette smoke alone did not impair 
proteasomal or mitochondrial function to an extent which is directly inducing pronounced 
impairment of cellular functions. Hence, this study shows that mitochondria as well as the 
proteasome system have some spare capacity which enables them to remain functional during mild 
insults. However, both insults might limit the spare capacity of the proteasome and mitochondria 
and thereby limit the ability of cells to further adapt to environmental alterations and challenges. 
Hence, the simultaneous burden of an age-related functional decline together with noxious 
environmental exposures such as cigarette smoke might push proteasomal and mitochondrial 
function beyond a damage threshold thereby contributing to the pathogenesis of disease states or to 
a combined functional decline of both systems as described in aging. Furthermore, as both systems 
are closely connected it can be speculated that more severe stress which exceeds the damage 
threshold might tip the balance and induce a vicious cycle of proteasomal dysfunction and 
mitochondrial dysfunction with each system further attenuating function of the respective other 
system (Figure 7-1). Hence, this suggests that the different hallmarks of aging should not be 
considered individually but should also be reflected in context of the interconnections between the 
different hallmarks. 
 
Figure 7-1: Working model: Proteasomal and mitochondrial functions in aging and disease 
Proteasome and mitochondria possess a functional spare capacity which enables the cell to adapt to stress and maintain 
homeostasis during healthy aging or mild environmental insults. However, exposure to stress can reduce the adaptive 
capacity of both systems. Since proteasomal and mitochondrial functions are closely connected decreasing the spare 
capacity of one system beyond a damage threshold might attenuate function of the other system and thus drive a vicious 
cycle leading to cellular dysfunction. 
Concluding remarks 
123 
This study describes alterations in mitochondrial and proteasomal function for both aging and 
cigarette smoke exposure which do not exceed the damage threshold but probably decrease the 
spare capacity of the cell to respond to additional damage. However, further research is necessary to 
fully understand the nature of these thresholds and to test the hypothesis that while single 
impairments of mitochondrial or proteasomal function during healthy aging or upon nontoxic 
cigarette smoke exposure do not exceed damage thresholds, a combined exposure leads to 
breakdown of mitochondrial and proteasomal function. Furthermore, this study shows that the 
interconnection of mitochondrial and proteasomal function is more complex as originally described 
and further research is needed to elucidate the different mechanistic steps in mitochondria to 
proteasome signaling. In summary, these experiments contribute to a deeper understanding of how 
risk factors in individual subjects add together towards a decline in both proteostasis and 
mitochondrial function during aging and eventually contribute to disease development.  
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